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ABSTRACT!
Paget’s disease of bone (PDB) is the most frequent metabolic bone disease after 
osteoporosis, and despite having a strong genetic component, Sequestosome 1 is the 
only gene directly linked, so far, to this disease. Genome wide linkage and association 
studies have suggested an association of PDB6 locus with PDB, however no 
functional studies were performed to try to explain that association. The main goal of 
this work was to assess the relative contribution of each significant variant identified 
in the PDB6 locus to the functionality of the candidate genes and their involvement in 
PDB pathophysiology. In this regard we analyzed the entire PDB6 locus to search for 
the best candidate genes likely to be involved in bone metabolism. OPTN, CCDC3, 
UCMA/GRP, CAMK1D, PHYH and SEPHS1 were selected and screened for genetic 
variants. Together with the variants found in a previous work from our group (Michou 
et al 2012) we studied 82 genetic variants, from which we selected rs2234968 and 
rs3829923 for an association study. The results showed that only rs2234968 was 
significantly associated with PDB (p-value = 6 x 10-3). In addition, we assessed the 
effect of a rare variant (RV) found in one PDB patient, RV -9906, and rs1561570, a 
SNP in OPTN strongly associated with PDB. Our functional studies showed that (i) 
rs3829923 was responsible for an increase of OPTN promoter activity due to the 
appearance of new binding sites for activator nuclear factors E47 and E2F1, while (ii) 
RV -9906 was responsible for an increase of OPTN promoter activity but due to the 
loss of SP1 binding and consequent loss of its inhibitory effect in gene transcription. 
Rs2234968 was found to be in linkage disequilibrium with two SNPs that changed 
OPTN splicing, thus creating a premature stop codon, and probably resulting in a non-
functional protein. In this work we showed that rs1561570, the SNP most associated 
to PDB, was responsible for the loss of a methylation site that subsequent increase in 
OPTN expression, which in turn increases NF-κB translocation into the nucleus and 
activation of NF-κB target genes. This will explain the increase in number and 
activity of the osteoclasts of PDB patients carrying of the rs1561570. In this work we 
provide new insights about OPTN regulation and its role in bone metabolism, with 
emphasis in osteoclastogenesis, and more importantly the contribution of OPTN 
variants to PDB pathophysiology.  
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RESUMO!
A doença óssea de Paget (DOP) é a doença óssea metabólica mais frequente a seguir à 
osteoporose, afectando 3% da população Caucasiana a partir dos 55 anos. Esta doença 
é caracterizada por um aumento focal e desorganizado do metabolismo ósseo devido 
ao aumento do número, tamanho e atividade dos osteoclastos, as células responsáveis 
pela reabsorção óssea. No entanto, posteriormente existe também um aumento no 
número e atividade dos osteoblastos que, na tentativa de recuperar o osso que foi 
reabsorvido, dão origem a um osso que não possui uma estrutura normal, tem fraca 
qualidade e é mais susceptível de sofrer deformações e fraturas. Este tecido ósseo 
desorganizado é caracterizado por apresentar hipertrofia, fragilidade e 
hipervascularização, podendo diminuir drasticamente a qualidade de vida dos 
pacientes. No entanto, a maioria dos casos são assintomáticos. A sua prevalência 
aumenta com a idade e é mais frequente em países da Europa, como a Inglaterra. As 
causas da DOP ainda não foram clarificadas. Pensa-se que possa ter uma componente 
ambiental e que a exposição a agentes como o fumo do tabaco ou arsénio, ou a 
factores relacionados com uma vida rural como o consumo de leite não pasteurizado e 
o contacto com animais de quinta, pode contribuir para um aumento da 
susceptibilidade para desenvolver DOP. A existência de uma infeção viral pelo vírus 
do sarampo também foi considerada um forte factor de risco, mas essa relação 
continua ainda por comprovar.  
A DOP possui também uma componente genética, com um padrão de hereditariedade 
autossómico dominante com penetrância incompleta, que vai desde os 17% antes dos 
50 anos de idade até aos 80% depois dos 60 anos de idade. Cerca de 15 a 40% dos 
pacientes apresentam uma história familiar positiva, no entanto pensa-se que este 
número será muito maior devido ao facto desta ser uma patologia assintomática. O 
único gene associado à DOP até ao momento é o Sequestosoma 1 (SQSTM1/p62), que 
codifica para a proteína p62 que, por sua vez, está envolvida na iniciação da via do 
NF-κB, regulando a ubiquitinação da TRAF6 e a consequente degradação do inibidor 
do NF-κB (IκB), o que resulta na libertação do NF-κB para o núcleo. No entanto mais 
de 60% dos pacientes não têm qualquer mutação no SQSTM1, o que sugere que outros 
genes estarão envolvidos na DOP. Em 2010 estudos de ligação e de associação 
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sugeriram que existia uma relação entre o locus PDB6, nomeadamente o 
polimorfismo rs1561570 localizado no gene da Optineurina (OPTN), e a DOP, mas 
não existem estudos funcionais que expliquem esta relação. Assim, o objectivo 
principal deste trabalho foi analisar o locus PDB6 e tentar explicar a contribuição das 
variações genéticas encontradas para a DOP. Para isso analisámos toda a região do 
locus PDB6 e procurámos genes que pudessem ter um papel no metabolismo ósseo. 
Assim, selecionámos os genes OPTN, CCDC3, UCMA/GRP, CAMK1D, PHYH e 
SEPHS1 que foram sequenciados utilizando uma amostra de 30 casos familiares e 5 
controlos saudáveis. Juntamente com um trabalho anterior elaborado pelo nosso grupo 
foram encontradas no total 82 variantes genéticas nos seis genes analisados. Destas, 
duas foram selecionadas devido à sua frequência no grupo de pacientes e devido à sua 
localização genómica – o rs2234968 (G>A), localizado no primeiro exão codante da 
OPTN, e o rs3829923 (C>T), localizado no promotor partilhado entre os genes OPTN 
e CCDC3. Posteriormente, foi feito um estudo de associação com 225 pacientes e 298 
controlos saudáveis que mostrou existir uma associação à DOP estatisticamente 
significativa (p-value = 6 x 10-3) unicamente para o polimorfismo rs2234968.  
Os estudos funcionais foram feitos com o objectivo de explicar o efeito (i) do 
polimorfismo rs1561570 - posteriormente associado à DOP -, (ii) do polimorfismo 
rs2234968 - descrito como associado à DOP neste trabalho -, e (iii) de duas variantes 
localizadas no promotor da OPTN, o polimorfismo rs3829923 - encontrada neste 
trabalho - e a variante rara RV -9906 - encontrada num único paciente, num trabalho 
anterior do nosso grupo. Os resultados obtidos mostraram que o polimorfismo 
rs3829923 era responsável por um aumento da atividade basal do promotor da OPTN 
devido à criação de um novo local de ligação dos factores de transcrição E47 e E2F1. 
Também foi demonstrado que a variante rara RV -9906 é responsável por um 
aumento da atividade do promotor da OPTN, mas neste caso devido à perda de 
ligação e consequente efeito inibitório do factor de transcrição SP1. Em relação ao 
polimorfismo rs2234968, os resultados mostram que este se encontra em desequilíbrio 
de ligação com outros dois polimorfismos - o rs10906303 e o rs79529484 - que são 
responsáveis por uma alteração no padrão de splicing da OPTN, alterando o quadro de 
leitura e originando um codão stop prematuro. A proteína resultante perde a maioria 
dos seus domínios proteicos e por isso é provável que seja degradada. Em relação ao 
polimorfismo rs1561570 (C>T), através do tratamento do DNA de pacientes e 
controlos saudáveis com bissulfito, e de técnicas como o qPCR ou western blot, 
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verificámos que o alelo mais comum nos pacientes - o alelo T - era responsável pela 
perda de um local de metilação e pelo aumento da expressão de OPTN. Também foi 
possível verificar que a presença do alelo T aumenta a translocação do NF-κB para o 
núcleo e a expressão dos seus genes alvo envolvidos na osteoclastogénese (tal como o 
NFATc1). Além disso a presença do alelo T também está relacionada com um 
aumento da taxa de diferenciação de osteoclastos, assim como um aumento no 
número de núcleos e na atividade destes osteoclastos, explicando assim o fenótipo 
pagético. 
Por fim, foi feita uma análise bioinformática em que se comparou a conservação, ao 
longo da evolução, dos genes mais relevantes para a DOP - o SQSTM1 e a OPTN -, 
nomeadamente entre o humano e o peixe-zebra. Através deste estudo verificou-se que 
ambos os genes são conservados entre humano e peixe-zebra e que aparentam possuir 
mecanismos de regulação semelhantes, com base na presença de locais putativos de 
ligação de factores de transcrição em comum nas duas espécies. É de destacar a 
conservação do resíduo P392 no SQSTM1 (frequentemente mutado em pacientes com 
DOP) nas duas espécies, o que mostra que o peixe-zebra poderá ser um bom modelo 
para estudar o efeito desta mutação no metabolismo ósseo. Em relação ao gene da 
OPTN é de realçar o facto deste gene ser expresso nos mesmos tecidos nas duas 
espécies, entre eles o tecido ósseo, o que indicia que o papel da OPTN possa ser 
semelhante nestas duas espécies.  
Este trabalho permite concluir que o locus PDB6 é relevante no estudo da DOP, dado 
que possui vários genes com um possível papel no osso, nomeadamente o gene da 
OPTN. Foi possível decifrar novos mecanismos de regulação do gene OPTN 
desconhecidos até à data e propor um mecanismo que relacione este gene com a 
osteoclastogénese e com a DOP. 
 
Palavras-passe: Doença Óssea de Paget, locus PDB6, optineurina, osteoclastogénese, 
variantes genéticas raras, polimorfismo, peixe-zebra 
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PREAMBLE!
This thesis is divided into six chapters. The first chapter is dedicated to a literature 
overview about bone metabolism, Paget’s disease of bone and OPTN function, with 
the objective of providing the necessary background to understand the data presented 
in this work. It is followed by a short description of the main goals.  
The second chapter describes the initial part of this work that consisted in the 
discovery and analysis of genetic variants that might be associated with Paget’s 
disease of bone.   
The third chapter describes the functional effect of two variants located in OPTN 
promoter - rs3829923 and RV -9906 - that could affect OPTN regulation and is based 
on a manuscript submitted for publication. 
The functional effects of rs2234968, found to be associated to PDB in this work, and 
rs1561570, the OPTN SNP most associated to Paget’s disease of bone, are described 
in the fourth chapter. 
A comparative analysis of SQSTM1 and OPTN genes among several species, namely 
human and zebrafish, giving a molecular and evolutionary perspective to this work is 
presented in the fifth chapter, part of it is based on two manuscripts, one published in 
the Journal of Applied Ichthyology and another submitted to ‘Bone’.  
Finally, chapter six gathers the main conclusions drawn from the data presented in 
this thesis, the relevance to this disease of the analyzed SNPs and the perspectives for 
future works.  
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1. GENERAL'INTRODUCTION'(
1.1  Bone metabolism 
Bone comprises the largest proportion of the human body’s connective tissue mass. 
Unlike most other connective tissue, bone matrix is physiologically mineralized and is 
a unique tissue since it is constantly regenerated throughout life as a consequence of 
bone turnover. This continuous remodeling is controlled by two distinct processes, 
bone formation and bone resorption, that are strongly linked and tightly regulated to 
control and maintain skeletal homeostasis (Raggatt and Partridge, 2010).  
There are three main cell types responsible for maintaining the correct balance in the 
remodeling process (Figure 1.1):  
! Osteoblasts are the cells found on the bone surface responsible for 
bone formation. They are cuboidal cells with a round nucleus, usually 
organized as a single layer adherent to the surface of bone, and are 
derived from primitive mesenchymal cells (Mackie, 2003). They are 
responsible for synthesizing and secreting the collagen fibers, as well 
as non-collagen proteins such as osteocalcin, which constitute the 
organic phase of the bone matrix (Berridge, 2012). Although 
osteoblasts are specialized cells with a determined function, they are 
not terminally differentiated.  
! Osteocytes are osteoblasts that became embedded in the bone matrix. 
They have a star-shape and are a type of cell that gradually stops 
secreting osteoid. These cells reside in lacunae and form a network of 
cytoplasmic extensions inside the canaliculated, dispersed throughout 
the mineralized bone tissue, and through which they communicate with 
each other and with surface osteoblasts (Marks and Odgren, 2002).  
! Osteoclasts, the multinucleated cells derived from fusion of 
mononuclear haemopoietic precursors, such as monocytes, are 
responsible for the resorption of both the organic and inorganic 
components of bone (Novack, 2011). After their formation the mature 
osteoclasts can migrate over the bone surface until they find an area 
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where the bone has to be resorbed. The interaction with the bone 
surface triggers the osteoclast activation process that converts the 
mobile cell into a sedentary cell that can begin to resorb bone by 
acidifying the region located within the resorption pit, which is isolated 
from the surrounding bone by an actin ring resulting from the 
rearrangement of the actin cytoskeleton by the osteoclast podosomes 
(Berridge, 2012).  
!
Figure 1.1 - Schematic representation of bone cells involved in bone remodeling. Osteoclasts 
(orange cells) are the cells responsible for bone resorption due to the action of its enzymes and 
acidification due to the production of chloridric acid. After bone resorption, osteoblasts (blue cuboid 
cells) are responsible for the formation of new bone, to maintain bone homeostasis. Osteoblast can also 
become embedded into the calcified matrix forming the osteocytes (star-shaped pink cells) that are 
connected through a complex network of cytoplasmic extensions inside lacunae and canaliculi. 
Adapted from (Matsuo and Irie, 2008).   
 
There is a continuous communication between osteoclasts and osteoblasts in order to 
maintain a proper bone remodeling process. There are at least three kinds of 
osteoclast–osteoblast communication. Osteoclasts and osteoblasts can make direct 
contact, through the binding of membrane-bound ligands and receptors in order to 
initiate intracellular signaling or by forming gap junctions allowing passage of small 
molecules between the two types of cells. Communication can also occur through 
paracrine factors, such as cytokines like interleukins, growth factors, chemokines and 
other small molecules secreted by either cell type and acting on the other via 
diffusion. Finally, during bone resorption, osteoclasts may liberate growth factors and 
other molecules deposited by osteoblasts in the mineralized matrix (Matsuo and Irie, 
2008). The osteoblasts exert a profound effect on the process of osteoclastogenesis 
where they provide the receptor activator of the nuclear factor κB (NF-κB) ligand 
(RANKL) that will bind to a receptor RANK - present in the osteoclast membrane 
Osteoclasts) Osteoblasts)
Bone)lining)cells)
Osteocytes) New)bone) Calciﬁed))
bone)matrix)
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(Figure 1.2) (Berridge, 2012). RANK signaling activates a cascade of transcription 
factors important for osteoclastogenesis, including NF-κB, AP-1 (c-Fos) and NFATc1 
(Matsuo and Irie, 2008). Osteoblast also release osteoprotegerin (OPG), which is a 
soluble RANKL-binding decoy receptor that inhibits the action of RANKL by 
masking it (Berridge, 2012). The osteoclastogenesis rate is controlled through the 
ratio between RANKL and OPG, both secreted by the osteoblasts.  
!
Figure 1.2 – Schematic representation of the crosstalk between osteoblasts and osteoclasts. The 
osteoblast produces the RANKL that will bind to its receptor in the membrane of the pre-osteoclasts 
inducing its differentiation. The mature osteoclast starts to resorb bone and releases growth factors that 
were trapped in the mineralized matrix, inducing the proliferation of pre-osteoblasts. RANK - Receptor 
activator of the nuclear factor κB, RANKL - Receptor activator of the nuclear factor κB ligand. 
Adapted from (Lee, 2010). 
 
This process, through which the osteoblasts induce the osteoclasts differentiation, is 
very well established. However the reverse case is not that well investigated. One 
hypothesis is that after resorbing the mineralized matrix the osteoclasts release some 
growth factors that are embedded in the bone, inducing the proliferation of the pre-
osteoblasts (Phan et al., 2004). Another theory is that through the interaction between 
ephrin-ligand and Eph-receptor expressing cells there is a bidirectional signal 
transduction. Reverse signaling through the ephrinB2 ligand into osteoclasts 
suppresses differentiation by blocking expression of the transcription factor AP1/c-
Fos, while forward signaling through the EphB4 receptor into mesenchymal 
precursors promotes osteoblast differentiation by inhibition of RhoA activity. Since 
Pre$osteoblast+
Pre$osteoclast+ Mature+Osteoclast+
Growth+factors+
RANKL+
RANK+
Mature+Osteoblast+
Prolifera:ng+osteoblast+
Prolifera:ng++
osteoclast+
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ephrinB2 is expressed in mature osteoclasts and EphB4 is expressed by osteoblast 
precursors, maybe the ephrinB2/EphB4 interaction facilitates the transition from bone 
resorption to formation (Matsuo and Irie, 2008). However, to this date, no protein or 
cytokine expressed by the osteoclasts was shown to have a specific paracrine function 
on osteoblasts. 
1.1.1 The role of NF-κB in osteoclasts 
An extremely important pathway for osteoclast differentiation is the NF-κB signaling. 
The pleiotropic NF-κB transcription factors are a family consisting of five members 
subdivided into two subfamilies (Figure 1.3): The ‘Rel’ proteins, which includes Rel 
A (also designated as p65), Rel B, and c-Rel (also known as Rel), and the NF-κB 
proteins, which include NF-κB1 (p105/p50) and NF-κB2 (p100/p52). Rel A, Rel B 
and c-Rel contain a transcription activation domain (TAD) and Rel B also has a 
leucine zipper domain (LZ), which is required for full transcriptional activity 
(Novack, 2011).  
 
!
Figure 1.3 – Protein structure of NF-κB family members. NF-κB family is composed by Rel A/p65, 
Rel B, c-Rel, NF-κB1 (p105/p50) and NF-κB2 (p100/p52). All of these proteins have a Rel-homology 
domain (RHD). All Rel family members have a transcription activation domain (TAD) and Rel B also 
has a leucine zipper domain (LZ). NF-κB1 and NF-κB2 also possess several ankyrin repeats (yellow 
stars). The numbers represent the protein length in amino acids (aa). Adapted from (Soysa and Alles, 
2009). 
 
NF-κB1 and NF-κB2 are synthesized as large precursors, p105 and p100, 
respectively, that become shorter following post-translational modifications into p50 
and p52, respectively, with long C-terminal domains that contain multiple ankyrin 
repeats (Figure 1.3). All of these NF-κB proteins share a Rel-homology domain 
(RHD) that contains a nuclear localization sequence and is important in dimerization, 
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DNA binding, and interaction with the inhibitor of NF-κB (IκB) proteins. Whereas 
the processing of p105 is constitutive upon activation, p100 processing is tightly 
regulated and highly inducible. NF-κB proteins, p50 and p52 are generally not 
activators of transcription unless they form dimers with Rel family members. All NF-
κB family proteins can form homodimers or heterodimers in vivo with the exception 
of Rel B, which only forms heterodimers. Of the 15 possible dimers, at least 12 are 
able to bind to 9–10 bp NF-κB DNA binding sites (Hoffmann and Baltimore, 2006).  
In most cells, NF-κB dimers are retained in the cytoplasm by inhibitory IκB proteins. 
These interactions are via the nuclear localization signal present in the RHD domain 
of the dimers and prevent nuclear localization and DNA binding. IκB proteins include 
IκBα, IκBβ, and IκBγ and contain ankyrin repeats that mediate binding of the RHD, 
allowing the binding of these inhibitory proteins with NF-κB1 or NF-κB2. There are 
two major NF-κB signaling pathways, named canonical (classical) and non-canonical 
(alternative) (Figure 1.4). 
!
Figure 1.4 – Canonical and non-canonical NF-κB activating pathways. Canonical NF-κB pathway 
is typically activated through binding of receptor activator of the nuclear factor κB ligand (RANKL), 
tumor necrosis factor α (TNFα) and interleukin-1 (IL-1) and non-canonical pathway is activated by 
RANKL, B-cell activating factor (BAFF), CD40L, TWEAK, and lymphotoxin-b (LT-b). When the 
canonical pathway is activated there is the degradation of inhibitor of NF-κB (IκB) and consequent 
release of p50/p65 dimers to the nucleus. When the non-canonical pathway is activated there is the 
processing of p100 and consequent release of p52/Rel B dimers to the nucleus. Adapted from 
(Madonna et al., 2012). 
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 Canonical NF-κB pathway 1.1.1.1
Canonical NF-κB pathway is typically activated through binding of RANKL, TNFα 
and IL-1 to their receptors on the cell surface (RANK, TNFR, and IL-1R, 
respectively), which in turn activates the IKK complex consisting of catalytic subunits 
IKKα, IKKβ, and the regulatory subunit IKKγ (or NEMO) (Figure 1.5) (Soysa and 
Alles, 2009). In response to activation of RANK by RANKL or of IL-1R by IL-1, the 
receptors undergo trimerization and their cytoplasmic domains associate with the 
adaptor protein TRAF6, which forms a complex with Sequestosome 1 (SQSTM1/p62) 
and an atypical protein kinase C.  
Upon activation by binding to RANK or IL-1R, TRAF6 uses its ubiquitin-ligase 
activity to conjugate multiple units of ubiquitin to form a Lys63-linked polyubiquitin 
chain. The downstream TAB2-TAB3 adaptor proteins (in a complex with TAK1), 
which recognize and bind to this ubiquitin chain, are then phosphorylated and activate 
a further complex including IKKα, IKKβ and IKKγ. After this step IκB is 
phosphorylated, subsequently ubiquinated and targeted for proteasomal degradation, 
releasing the NF-κB dimers (mostly p50/p65) that than enter into the nucleus and 
selectively activate gene expression and stimulate osteoclast differentiation (Layfield, 
2007).  
The canonical pathway is rapidly activated by a large number of stimuli and is 
regulated by auto-regulatory feedback mechanisms to ensure transient activation. This 
is done by replenishing the pool of IκB proteins via NF-κB activation itself. The 
newly synthesized IκB proteins enter the nucleus and transport NF-κB dimers back to 
the cytoplasm. In addition, inactivation of IKK catalytic activity prevents degradation 
of newly synthesized IκB proteins (Soysa and Alles, 2009).  
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!
Figure 1.5 - The canonical NF-κB signaling pathway. RANKL is an osteoblast-derived cytokine that 
stimulates osteoclast activity and its binding to the cell-surface receptor RANK promotes recruitment 
of TRAF6 to the intracellular tail of RANK. TRAF6 uses its ubiquitin-ligase activity to undergo 
autoubiquitination. SQSTM1/p62, which complexes with aPKC, uses its ubiquitin-associated domain 
to regulate this ubiquitination of TRAF6. Assembly of a polyubiquitin chain on TRAF6 leads to 
activation of TAK1, a kinase that forms a complex with TAB2 and TAB3. TAK1 phosphorylates and 
activates the complex IKKβ, IKKα and IKKγ/NEMO. This complex in turn phosphorylates IκB, which 
is subsequently ubiquitinated; in this protein the polyubiquitin chain serves as a signal for the 
degradation of IκB by the proteasome complex. The NF-κB transcription factor (p65/p50) is then free 
from its inhibitor IκB and enters the nucleus to stimulate selective gene expression. aPKC - atypical 
protein kinase C, IκB - inhibitor of NF-κB; IKK - IκB kinase; NEMO - NF-κB essential modulator; 
NF-κB - nuclear factor κB; OPG - osteoprotegerin; RANK - receptor activator of NF-κB; RANKL - 
RANK ligand; SQSTM1/p62 - sequestosome 1; TRAF6 - TNF receptor-associated factor 6; Ub – 
ubiquitin. Adapted from (Layfield, 2007). 
 
 Alternative NF-κB pathway 1.1.1.2
In contrast to the canonical pathway, which depends on IKKβ and IKKγ/NEMO, 
IKKα is the only protein required for activation of the alternative pathway. This 
pathway is activated by TNF cytokine family members, including RANKL, B-cell 
activating factor (BAFF), CD40L, TWEAK, and lymphotoxin-b, but not by TNFα 
itself. Activation of NF-κB-inducing kinase (NIK) by the binding of these ligands to 
their receptors results in activation of IKKα homodimers and the phosphorylation and 
proteasome-induced processing of p100 by ubiquitination (Figure 1.6). Ubiquitinated 
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p100 is not completely degraded; instead it is cleaved to generate an active p52 
product. Hence this process is slower than the activation of the classical pathway and 
leads to delayed activation and nuclear translocation of p52/Rel B under physiological 
conditions (Dejardin, 2006).  
Given the ubiquity of NF-κB in normal cellular metabolism, as well as its association 
with a wide variety of diseases from autoimmunity to cancer, it is not surprising that 
the study of NF-κB in bone has now spread beyond to other cell types rather than 
osteoclasts. 
 
!
Figure 1.6 - The non-canonical NF-κB signaling pathway. RANKL and other ligands bind to the 
cell-surface receptor and activate NIK. NIK phosphorylates and activates IKKα homodimers that will 
label p100 for processing. After conversion into p52, the complex p52/Rel B is translocated to the 
nucleus and activates target gene expression. IKK - IκB kinase; NIK - NF-κB-inducing kinase; RANK-
L - RANK ligand; Ub – ubiquitin. Adapted from (Layfield, 2007). 
 
1.2 Paget’s disease of bone 
In 1876, Sir James Paget described five patients who had at least two deformed areas 
of the skeleton (Paget, 1877). These patients had what he called osteitis deformans. 
He believed he was describing a rare inflammatory bone disorder, but after the 
discovery of X-rays in 1895, the physicians realized that this disease was indeed not 
that rare, with numerous publications describing similar patients in England, France, 
and the United States (Leopold-Levi and Londe 1897). By this time, the condition 
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commonly became known as Paget's disease of bone (PDB).  
1.2.1 Epidemiology 
PDB is the second most common metabolic bone disorder after osteoporosis, and it 
affects 3% of Caucasians older than 55 years, and up to 10% of Caucasians older than 
80 years (Ralston et al., 2008). It is slightly more common in men than in women and 
its prevalence increases with age (Figure 1.7A) (Siris and Roodman, 2008). However 
the prevalence differs amongst various ethnic/geographic groups (Figure 7B).  
!
Figure 1.7 – Paget’s disease of bone prevalence. A) Demographic data showing an increase in PDB 
prevalence with age both in males and females. B) World atlas representing the countries with higher 
PDB prevalence. Adapted from (Corral-Gudino et al., 2013). 
 
This disease is most common in the United Kingdom (UK) and Western Europe but 
also in former British colonies such as Australia, New Zealand, South Africa, and 
South America. It is uncommon in Africa, Scandinavia, China, Japan, Southeast Asia, 
and India (Altman, 2002).  
Furthermore, there is evidence of decreasing incidence and severity of PDB in the UK 
(Cooper et al., 2006) and New Zealand (Doyle et al., 2002) over the past 25-30 years. 
This decrease in the prevalence of PDB could be due to changes in the influx of 
migrants from low-prevalence regions, such as India and the Far East. It seems likely 
that other factors also contribute for this decrease, such as changes in environmental 
conditions that may trigger an increase in the susceptibility to develop the disease in 
genetically prone individuals. In fact, in the high prevalence region of Lancashire, 
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UK, it was reported the presence of arsenic in the water supply, indicating that this 
could be a risk factor (Lever, 2002). Also, the high prevalence of PDB in Campania, 
Italy, has been associated with a rural lifestyle, and with non-pasteurized milk 
consumption and meat that has not undergone health control (Rendina et al., 2006). 
The contact with domestic animals such as dogs and livestock, also appears to be a 
risk factor, although controversial (Siris et al., 1990). Cigarette smoke and wood 
heating were also described as potential risk factors (Guay-Bélanger et al., 2015). 
These studies show that although PDB prevalence depends on geographical regions, 
changes in the lifestyle and environmental exposure may contribute to change PDB 
onset and/or severity. 
1.2.2 Clinical features  
PDB is characterized by focal abnormal bone remodeling, with increased bone 
resorption and accelerated, excessive, and disorganized new bone formation. This 
deregulation of bone metabolism gives rise to a weaker bone, with poor quality, prone 
to deformities and fracture. It can be classified as monostotic (when only one bone in 
the skeleton is affected) or polyostotic (when a few bones display pagetic 
characteristics), the latest producing a more complex clinical setting (Kanis, 1998).  
 Disease progression 1.2.2.1
Clinically, three phases can be distinguished: first, the initial lytic phase, where there 
is an increase in osteoclast number. Osteoclasts are believed to be the first type of 
cells affected, which are increased in number, size and activity, resorbing bone at an 
incredible rate (Vinod and Reid, 2006). These osteoclasts are also hypersensitive to 
RANKL, 1,25-(OH)2D3 (1,25-dihydroxyvitamin D3), and TAFII17 (TATA-binding 
protein–associated factor [17 kDa], a vitamin D receptor binding protein) and display 
nuclear and cytoplasmic inclusion bodies (Chung and Van Hul, 2012). Clinical 
observations suggest that osteoclast-driven bone resorption is an early and progressive 
event: serial radiographs in several types of bone in the same patient show the 
progression of a lytic front (Figure 1.8) (Cundy and Bolland, 2008).  
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Figure 1.8 – Lytic phase in Paget’s disease of bone. Progression of a lytic wedge (white arrows) in a 
patient’s tibia visible on radiographs taken 58 months apart. Adapted from (Cundy and Bolland, 2008). 
 
In the second phase, the mixed phase, and in response to the exaggerated osteoclast 
activity, bone formation also increases (Vinod and Reid, 2006). The bone formation 
rate can be exceptionally high: histological studies show that affected bones increase 
six or seven fold over normal (Kanis, 1998). This phase corresponds to the presence 
of both abnormally large and active osteoclasts resorbing bone and osteoblasts, which 
increase in number and try to compensate for the bone loss. Finally, the bone gets into 
a third phase, the sclerotic phase, in which bone formation is predominant, but that 
process is so rapid that the new bone is deposited in a chaotic fashion with loss of its 
normal lamellar pattern (Vinod and Reid, 2006). Therefore, despite affected bones 
being larger than normal, they are of poor quality – explaining the increase tendency 
to deform and fracture (Cundy and Bolland, 2008). In this last phase the increased 
osteoblast activity leaves a highly sclerotic signature in the affected bone, named 
“woven bone” or “cotton-like bone”. 
 Symptoms 1.2.2.2
PDB patients can have any bone affected, but the axial skeleton, long bones and the 
skull are usually involved. The bones of the hands and feet are rarely involved. About 
5% of patients with radiological PDB experience symptoms. The most common 
symptom is bone pain but other symptoms include increased skeletal warmth and 
erythema, due to an increase in the bone vascularity. Complications of PDB such as 
bowing deformities, due to the week bone structure, and deafness, due to skull 
enlargement and cranial nerve compression may occur (Figure 1.9) (Vinod and Reid, 
CHAPTER!1!–!GENERAL!INTRODUCTION!
!18!
2006).  
!
Figure 1.9 – Paget’s disease of bone clinical symptoms. Due to a weaker and disorganized bone 
structure, PDB patients tend to have several clinical manifestations, such as bowing of long bones, 
skull enlargement or vertebrae collapse. (Pictures kindly provided by Dr. Brown, from the Research 
center of the CHU de Québec-Université Laval, Québec City, Canada) !
Pagetic bone is brittle and may fracture spontaneously, particularly the femur, the 
humerus, the tibia, and the forearm; these acute fractures, typically transverse, can 
repair rapidly, although mal union is frequent. Fissure fractures represent a unique 
feature of PDB that can be distinguished from fractures occurring in other bone 
diseases (Rousière et al., 2003). However, this disease is mainly asymptomatic. The 
diagnosis is usually detected as incidental radiological abnormality or by an increased 
concentration of alkaline phosphatase in serum detected in regular blood analysis. 
Some of these clinical features may give rise to secondary complications, associated 
with PDB. Secondary osteoarthritis is a common complication if a bone is affected 
next to a joint. If the skull is involved, the patient may develop dental malocclusion or 
nerve compression that can lead to deafness. Also, hypervascularization in the skull 
may divert blood from external carotid artery system affecting the brain blood 
support. This “vascular steal” may provoke drowsiness and apathy. Furthermore, 
when PDB affects more than 35% of the skeleton, it may cause a high cardiac output 
failure. This “vascular steal” can also affect the spine causing pain, dysesthesias or 
paralysis (Kanis, 1998).  
The most feared PDB complication is bone malignant degeneration (Figure 1.10), 
which is estimated to occur in less than 1% of the cases, although the overall risk for 
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osteosarcoma is 30 times greater in pagetic patients than in the general population 
(Grimer et al., 2003). There might be an increased concern about the development of 
sarcoma if a new mass in soft tissue around the bone or a sudden and painful fracture 
is detected (López et al., 2003).  
 
!
Figure 1.10 – Osteosarcoma in Paget’s disease of bone. A) Radiograph of a PDB patient pelvis and 
left tibia showing the typical changes of uncomplicated PDB. B) Radiograph of the same PDB patient 
six years later, showing massive sclerotic masses suggestive of malignant transformation. Adapted 
from (Vuillemin-Bodaghi et al., 2000). !
 Diagnosis 1.2.2.3
PDB diagnosis is often fortuitous, since PDB is asymptomatic in up to 80% of the 
cases (Selby et al., 2002). PDB hallmarks are found when patients are examined for 
other reasons. Usually characteristic focal bone lesions with accelerated bone turnover 
can be detected on bone scan using radionuclide-labeled bisphosphonates or on X-
rays. These radiological investigations are important to conform the diagnosis and at 
determining the extent of the disease (Chung and Van Hul, 2012). When PDB is 
diagnosed, radiographs typically show a mixed picture of lysis and sclerosis typical of 
PDB distinctive radiographic appearance (Cundy and Bolland, 2008). Radiographs 
can also assess complications such as fracture, secondary osteoarthritis and 
sarcomatous degeneration. Radionuclide bone scintigraphy is also helpful but a little 
less sensitive than X-rays (Vinod and Reid, 2006). The increased rate of remodeling is 
also reflected by an increase in bone turnover markers. All bone formation and 
resorption markers are affected similarly, such as alkaline phosphatase (ALP) and 
procollagen I N-terminal peptide for bone formation, and urinary N-telopeptide and 
A"
B"
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alpha-C-telopeptide for bone resorption (Shankar and Hosking, 2006). In the 
untreated state, the degree to which bone turnover markers are elevated is dependent 
on both the activity and the extent of the disease. Bone biopsy may be necessary to 
confirm the diagnosis, particularly if the results of radiographic studies and 
biochemical markers are inconclusive (Vinod and Reid, 2006).  
 Treatment 1.2.2.4
It is unclear whether there is value in treating this asymptomatic disease unless there 
is a clear and imminent risk of fracture. Treatment is indicated in those patients with 
bone pain, progressive skeletal deformity, compression of the spinal cord or nerve 
roots, and secondary fractures (Vinod and Reid, 2006).  
PDB was an untreatable condition until the mid 1970s, when calcitonin was registered 
in many countries for the treatment of this disease. However, both salmon and human 
calcitonin have demonstrated to be ineffective in reducing bone turnover in most 
cases; moreover, they were shown to be associated with unpleasant side effects. The 
current first line treatment is bisphosphonates, which act by inhibiting osteoclast 
function. The greater advantage of these drugs over calcitonin relies in prolonged 
remissions, which can last for years, and in the healing of the resorption front 
(Langston and Ralston, 2004).  
PDB can be monitored during the treatment with serial evaluations of bone markers. 
Indications for surgical treatment include secondary osteoarthritis, bone deformity 
fractures, and compression of nerve roots. After surgery, bone healing may be 
prolonged and rehabilitation may be delayed. The worst complication of surgery in 
pagetic patients is bleeding. Because of this, surgery has to be preceded by therapy 
with bisphosphonates in order to reduce the vascularity of the lesion as much as 
possible and to improve bone quality. Secondary osteosarcomas require 
chemotherapy, radiotherapy and/or surgery (Colina et al., 2008). In the end, operative 
procedures are useful for the relief of pain and for locomotion (Tancioni et al., 2006).  
 PDB-like pathologies 1.2.2.5
Other rare inherited bone disorders have also been described as having a phenotypic 
similarity with classical PDB, since they are also characterized by increased bone 
turnover, bone deformity, bone expansion, and elevated serum ALP concentrations. 
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These diseases include: familial expansile osteolysis (FEO), expansile skeletal 
hyperphosphatasia (ESH), early onset familial PDB, juvenile PDB (JPD), and the 
syndrome of hereditary inclusion-body myopathy, PDB and frontotemporal dementia 
(IBMPFD). 
FEO is a bone dysplasia with many clinical features similar to PDB. The patients 
present generalized and focal skeletal abnormalities associated with elevated serum 
ALP and urinary hydroxyproline values, bone pain at affected sites, tooth loss, 
progressive loss of hearing, and nuclear inclusion bodies similar to those found in 
PDB patient osteoclasts (Wallace et al., 1989). However, the first symptom in most 
patients is hearing loss, sometimes in patients with four years old. Bone pain also 
appears much earlier than in PDB – in the second decade of life - and in some cases is 
so severe that it is resistant to pain killers and require limb amputation. The disease 
progression in long bones is almost twice the rate of lesion progression in PDB 
patients. The most remarkable difference between FEO and PDB is the apparent 
difference of the rates of osteoblast and osteoclast activity in the late stages of FEO, 
leading to notable expansion of the medullary cavity and thinning of the cortex, with 
almost complete replacement of the bone with vascularized adipose tissue (Osterberg 
et al., 1988).  
ESH is a disorder that particularly affects the fingers but it is also characterized by 
early onset deafness, premature tooth loss, and involvement of the entire skeleton with 
striking progressive expansion of the long bones. Serum ALP and other markers of 
bone turnover are considerably elevated in these patients. However, ESH was not 
considered to be a variant of PDB because the patients also present hypercalcemia and 
widespread diffuse bone involvement without the presence of focal osteolytic lesions. 
Also, although an increased number of osteoblasts and osteoclasts were detected on 
bone biopsy, the osteoclasts were not enlarged to the same extent as seen in PDB 
(Whyte et al., 2000).  
Early onset familial PDB was found in a Japanese family with severe form of PDB, 
whose symptoms arose in the second or third decade of life. The affected individuals 
had, for example, 2 to 17 times more serum ALP than normal. This condition had 
features similar to classic PDB, including axial skeletal involvement, bone expansion, 
and osteosclerotic lesions, but differed from PDB since they had an earlier age of 
onset, premature deafness, and premature tooth loss (Nakatsuka et al., 2003).  
JPD is a rare autosomal recessive condition with approximately 50 cases reported 
CHAPTER!1!–!GENERAL!INTRODUCTION!
!22!
worldwide. It is characterized by a high rate of bone turnover; skeletal deformity, 
bone expansion, bone pain, and an increased risk of pathological fractures, as PDB. 
However, the first symptoms appear in the early infancy, and its severity increases in 
the adolescence, therefore this is clearly a more severe condition than PDB (Cundy et 
al., 2002; Whyte et al., 2002).  
IBMPFD is a rare syndrome found in a series of families from the United States 
where the most prominent feature (occurring in 90% of individuals) is myopathy, 
present at a mean age of 42 years (range: 3–66 years). The pattern of muscle 
involvement included proximal and sometimes distal or facial muscles, often in an 
asymmetric and patchy distribution. Muscle biopsies revealed the presence of 
vacuolar inclusion bodies in muscle fibers. The PDB component had a penetrance of 
43%, and was characterized by typical pagetic lesions involving the skull, spine, and 
pelvis. Dementia developed at an average age of 54 years and was 37% penetrant. 
Death typically occurred at a mean age of 58 years because of respiratory and cardiac 
failure (Kovach et al., 2001).  
Despite the similarities with PDB features, all of these conditions have their own 
particularities; either they are characterized by an earlier diagnosis or by different 
and/or more severe symptoms. That can be explained by the different genetic 
mutations present in each type of patient, as described in figure 1.11.  
!
Figure 1.11 – Genes involved in the NF-κB pathway that are important for PDB and PDB-like 
disorders. Mutations in OPG were found in patients with juvenile PDB, RANK was associated with 
FEO, ESH and early onset PDB, SQSTM1/p62 with classical PDB and VCP with IBMPFD. RANK - 
Receptor activator of nuclear factor κB, RANKL – RANK ligand, OPG - Osteoprotegerin, VCP - 
Valosin containing protein, TRAF 6 - TNF receptor-associated factor 6, NF-κB – Nuclear factor κB, 
IκB - inhibitor of NF-κB. Adapted from (Lucas et al., 2006a). 
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By screening FEO families a duplication of 18-bp (84dup18), affecting the RANK 
signal peptide that segregated with the disease in all affected members, was identified. 
These results were replicated in families from Spain and the United States (Johnson-
Pais et al., 2003; Palenzuela et al., 2002). At the same time, also in the RANK signal 
peptide, a 75dup27 mutation was found in the Japanese family with early-onset PDB. 
These mutations were not found in any healthy controls or sporadic PDB cases 
analyzed. Functional studies confirmed that these mutations are associated with 
failure of signal peptide cleavage resulting in an increase of RANK protein size. 
Expression of the 84dup18 and 75dup27 mutants showed increased constitutive 
activation of NF-κB signaling using promoter-reporter assays (Hughes et al., 2000). 
These observations led to the search for evidence of RANK mutations in individuals 
with classical PDB, but none were found, showing that mutation in the RANK gene 
are not a common cause of the classical PDB (Sparks et al., 2001). Other mutations in 
this gene were found in early-onset PDB, revealing the importance of RANK in this 
disease (Ke et al., 2009). Subsequently, after a screening of the RANK gene in two 
ESH patients there was an association of a 15-bp duplication to the FEO mutation 
(84dup15), and that was not present in 70 unaffected controls (Whyte and Hughes, 
2002). In ESH patients, a 15-bp tandem duplication (84_98dup15) in TNFRSF11A 
exon 1 was shown to be associated with this disease (Whyte and Hughes, 2002). A 
mutation screening of TNFRSF11B/OPG was also performed in an Iraqi family in 
which three of nine siblings had JPD, revealing a homozygous 3-bp deletion in all 
affected siblings (Cundy et al., 2002). This deletion was predicted to result in the loss 
of an aspartate residue in OPG protein, which was shown to be crucial for OPG ability 
to inhibit osteoclastic resorption. Other groups found JPD patients with no OPG 
mutations, but in these cases their phenotype was much less severe (Chong et al., 
2003). The gene associated with IBMPFD was valosin-containing protein (VCP). 
Thirteen IBMPFD families were screened for mutations in this gene, and six different 
disease-segregating mutations were identified (Watts et al., 2004). All of those 
mutations were localized near the VCP CDC48 domain, which is involved in 
ubiquitin binding. These IBMPFD associated mutations were considered relatively 
subtle, and only functional in response to oxidative stress and old age. No disease-
causing mutations and no evidence of an association between VCP and PDB were 
found (Lucas et al., 2006b). Therefore, VCP appears to neither cause nor contribute to 
the pathogenesis of classical, late-onset PDB. 
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1.2.3 Pathophysiology 
The cause of PDB is currently under intensive investigation, and both genetic and 
non-genetic factors have been implicated in the pathogenesis of this disorder.  
 Environmental Factors 1.2.3.1
Several observations suggest that environmental factors may contribute to the 
pathogenesis of PDB. The variable penetrance of this disease within families with a 
genetic predisposition to PDB, the fact that PDB affects a particular bone or bones 
rather than the entire skeleton, and the finding that the incidence and severity of the 
disease has been changing over the last 25 years (Doyle et al., 2002; van Staa et al., 
2002) all support the hypothesis that non-genetic factors may be involved in PDB 
pathogenesis. The first implicated environmental trigger for PDB was a viral 
infection. That supposition arose from the observation that osteoclasts from PDB 
patients contained inclusion bodies in their nuclei and cytoplasm that were 
paramyxoviral-like nucleocapsids (Rebel et al., 1974). Many attempts have been 
made to detect the expression of paramyxoviral protein and/or DNA in osteoclasts and 
bone tissue from patients with PDB, but this question remains contradictory.  
In a set of reports immunohistochemistry in PDB patients’ osteoclast-like cells 
showed positive staining with antibodies directed against measles virus nucleocapsid 
protein (MVNP) and respiratory syncytial virus (Mills et al., 1994, 1981) and in situ 
hybridization showed MVNP expression in pagetic bone (Baslé et al., 1986) and in a 
subset of peripheral blood cells from pagetic patients (Reddy et al., 1996). Other 
groups have focused on the possibility that canine distemper virus (CDV), rather than 
MVNP, might be responsible for PDB, based on the observation that patients with 
PDB were more likely to have owned a dog than non pagetic controls (O’Driscoll and 
Anderson, 1985), and they detected the CDV mRNA in pagetic bone samples from 
British patients (Mee et al., 1998). However, none of these studies have demonstrated 
that a virus may cause PDB. These results suggest that, if involved, a viral infection 
by itself does not cause PDB but is probably a disease trigger. Transfection of normal 
human osteoclast precursors with the MVNP gene resulted in the formation of 
osteoclasts with many of PDB characteristics, including increased rate of osteoclast 
formation, increase in osteoclast numbers and size, increased bone resorbing capacity, 
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and hypersensitivity of transfected osteoclast precursors to 1,25-(OH)2D3. These 
characteristics are also observed in osteoclasts formed in vitro from freshly isolated 
marrow samples from PDB patients (Kurihara et al., 2000). Additional data was 
provided by the transgenic mice that express MVNP in the osteoclast lineages 
(MVNP mice) (Kurihara et al., 2006). Histomorphometric analysis of bones from 17 
MVNP and 16 wild-type mice examined between 3 and 14 months of age showed a 
significant increase in osteoclast numbers and osteoblast activity. These results 
suggest that expression of MVNP in osteoclasts in vivo can induce bone changes that 
share many of the features of PDB. However, only 30% of the transgenic mice 
presented this pagetic phenotype (Kurihara et al., 2011, 2000), suggesting that virus 
may act as a modifier factor rather than a PDB cause.  
Still, several groups have failed to detect MVNP or CDV in pagetic bone, peripheral 
blood, or cultured bone marrow using the same techniques (Birch et al., 2009; 
Helfrich et al., 2000; Nuovo et al., 1992; Ooi et al., 2000; Ralston et al., 2007). Also, 
a work from Helfrich and colleagues found no evidence of paramyxoviral protein or 
nucleic acids in pagetic bone samples or peripheral blood using a wide range of 
techniques including nested RT/PCR, immunohistochemistry, and in situ 
hybridization (Helfrich et al., 2000). Other recent studies using highly sensitive 
quantitative PCR-based techniques have also failed to detect evidence of MVNP in 
peripheral blood cells (Ralston et al., 2007) or in cultured osteoblasts from patients 
with PDB (Matthews et al., 2008). Another argument against this role of MVNP is the 
fact that, prior to the era of measles virus vaccination, measles was a ubiquitous 
infection, while PDB has a distinct geographic and racial distribution, being rare in 
the Far East but relatively common in the UK, Australia, and New Zealand (Roodman 
and Windle 2005).  
Therefore, several questions remain concerning the involvement of measles in the 
pathogenesis of PDB. The osteoclast is not a self-renewing cell but is formed by 
fusion of post-mitotic precursors - thus, other cell types must act as a reservoir for 
measles virus to persist for long periods of time in patients with PDB (Roodman and 
Windle, 2005). Also, measles virus infections predominantly occur in children, while 
PDB is usually diagnosed in patients with more than 55 years old (Roodman and 
Windle, 2005), suggesting that a viral infection may increase the probability of 
developing PDB but another trigger is needed later in life. 
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 Genetic Factors 1.2.3.2
Epidemiological studies show a variable prevalence of PDB in different ethnicities, 
with a higher number of PDB patients in Europe (Altman, 2002); first-degree relatives 
of patients with PDB have about a sevenfold greater risk for the development of PDB 
(Siris and Roodman, 2008); if a patient has an early age of diagnosis or deforming 
bone disease the first-degree relatives also have an increased risk of PDB (Siris et al., 
1991); familial PDB also tends to be diagnosed at a younger age and involve more of 
the skeleton than sporadic disease (Seton et al., 2003). All of these findings suggest 
that PDB has a clear genetic cause.  
Generally, patients with a known PDB family are assigned as familial cases 
(designated as “familial PDB”) and those who are not aware of their positive PDB 
family history may have the complex or multifactorial form of PDB (also termed 
“sporadic PDB”, although they may have a familial form, but not known by the 
patient, reason why affected unrelated PDB is probably a better term for PDB without 
any known family history than sporadic PDB).  
There is a positive family history in approximately 15-30% of PDB patients and PDB 
seems to have an autosomal dominant mode of inheritance (Figure 1.12), with 
incomplete penetrance (17% before the fifth decade, 80% after the seventh decade of 
life), however it is hard to determine properly the truly familial cases due to the high 
percentage of asymptomatic patients (Siris et al., 1991).  
!
Figure 1.12 – Paget’s disease of bone family pedigree. Evaluation of several PDB families shows an 
autosomal dominant mode of inheritance. Members of family with determined clinical evidence of 
PDB are represented by black symbols. Open symbols indicate subjects not exhibiting clinical evidence 
of PDB. Question marks identify individuals whose clinical phenotype is not verifiable. Pedigree 
developed in this thesis. 
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The genetic architecture of PDB is not fully understood, but accumulating evidence 
suggests that it is caused by a combination of rare, high-penetrance variants in several 
genes, which cause the autosomal dominant inheritance of PDB, and common 
variants, which individually are not sufficient to cause the disease but act together to 
increase the risk of developing PDB considerably (Albagha et al., 2011, 2010). These 
genes are usually key regulators of osteoclast differentiation or function (Figure 1.13). 
!
Figure 1.13 – Osteoclast differentiation pathway and genes involved in Paget’s disease of bone. 
Several genes that increase the predisposition to PDB play central roles in the several osteoclast 
differentiation stages. CSF1 - Macrophage colony-stimulating factor, RANK - Receptor activator of 
nuclear factor κB, OPG - Osteoprotegerin, DC-STAMP - Dendritic cells specific transmembrane 
protein, SQSTM1 - Sequestosome 1, VCP - Valosin containing protein, OPTN – Optineurin. Adapted 
from (Ralston and Layfield, 2012). !
Linkage studies of PDB families have identified a number of susceptibility loci on 
chromosomes 6p21 (PDB1) (Fotino et al., 1977), 18q21.1-22 (PDB2) (Cody et al., 
1997), 5q35 (PDB3) (Laurin et al., 2001), 5q31 (PDB4) (Laurin et al., 2001), 2q36 
(PDB5) (Good et al., 2002), 10p13 (PDB6) (Hocking et al., 2001) and 18q23 (PDB7) 
(Laurin et al., 2002). The regions identified are typically large and contain many 
genes that could be plausible candidate genes for PDB pathogenesis (Helfrich and 
Hocking, 2008).  
1.2.3.2.1 Disease causing genes – SQSTM1 gene 
A strong susceptibility locus for familial PDB on chromosome 5q35 was identified in 
genome wide linkage scans in French-Canadian and British affected families 
(Hocking et al., 2001; Laurin et al., 2001). Sequencing of the genes within the 
selected region identified a mutation that changes a proline to a leucine in the amino 
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acid 392 (P392L) of the SQSTM1/p62 protein as the cause of the disease in French-
Canadian families (Laurin et al., 2002), and subsequently this and other mutations 
clustering in the UBA domain of SQSTM1 were identified as the cause of the disease 
in patients of British descent (Hocking et al., 2002). Many missense and truncating 
SQSTM1 mutations have now been identified in PDB patients, and all were found in 
or surrounding the UBA domain of the SQSTM1/p62 protein (Figure 1.14) (Cavey et 
al., 2006; Morissette et al., 2006).  
 
Figure 1.14 – SQSTM1/p62 protein domains and PDB most frequent mutations. SH2 - Scr 
homology 2, AID - acidic interaction domain, RIP - receptor interaction protein, LB - LIM-containing 
proteins binding domain, p38/MAPK - p38/mitogen-activated protein kinase, TRAF6 - TNF receptor-
associated factor 6-binding domain. PEST - domain rich in proline (P), glutamic acid (E), serine (S) 
and threonine (T), LIR - LC3-interacting region, UBA - Ubiquitin binding association domain. The 
numbers represent the domain positions in the protein sequence. The most frequent PDB-related 
mutations are all localized in the UBA domain, being the P392L the most frequent (present in more 
than 80% of the cases). Adapted from (Chung and Van Hul, 2012). 
 
SQSTM1/p62, as described in earlier sections, is an adaptor protein that binds 
ubiquitin and plays an important role in regulating NF-κB signaling (Layfield and 
Hocking, 2004) as well as autophagy (Ang et al., 2007; Bjørkøy et al., 2009; Pankiv et 
al., 2007). Mutations in SQSTM1/p62 are found in 40–50 % of patients with a familial 
history of PDB and 2.5–10 % of sporadic PDB cases (Hocking et al., 2002; Laurin et 
al., 2002). These mutations were shown to increase osteoclastogenesis. The osteoclast 
precursors expressing the P392L mutation are hyper-responsive to osteoclastogenic 
factors, such as RANKL and TNFα, and SQSTM1/p62 P392L-transfected cells have 
an enhanced ability to resorb bone (Cavey et al., 2006). The presence of the P392L 
mutation also leads to a reduction of Cylindromatosis (CYLD) expression, and 
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therefore to an increase of the NF-κB signaling and NFATc1 expression in pre-
osteoclasts, favoring the progression of osteoclastogenesis and osteoclast activity 
associated with metabolic bone diseases (Figure 1.15) (Bjørkøy et al., 2005; Mills et 
al., 1981).  
 
Figure 1.15 – Effect of SQSTM1/p62 mutations in osteoclastogenesis. Proposed mechanism of the 
effect of SQSTM1/p62 mutations in osteoclast activation. Under normal circumstances, the 
deubiquitinating enzyme CYLD is recruited by the UBA domain of SQSTM1/p62 (dark blue box) to 
the RANK receptor, where it deubiquitinates TRAF6 (scissors), resulting in inhibition of RANK 
signaling and osteoclastogenesis. Certain mutations of the SQSTM1/p62 UBA domain (white box) 
prevent CYLD being recruited, resulting in increased ubiquitination of TRAF6 (gray circles) and 
activation of RANK signaling. Adapted from (Ralston and Layfield, 2012). 
 
To this date, SQSTM1/p62 is the only causal gene with mutations in the coding region 
associated with PDB. However, studies of familial PDB in various populations 
indicate that SQSTM1/p62 mutations are found in only about half of the cases 
analyzed. Positional cloning studies identified other potential susceptibility loci, 
which may contain other PDB-associated genes to explain the other familial forms of 
PDB. 
1.2.3.2.2  Disease associated variants 
Genome wide studies have recently identified other loci with genetic polymorphisms 
that have been linked to an increase susceptibility to develop PDB and together 
account for 13% of the familial risk of PDB. These regions contain several genes that 
have either known or theoretically likely effects on osteoclast functions: M-CSF/CSF1 
- macrophage colony stimulating factor in chromosome 1p13, TNFRSF11A/RANK - 
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18q21.33, TM7SF4/DC-STAMP - dendritic-cell-specific transmembrane protein in 
chromosome 8q22.3, NUP205 - nucleoporin 205 kDa in chromosome 7q33, RIN3 - 
Ras and Rab interactor 3 in chromosome 14q32, PML - promyelocytic and GOLGA6A 
- golgin A6 family member A, both in chromosome 15q24, and OPTN - optineurin in 
chromosome 10p13 (Albagha et al., 2011, 2010; Chung et al., 2010; Daroszewska et 
al., 2004).  
! CSF1: Genetic alterations in the CSF1 gene on chromosome 1p13 were 
first identified as a PDB predisposing factor by a genome wide association 
study (GWAS) (Albagha et al., 2010), and the association was reinforced 
and confirmed in a subsequent study involving seven different populations 
(Albagha et al., 2011). The higher association observed was with the SNP 
rs484959, located about 87 kb upstream of CSF1 transcription start site. 
The CSF1 gene encodes M-CSF, an important protein in initiating 
osteoclast and macrophage differentiation (Figure 1.13) (Tanaka et al., 
1993; Yoshida et al., 1990). Loss-of-function mutations of CSF1 in rats and 
mice models cause osteopetrosis (Van Wesenbeeck et al., 2002; Yoshida et 
al., 1990). The mechanisms by which genetic alterations in the CSF1 gene 
cause PDB remain unknown, but it seems likely that they upregulate CSF1, 
given the fact that serum M-CSF levels are increased in PDB patients 
(Neale et al., 2002). That increase in CSF1 expression will increase the 
differentiation of haematopoietic stem cells into the monocyte lineage, and 
those monocytes will later differentiate into osteoclasts, explaining the PDB 
phenotype (Ralston and Layfield, 2012).  
! TNFRSF11A/RANK: The TNFRSF11A gene encodes the receptor activator 
of NF-κB (RANK), which belongs to the TNF receptor family and plays an 
essential role in osteoclast differentiation and bone resorption (Figure 1.13) 
(Li et al., 2000). Mutations have not been detected in the exons or intron-
exon boundaries of RANK in classical PDB (Sparks et al., 2001; Wuyts et 
al., 2001), but there is evidence from candidate gene studies and GWAS 
that common variants at the RANK locus could predispose to PDB 
(Albagha et al., 2011, 2010; Chung et al., 2010). Two common 
polymorphisms have been described in the protein-coding region of RANK 
- H141Y (a change from a histidine to a tyrosine at codon 141) and A192V 
(a change from an alanine to a valine at codon 192). (Sparks et al., 2001) 
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Functional analyses of these polymorphisms have yielded contradictory 
results; in one study they performed a reporter assay but no effect of these 
polymorphisms on RANK-induced NF-κB activation was found (Chung et 
al., 2010), whereas in the other study the A192V was described as 
activating RANK signaling in both the presence and the absence of the 
SQSTM1/p62 P392L mutation (Gianfrancesco et al., 2012). Further studies 
will be required to confirm these observations and to determine if the 
A192V variant is fully responsible for the robust association that has been 
observed between PDB and common variants at the TNFRSF11A/RANK 
locus (Albagha et al., 2011, 2010; Chung et al., 2010; Wild et al., 2011a).  
! TM7SF4/DC-STAMP: The TM7SF4 gene is localized on chromosome 
8q22 and encodes the dendritic cell–specific transmembrane protein (DC-
STAMP), an essential cell surface protein that allows the fusion of pre-
osteoclasts and formation of multinucleated active osteoclasts (Figure 1.13) 
(Yagi et al., 2005). The SNP rs2458415 has been strongly associated to 
PDB in an extended GWAS (741 cases and 2,699 controls), along with six 
independent replication populations (1,474 cases and 1,671 controls). It 
seems likely that the genetic variants in this gene that predispose to PDB 
increase TM7SF4 expression or cause a gain of function effect at the 
protein level, increasing the fusion of mononuclear pre-osteoclasts, but 
further studies will be required to investigate these possibilities (Albagha et 
al., 2011).  
! NUP205: This gene was also associated to PDB by a GWAS (Albagha et 
al., 2011). The strongest signal was within intron 22 of NUP205 in the 
region of the SNP rs4294134. This protein is a component of the nuclear 
pore complex, which is involved in the regulation of transport of substances 
between the cytoplasm and nucleus (Grandi et al., 1997). However, this 
gene has not been so far implicated in bone metabolism. Further studies 
will be required to investigate how can NUP205 affect bone cell function. 
! RIN3: The RIN3 gene is localized in chromosome 14q32.12 and encodes 
the Ras and Rab interactor 3, a protein that interacts with small GTPases 
such as Ras and Rab, being important in vesicular trafficking (Kajiho et al., 
2003; Saito et al., 2002). This gene was tagged by the association of 
rs10498635 with a large group of PDB patients in a GWAS (Albagha et al., 
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2011). The function of RIN3 in bone is not known, but it could play a role 
in bone resorption since small GTPases are important in vesicular 
trafficking and in osteoclast function (Coxon and Rogers, 2003; Van 
Wesenbeeck et al., 2007). Also, mutations in VCP, a protein also involved 
in vesicular trafficking, cause a PDB-related pathology - IBMPFD (Watts et 
al., 2004).  
! PML and GOLGA6A: The 15q24 locus was also identified as associated to 
PDB by the same GWAS as NUP205 and RIN3 (Albagha et al., 2011). The 
strongest associated SNP (rs5742915) lies within the PML gene and causes 
a change of a phenylalanine to a leucine at codon 645 of the PML protein 
(P645L). PML is involved in regulating cell growth, apoptosis, and 
senescence by interacting with various proteins such as p53, Rb, and death-
domain associated protein (DAXX) (Salomoni and Pandolfi, 2002). There 
is evidence that there is a defect in apoptosis in pagetic osteoclasts 
(Chamoux et al., 2009), providing a potential mechanism through which 
PML could explain the PDB phenotype. The GOLGA6A gene encodes a 
member of the golgin family of coiled-coil proteins associated with the 
Golgi apparatus, which are important for membrane fusion and as structural 
supports for the Golgi cisternae. The previously referred SNP (rs5742915) 
lies near this gene, and therefore the association can be due to the effect of 
this SNP in GOLGA6A and not in PML(Albagha et al., 2011). The role of 
the GOLGA6A gene in bone metabolism is unknown at this time but 
mutations in other members of the golgin family have been shown to cause 
lethal skeletal dysplasia and a severe form of osteoporosis (Hennies et al., 
2008; Smits et al., 2010). Therefore, further functional studies will be 
required to identify the effect of this genetic variant in these two genes and 
how they affect bone metabolism. 
! VCP: VCP protein coding mutations have also been associated with 
IBMPFD but have not been detected in classical PDB (Lucas et al., 2006b). 
However, two groups have investigated the effect of common genetic 
variants in the VCP gene in this disease. A study in the Belgian population 
showed evidence of an association between the rs565070 SNP in the VCP 
gene and PDB (Chung et al., 2011). However, in another study in the 
British population no evidences were found for an association between 
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common variants at the VCP gene and PDB, nor was there evidence of 
allele sharing at this locus in subjects with familial PDB (Lucas et al., 
2006b) Therefore., it remains uncertain whether common variants at the 
VCP locus contribute to the pathogenesis of PDB in the absence of other 
features of the IBMPFD syndrome.  
The association of OPTN and PDB will be addressed further in this thesis. 
 Autophagy 1.2.3.3
There is increasing interest in the possibility that abnormalities in macroautophagy 
may contribute to the pathogenesis of PDB (Goode and Layfield, 2010). Autophagy is 
the biological process that allows the degradation of cytoplasmic proteins, protein 
aggregates, and damaged organelles. After the encapsulation of the target protein into 
a double membrane bound structure designed as autophagosome, there is a fusion 
between the autophagosome and lysosomes or endosomes containing hydrolases (that 
are responsible for destroying its contents) (Figure 1.16) (Ravikumar et al., 2010). 
This process involves SQSTM1/p62, OPTN and other ubiquitin-binding proteins, 
which also play a role in regulating bone cell function (Whitehouse et al., 2010). All 
of these proteins contain an ubiquitin binding associated (UBA) domain, which allows 
them to bind to ubiquitinated proteins and organelles that were targeted for 
degradation (Kirkin et al., 2009a). The SQSTM1/p62 and similar proteins then act as 
autophagy receptors and bind proteins present in the autophagosomal membranes 
such as LC3. This allows SQSTM1/p62 and their ubiquitinated cargo to bind to the 
autophagosome, resulting in degradation of the ubiquitinated cargo and receptor 
protein.  
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Figure 1.16 - Mechanisms of autophagy. Autophagy receptors, including SQSTM1/p62 or OPTN, 
interact with polyubiquitinated substrates for autophagy (light blue) through their ubiquitin-binding 
domains (UBA) (grey box) and with autophagosome-associated proteins such as LC3 (orange circles) 
through LC3-interacting motifs (red). The substrates are engulfed by the forming autophagosome, 
which fuses with lysosomes or other endosomes containing hydrolases that degrade the contents of the 
autophagosome. Adapted from (Ralston and Layfield, 2012) 
 
Several lines of evidence suggest that PDB may be associated with dysregulation of 
autophagy. First is the fact that genetic variants in PDB patients usually affect genes 
involved in the process of autophagy, such as SQSTM1/p62, VCP, and OPTN. Indeed, 
a requirement for SQSTM1/p62’s ability to regulate autophagy is the presence of a 
functional UBA domain, which is the region commonly mutated in PDB (Bolland et 
al., 2007). Second is the recent observation that mice models harboring the P394L 
Sqstm1/p62 mutation exhibit a PDB-like skeletal phenotype and have an increased 
gene expression of Sqstm1, as well as several autophagy related genes, such as 
autophagy-related gene 5 (atg5), and light chain 3 gene (lc3) in osteoclast precursors, 
consistent with an dysregulation of the autophagy process. Third is the fact that 
SQSTM1/p62 protein levels are increased in peripheral blood cells and in osteoclasts 
from patients with PDB, regardless of the SQSTM1 mutation status (Chamoux et al., 
2009; Collet et al., 2007). Since SQSTM1/p62 is degraded as part of the process of 
autophagy, raised levels of this protein may indicate a reduced autophagic flux. 
Fourth, defective autophagy may be a feature of IBMPFD (caused by VCP 
mutations), at least in muscle cells (Ju et al., 2009; Tresse et al., 2010). A final 
connection between changes in autophagic function and PDB patients’ osteoclasts is 
the presence of nuclear inclusions, which may indicate a lack of protein clearance. 
Although all of these data indicate that autophagy may be dysregulated or defective in 
PDB, further work will be required to determine if this is related to abnormalities of 
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osteoclast activity or to the presence of nuclear inclusions that occur in the disease. 
1.3 Hypothesis - Does OPTN gene mutations 
contribute to PDB pathogenesis? 
Optineurin (OPTN) has been associated to PDB by an extensive GWAS by Albagha 
and co-workers, who have found an association between the SNP rs1561570 and PDB 
in British patients (Albagha et al., 2011). This strong association was also replicated 
in the French-Canadian population (Michou et al., 2012). However, little is known 
about the role of this gene in PDB.  
1.3.1 Optineurin molecular structure 
OPTN is a 67-kDa protein that was first isolated in 1998 in a yeast 2-hybrid screen (Li 
et al., 1998) and has been shown to have a strong homology to NF-κB essential 
molecule (NEMO/IKKγ), an important protein in the canonical NF-κB pathway, 
being named NEMO related protein (NRP) (Schwamborn et al., 2000). In 2002, 
optineurin or “optic neuropathy inducing” gene was identified as a strong candidate to 
be one of the leading causes of irreversible bilateral blindness worldwide - primary 
open-angle glaucoma (POAG) (Rezaie et al., 2002). The human OPTN gene is located 
in chromosome 10 (13099449-13138308) and spans about 39 kb of genomic DNA. It 
contains three noncoding exons in the 5’ untranslated region (UTR) and 13 exons that 
code for a 577 amino acid protein. Alternative splicing in the 5’ UTR generates at 
least four different transcripts (NM_001008211.1, NM_001008212.1, 
NM_001008213.1, and NM_001008214.1), but all have the same open reading frame. 
Alternative splicing in the coding region give rise to three different protein isoforms 
with 571 (ENST00000378764), 126 (ENST00000424614) and 107 
(ENST00000486862) amino acids. In addition, two partial transcripts were also 
described, but there is no indication of being protein coding. Finally, in 2012 a ‘new 
first exon’ was described, upstream from the previously known exon 1, and was 
labeled as exon 1a (Michou et al., 2012).  
The OPTN protein consists of a NEMO-like domain, a leucine zipper motif, multiple 
coiled-coil motifs, an ubiquitin binding domain (UBD), a microtubule associated 
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protein 1 light chain 3 (LC3)-interacting motif, and a C-terminal zinc finger (Figure 
1.17) (Ying and Yue, 2012).  
 
Figure 1.17 - OPTN protein structure and domains. OPTN has several domains such as coiled coil 
motifs (CC), an ubiquitin binding domain (UBD), a leucine zipper (LZ), a LC3 interacting region 
(LIR), and a zinc finger (ZnF). The black bars represent the sites of interactions of OPTN with various 
proteins, including Huntingtin (Htt), Rab8, Light chain 3 (LC3), Cylindromatosis (CYLD), 
metabotropic glutamate receptor (mGluR), myosin VI, TANK binding kinase 1 (TBK1), and receptor 
interacting protein 1 (RIP1). The numbers represent the position (in amino acids) in the OPTN protein. 
Adapted from (Kachaner et al., 2012). 
 
OPTN is a cytosolic protein that is not secreted (Ying et al., 2010). It is ubiquitously 
expressed in many non-ocular tissues such as heart, brain, placenta, skeletal muscle, 
kidney, pancreas, adrenal cortex, liver, and the eye (Li et al., 1998; Rezaie and 
Sarfarazi, 2005; Rezaie et al., 2002). In the eye, OPTN is expressed in the trabecular 
meshwork, nonpigmented ciliary epithelium, and remarkably, also in retina (Rezaie 
and Sarfarazi, 2005; Schwamborn et al., 2000; Ying and Yue, 2012). OPTN seems to 
suffer posttranslational modifications. Since it possesses an ubiquitin binding domain 
(UBD), after being ubiquitinated it is processed through the ubiquitin-proteasome 
pathway (Ying et al., 2010). It is also phosphorylated at Ser177, which is adjacent to 
the LC3 interacting region (LIR) site (Wild et al., 2011b).  
1.3.2 Optineurin functions 
OPTN is a multifunctional protein involved in regulating several biological functions 
such as signal transduction, membrane vesicle trafficking, autophagy, NF-κB 
signaling, and cell survival (Kachaner et al., 2012; Ying and Yue, 2012). These 
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functions are mediated through interaction with a wide variety of proteins (Figure 
1.17). 
 Role of optineurin in vesicular trafficking 1.3.2.1
Vesicular trafficking is one of the most fundamental biological processes of 
eukaryotic cells. As the name suggests, it refers to the movement of cargo packaged in 
the vesicles or cell organelles across the cytosol of the cell. It ensures supply of 
nutrients and signals to various compartments of the cell, crosstalk between the 
various organelles inside the cell, secretion and exocytosis (Jahn and Südhof, 1999; 
Mellman, 1996). Since OPTN interacts with multiple proteins like Rab8, huntingtin, 
myosin VI, or transferrin receptor (TfR), which are involved in various intra-cellular 
trafficking pathways, its role in vesicular trafficking is evident (Chalasani et al., 2009; 
del Toro et al., 2009; Hattula and Peränen, 2000; Sahlender et al., 2005; Vaibhava et 
al., 2012). But the exact mechanisms by which OPTN performs its functions in 
trafficking started to be uncovered only recently.  
 Role of optineurin in autophagy 1.3.2.2
Autophagy receptors are believed to play a crucial role in the selection and 
recruitment of cargo to autophagosomes by simultaneously binding to LC3 and 
ubiquitinated cargo (Kirkin et al., 2009b; Kraft et al., 2010; Yang and Klionsky, 
2009). OPTN was identified as an autophagy receptor due to its ability to bind LC3 
and ubiquitin directly and simultaneously through LIR and UBD domains, as 
described in section 1.2.3.3 (Figure 1.17) (Wild et al., 2011b). OPTN is involved in 
clearance of cytosolic Salmonella in macrophages (Wild et al., 2011b). However, so 
far no specific protein of Salmonella has been identified to bind to OPTN and be 
targeted to autophagosomes for degradation.  
 Role of optineurin in cell survival and cell death 1.3.2.3
Recently, using a mouse retinal ganglion cell line, RGC-5, it was shown that 
knockdown of endogenous Optn results in induction of apoptotic cell death due to 
reduced secretion of neurotrophin 3 (Nt3) and ciliary neurotrophic factor (Cntf) (Sippl 
et al., 2011). Addition of Nt3 rescued cell death. The levels of Nt3 or Cntf mRNAs 
were not affected significantly upon knockdown of Optn. Rather, knockdown of Optn 
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resulted in collapse of the Golgi structure and accumulation of Nt3 positive vesicles 
due to a block in vesicle trafficking in the secretory pathway (Sahlender et al., 2005; 
Sippl et al., 2011). Overexpression of Optn sensitizes RGC-5 cells to TNFα induced 
cell death (Chalasani et al., 2007). Thus it appears that maintenance of optimum level 
of Optn is important for survival of RGCs.  
 Role of optineurin in antiviral signaling 1.3.2.4
Our body responds to viral infection through innate immune response and produces 
type I interferons (IFNα/IFNβ). These activate transcription of specific genes to 
produce an antiviral state in the cells (Müller et al., 1994). A tight regulation of this 
antiviral signaling is necessary to prevent unwanted tissue damage due to 
inflammatory response. OPTN has emerged as a negative regulator limiting IFNβ 
production in response to RNA virus infection (Mankouri et al., 2010). This negative 
regulation of IFNβ production is mediated by interaction of OPTN with TANK 
binding kinase 1 (TBK1), a protein kinase involved in the activation of interferon 
regulatory factor 3/7 (IRF3/7) (Fitzgerald et al., 2003). OPTN inhibits TBK1 
mediated phosphorylation of IRF3 induced by Sendai virus or extracellular poly (I:C) 
(Sakaguchi et al., 2011), controlling the inflammatory response. But another group 
has suggested that OPTN is an activator of TBK1 and mediates IFNβ production in 
response to lipopolysaccharide (LPS) or poly (I:C) (Gleason et al., 2011). The UBD 
of OPTN plays an essential role in this process. It still remains to be clarified the role 
of OPTN in immune response, and if that depends solely on the immunogenic signal.  
1.3.3 OPTN associated pathologies 
 Glaucoma 1.3.3.1
Glaucoma is the major cause of bilateral blindness and it is characterized by 
degeneration of the optic nerve, retinal ganglion cell death, and progressive axonal 
and visual field loss (Kerrigan et al., 1997; Kuehn et al., 2005; Quigley, 2011). Rezaie 
and coworkers in 2002 studied 54 families that suffered from autosomal dominant 
inherited adult-onset primary open-angle glaucoma (POAG), leading to the 
identification of the causative gene on chromosome 10p13, which they designated as 
optineurin. DNA sequence analyses detected four mutations in patients with POAG: 
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E50K, M98K, R545Q, and 691_692insAG (2-bp “AG” insertion) (Figure 1.18). 
These mutations were reported to be responsible for 16.7% of hereditary forms of 
glaucoma with an additional attributable risk factor of 13.6% in both familial and 
sporadic cases (Rezaie et al., 2002). In addition to the genetic link, a causal role for 
E50K in glaucoma was also referred by a recent study of Chi et al. (2010) that 
observed loss of RGC, reduction of retinal thickness, and excavation of the optic 
nerve head in E50K-expressing transgenic mice (Chi et al., 2010). Other OPTN gene 
alterations observed in various patient populations include: a missense mutation 
E322K in OPTN exon 10 in Chinese POAG family, H26D alteration in Japanese 
POAG families, and H486R in POAG and juvenile open-angle glaucoma families 
(Figure 1.18) (Funayama et al., 2004; Leung et al., 2003; Willoughby et al., 2004; 
Xiao et al., 2009).  
 
Figure 1.18 – Localization of glaucoma and ALS associated mutations in OPTN protein 
structure. Various glaucoma causing mutations were identified in the OPTN gene. Of these, R545Q 
and M98K are polymorphisms. Deletion of some of the exons has been found in ALS patients but not 
in glaucoma patients. CC- coiled coil, UBD- ubiquitin binding domain, LZ- leucine zipper, LIR- LC3 
interacting region, ZnF- zinc finger. The numbers represent the position (in amino acids) for some 
domains in OPTN protein. Adapted from (Kachaner et al., 2012). 
 
 Amyotrophic lateral sclerosis (ALS) 1.3.3.2
ALS is a progressive disorder characterized by degeneration of motor neurons of the 
primary motor cortex, brainstem, and spinal cord (Leigh, 2007). It is a genetically 
heterogeneous disease. Besides OPTN, genes that encode TAR DNA-binding protein 
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of 43kDa (TDP-43) (Sreedharan et al., 2008), Cu/Zn superoxide dismutase (SOD-1) 
(Rosen et al., 1993), angiogenin (Greenway et al., 2006), vesicle-associated 
membrane protein (Nishimura et al., 2004), and VCP (Johnson et al., 2010) are 
reported to be associated with the classic familial ALS. Maruyama et al. in 2010 
reported three mutations in the OPTN gene in Japanese familial or sporadic ALS 
patients: a homozygous deletion of exon 5, a homozygous nonsense mutation Q398X 
in exon 12, and a heterozygous missense mutation E478G in exon 14. The deletion of 
exon 5 causes a frame shift leading to the appearance of a premature stop codon, 
which would be expected to originate a peptide with 58 amino acids in length. Q398X 
mutation generates a premature stop codon at amino acid 398, truncating the 577 
amino acid optineurin protein to one of 397 amino acids in length. This truncation 
results in a deletion of one of the coiled-coil domain. E478G mutation is located in the 
UBD domain. The Q398X nonsense mutation and probably the exon 5 deletion 
mutation as well could cause a decrease in OPTN expression resulting from nonsense-
mediated mRNA decay of the transcripts carrying the nonsense mutations. The 
mechanism of recessive mutation causing ALS is expected to be loss of function. On 
the other hand, the E478G missense mutation increased the immunoreactivity for 
OPTN in the neural cells. The increased amount and different distribution of the 
mutated protein might disturb neuronal functions, and accelerate the formation of 
inclusion bodies in sporadic ALS (Maruyama et al., 2010).  
In French familial ALS patients, a heterozygous nonsense 382_383insAG (2-bp AG 
insertion) mutation and a novel missense mutation R96L were reported (Millecamps 
et al., 2011). This mutation presumably induces a premature stop codon in exon 6. 
This will decrease the levels of functional OPTN and therefore is considered to be a 
loss of function mutation. The missense mutation R96L on the contrary might lead to 
a gain of function, although no accumulation of OPTN protein was detected in the 
patients’ lymphoblasts. In sporadic ALS patients from a Dutch population, a nonsense 
Q165X and a missense Q454E mutations were identified. Since the Q165X mutation 
would probably result in a 72% truncated optineurin protein, binding to Rab8, 
mGluR1a, TFIIIA, Htt, and myosin VI might be eradicated. The Q454E mutation is 
located near the area that contains binding sites for Htt and myosin VI and may affect 
those interactions. However, these mutations were not detected in the Dutch familial 
ALS patients, suggesting that the genetic background of ALS may be different from 
one population to another population (van Blitterswijk et al., 2012).  
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 Other neurodegenerative diseases 1.3.3.3
OPTN was shown to be located not only in the skein-like inclusions and round 
hyaline inclusions in ALS but also in the senile plaques and neurofibrillary tangles in 
Alzheimer’s disease, Lewy bodies and Lewy neuritis in Parkinson’s disease, 
ballooned neurons in Creutzfeldt–Jakob disease, glial cytoplasmic inclusions in 
multiple system atrophy, and Pick bodies in Pick’s disease. This indicates that OPTN 
is often altered in neurodegenerative conditions (Osawa et al., 2011). The significance 
of such a finding, however, is unknown. Optineurin aggregates are generally found to 
be ubiquitin positive, and the OPTN aggregation may be the common process 
involved in neurodegeneration and cell death. OPTN may be itself an aggregation-
prone protein present in the affected neurons and glia. Alternatively, OPTN could also 
be just secondarily entrapped in the inclusion bodies in various conditions or in 
ubiquitin (Turturro et al., 2014).  
1.3.4 OPTN role in bone metabolism 
As stated earlier, the role of OPTN in bone metabolism is not known to this date. The 
link between OPTN and bone was first suggested by a GWAS performed using a 
large cohort of PDB patients from the British population (Albagha et al., 2011). A 
strong association was described between a SNP located in OPTN and this disease, 
showing that when mutated OPTN can contribute to bone phenotypes. This 
association was later reproduced in the French-Canadian population, confirming its 
relevance. In this study our group showed that in the French-Canadian population the 
C allele was more frequent in healthy controls (present in 52%) while the T allele was 
more frequent in PDB patients (present in 64%) (p-value=!5.65×10−7) (Michou et al., 
2012). Since the T risk allele is also very common in healthy controls, this gene is 
more likely to contribute to pathogenesis with other factors than being by itself a 
disease-causing gene. Several studies have tried to explain the role of OPTN in bone, 
but the results obtained so far appear to be contradictory.  
The role of OPTN in TNFα and NF-κB signaling was long suspected, when it was 
observed that this protein shares 53% similarity to NEMO (Schwamborn et al., 2000). 
TNFα was shown to induce OPTN expression (Li et al., 1998) and the role of OPTN 
in NF-κB signaling was shown by Zhu et al. (2007) who demonstrated that OPTN 
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acts as a negative regulator of TNFα induced NF-κB signaling, by binding to 
polyubiquitinated RIP (Zhu et al., 2007). In the presence of a signal as TNFα, OPTN 
interacts with CYLD, a deubiquitinase that negatively regulates NF-κB signaling. 
CYLD removes the ubiquitin from the polyubiquitinated receptor interaction protein 
(RIP) (Figure 1.19A) (Chalasani et al., 2009; Kovalenko et al., 2003; Sun, 2010; 
Trompouki et al., 2003). By interacting with CYLD and also with polyubiquitinated 
RIP, OPTN facilitates deubiquitination of polyubiquitinated RIP by CYLD, 
inactivating the NF-κB signaling (Nagabhushana et al., 2011). In the absence of 
OPTN, CYLD is unable to deubiquitinate RIP, leading to the accumulation of 
polyubiquitinated RIP, phosphorylation and activation of the IKK complex, resulting 
in enhanced NF-κB activity (Figure 1.19B). Thus, in NF-κB signaling, OPTN seems 
to act as an adaptor protein that brings together the enzyme CYLD and its substrate - 
the polyubiquitinated RIP (Figure 1.19) (Nagabhushana et al., 2011).  
 
Figure 1.19 - Regulation of TNFα induced NF-κB signaling by OPTN. A) OPTN regulates RIP 
ubiquitination by acting as a competitive inhibitor of NEMO and binds to ubiquitinated RIP by 
displacing NEMO. OPTN then recruits CYLD (a deubiquitinase) to the molecular complex facilitating 
deubiquitination of polyubiquitinated RIP leading to downregulation of downstream pathway. B) In the 
absence of OPTN, after the binding of TNFα to its receptor and assembly of a multimolecular complex 
on TNF receptor that binds ubiquitin to RIP, NEMO is recruited, leading to activation of IKK complex. 
Active IKK phosphorylates IκB, which acts as a trigger for ubiquitination and degradation of IκB. This 
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leads to the release of p50/p65 complex of NF-κB to the nucleus leading to transcription activation. 
Adapted from (Zhu et al., 2007). 
Concerning PDB, Obaid et al. used in vitro knockdown experiments to investigate the 
expression of OPTN during osteoclast formation. OPTN expression was not detected 
after the first day of RANKL treatment but there was a significant increase of its 
expression from days two to five of osteoclast differentiation. Then, after OPTN 
depletion using lentiviral particles expressing short hairpin RNA targeted against the 
OPTN gene, they found that the number of osteoclasts formed from OPTN-depleted 
cells were significantly higher than those formed from non-targeted cells (number ± 
SD; 151 ± 21 vs. 69 ± 18; P = 0.002) (Obaid et al., 2012).  
Alternatively, functional studies also show that due to its high similarity to NEMO 
(Figure 1.20), OPTN could be competing for its functions. In terms of structure, the 
C-terminal NEMO UBD is highly similar to OPTN UBD, and some works showed 
that the UBD of NEMO can be replaced for the one in OPTN without interfering!with 
its activity, which suggested that they could have similar functions and participate in 
similar pathways (Laplantine et al., 2009).  
 
Figure 1.20 - NEMO and OPTN protein structure similarity.!Human NEMO and OPTN proteins 
display strong homology between their domains including coiled-coil regions (CC), zing fingers (ZF), 
and ubiquitin binding domain (UBD) but differ by a 166 amino acid insert region present in OPTN that 
is absent from NEMO, and the presence of a leucine zipper (LZ) and a LC3 interacting region (LIR). 
The protein lengths are represented in amino acids (aa). Adapted from (Kachaner et al., 2012). 
 
OPTN was also shown to cooperate with TAX1 binding protein (TAX1BP1) to 
potentiate the activation of NF-κB. In an extensive work, human T-lymphotropic 
virus type 1 (HTLV-1) was shown to encode regulatory and accessory proteins that 
are involved in viral replication and cell proliferation. Among them, TAX1 plays a 
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critical role by triggering cell immortalization through various mechanisms (Akagi et 
al., 1995), including activation of signaling pathways such as NF-κB (Sun and 
Yamaoka, 2005). This process occurs predominantly in the cytoplasm where TAX1 
binds to NEMO and triggers the activation of IKKα and IKKβ (Figure 1.21) (Chu et 
al., 1999; Harhaj and Sun, 1999; Jin et al., 1999). !
!
Figure 1.21 - Dysregulation of the NF-κB canonical and non-canonical pathways by TAX1/OPTN 
interaction. After HTLV-1 infection, dysregulation of the canonical pathway occurs, with the 
assembly of the TAX1/TAX1BP1/OPTN complex that is responsible for TAX1 ubiquitination. 
Interaction of ubiquitinated TAX1 with the cytoplasmic IKK complex specifically bound to the IKKγ 
subunit leads to phosphorylation of IκB, as well as its ubiquitination and subsequent degradation. NF-
κB is subsequently activated and translocated into the nucleus. Adapted from (Journo et al., 2009). 
 
To control this process, TAX1 binding protein TAX1BP1 recruits the A20 
deubiquitinase and act as a negative control of TNFα, IL-1 and LPS-mediated NF-κB 
activation, suggesting that TAX1-dependent activation of NF-κB could also be more 
complex than originally thought (Shembade et al., 2007a). OPTN and TAX1BP1 were 
shown to form a functional complex with TAX1. Furthermore, this synergistic 
interaction between TAX1BP1 and OPTN contributes to TAX1 mediated NF-κB 
activation. OPTN UBD domain binds to TAX1 and facilitates its ubiquitination, 
allowing its activation and triggering the activation of the IKK system, 
phosphorylation of IκB and consequently NF-κB signaling. (Shembade et al., 2007b) 
Therefore this pathway might have a negative regulation mediated by a quaternary 
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complex containing TAX1BP1, A20, Itch and RNF11 (De Valck et al., 1999; Iha et 
al., 2008; Shembade et al., 2009, 2008), but TAX1 induced NF-κB activation is 
mediated by a ternary complex containing TAX1, TAX1BP1 and OPTN (Figure 1.21) 
(Journo et al., 2009), confirming that the presence of OPTN can also be a positive 
regulator of NF-κB translocation to the nucleus and activation of its target genes, 
namely those important for osteoclastogenesis. 
1.4 Main Objectives 
PDB is the second most frequent metabolic bone disorder after osteoporosis and, 
despite having a clear genetic background, SQSTM1 has been so far the only gene 
which mutations are associated with this disorder. However, mutations in SQSTM1 
only account for around 50% of the reported familial cases, suggesting that other 
genes may be involved in PDB. After the GWAS performed by Albagha and 
coworkers (Albagha et al. 2010), a strong association between the PDB6 locus in 
chromosome 10 and PDB patients has confirmed previous linkage studies (Hocking et 
al., 2001; Lucas et al., 2008). Data from this GWAS indeed confirmed the previous 
linkage to PDB6 (10p13) locus, indicating that there is a high probability for the 
existence of a gene related to PDB in this locus (Albagha et al. 2010). But no PDB 
causal mutation was reported until the beginning of this thesis in this locus, and 
therefore PDB6 was considered to be a good ‘target locus’ to be further investigated. 
So the general objective of this work!was to characterize the PDB6 (10p13) locus in 
PDB and attempt to identify possible molecular players/targets involved in its 
pathogenesis. 
With this general goal in mind we divided our work plan in four main tasks:  
1) Analysis of the PDB6 locus to search for the best candidate genes that could 
have a role in a bone disease, and screening by Sanger sequencing to search for 
variants that could have a genetic association with PDB, in a discovery group of 30 
familial cases and 5 healthy controls from the French-Canadian population, all 
without SQSTM1 mutations;  
2) Selection of the most relevant variants and identification of disease-
associated variants in a group of 225 unrelated PDB individuals and 298 healthy 
controls, all without SQSTM1 mutations;  
3) Perform functional analysis of the significant genetic variants using 
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bioinformatics approaches complemented by functional studies adjusted to each 
variant.  
4) Perform functional analysis of rs1561570, the OPTN SNP most associated 
to PBD. Since our group had found a genetic association of the SNP rs1561570 in 
OPTN gene with PDB in the French-Canadian population (Frequency in patients – 
36%; frequency in controls 52%; p-value = 5.65×10−7; OR = 0.53; 95% CI = 0.42–
0.69) (Michou et al., 2012), but no functional studies were available that could 
explain the role of this OPTN variant in PDB pathogenesis, we also aimed to analyze 
and predict how this important SNP may affect OPTN transcription or function.  
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2.1.1 Abstract 
Paget’s disease of bone (PDB) is a common metabolic bone disorder where genetic 
factors play an important role, but to date PDB causing mutations were only identified 
in the Sequestosome 1 (SQSTM1) gene at the PDB3 locus. PDB6 locus has been 
highly associated with PDB in several European populations and in the French-
Canadian population, but no PDB causal mutations were reported in this locus. 
Therefore, PDB6 was considered a good ‘target locus’ for further investigation. 
Relevant candidate genes from PDB6 locus were selected based on their known or 
possible biological function in bone. For each selected gene, the coding region, splice 
sites, 5’ and 3’ untranslated regions and promoter were amplified, using an initial 
discovery sample of French-Canadian SQSTM1 non-carriers PDB patients from 30 
familial cases and 5 healthy controls. PCR-amplified products were purified and 
sequenced. Several variants were found and an in silico analysis was performed to 
explain the possible effect of each SNP. We screened OPTN, PHYH, UCMA/GRP, 
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SEPSH1, CAMK1D, and CCDC3 and sequence analysis of our sample allowed us to 
detect 59 variants already described and 6 variants never reported to date. The in 
silico analysis showed that the majority of the SNPs could be related to alterations in 
bone biology possibly resulting in bone related diseases. Two variants were selected 
for association analysis (in 225 unrelated PDB patients and 298 healthy controls) due 
to their localization and frequency - rs3829923, rs2234968. The genetic association 
study demonstrated that only rs2234968 was associated with PDB. In conclusion, 
PDB6 appears to be a good target to be analyzed and this first step was crucial to 
identify some genetic variants in these six genes that could explain the association of 
this locus with PDB. 
2.1.2 Introduction 
Paget’s disease of bone (PDB) is the second most common metabolic bone disorder, 
after osteoporosis (Kanis, 1998), affecting between 1% to 3% of individuals over the 
age of 55 years in white populations (Altman et al., 2000; van Staa et al., 2002). The 
disease is characterized by focal regions of highly exaggerated bone remodeling, with 
abnormalities in all phases of the remodeling process. The initial phase of PDB is 
characterized by excessive bone resorption in a focal region. Subsequently, bone 
formation is also markedly increased, with increased numbers of osteoblasts. The 
increased population of osteoblasts rapidly deposits new bone in a chaotic fashion so 
that the bone formed in pagetic lesions has poor quality and is disorganized. The poor 
quality of pagetic bone accounts for the bowing or even fracture of bones affected by 
PDB. As rapid bone formation predominates in the more advanced stages of PDB, the 
lesions become sclerotic, with observed replacement of the bone marrow with 
vascular and fibrous tissue and thickening of the bone (Hosking, 1981).  
The cause of PDB is currently an area of intensive investigation, and both genetic and 
non-genetic factors have been implicated in the pathogenesis of this disease. The 
possibility that heredity might play a role in the pathogenesis of PDB was first raised 
in 1948 (Montagu, 1948). Over the recent years, there has been an increasing interest 
on the role of genetic factors in the pathogenesis of the disease (Laurin et al., 2001; 
Michou et al., 2012). Another argument that favors the genetic inheritance of PDB is 
that 15–40% of affected patients have a first-degree relative with PDB, and numerous 
studies have described extended families with PDB exhibiting an autosomal dominant 
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mode of inheritance (Hocking et al., 2000; Laurin et al., 2001; Morales Piga et al., 
1995). Linkage studies in these families have identified a number of susceptibility loci 
on chromosomes 6p21 (PDB1) (Fotino et al., 1977), 18q21.1-22 (PDB2) (Haslam et 
al., 1998), 5q35 (PDB3), 5q31 (PDB4) (Laurin et al., 2001), 2q36 (PDB5) (Good et 
al., 2002), 10p13 (PDB6) (Hocking et al., 2001) and 18q23 (PDB7) (Good et al., 
2002). Moreover, a genome wide association scan (GWAS) in British PDB families 
has suggested a linkage to the 10p13 (PDB6) locus (Hocking et al., 2001; Lucas et al., 
2008). Recently, reanalysis of data from this genome wide scan confirmed a genetic 
association to PDB6 locus (Albagha et al., 2010), but no PDB causal mutation was 
reported to date in this locus, and therefore PDB6 could be a good ‘locus target’ to be 
further investigated.  
The PDB6 locus has several genes that could have a functional role in PDB, and more 
interesting, this locus is conserved in all species analyzed, from zebrafish to human, 
suggesting an evolutionary conservation in their involvement in physiological 
pathways. In this work, we thus proposed to analyze which could be the most relevant 
genes in the entire PDB6 locus to the bone biology and assess the possible 
contributions of each significant variant identified in this locus to the functionality of 
those genes and their involvement in the pathophysiology of PDB. 
2.1.3 Materials and Methods 
 Study participants  2.1.3.1
This study was approved by the CHU de Québec Ethics Committee and all 
participants have signed a consent form before inclusion in the study. Phenotype 
assessment comprised a complete bone evaluation, including total serum alkaline 
phosphatase, a total body bone scan and skull and pelvis X-rays. We investigated 
patients with familial form of PDB (one patient per family), unrelated PDB patients 
and healthy controls, all from the French-Canadian population. Clinical characteristics 
of these cohorts!were previously published (Laurin et al., 2002; Michou et al., 2011; 
Morissette et al., 2006). For each individual, peripheral blood was obtained by 
venipuncture and DNA was extracted from blood samples, as already described in 
Michou et al. (2012). All patients and healthy donors studied here were non-carrier of 
the P392L mutation within the SQSTM1 gene (PDB3 locus). RNA from total blood 
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was collected in a subset of patients and controls, on PAXgene tube (Qiagen) and 
RNA extraction was performed as previously described (Michou et al., 2012).  
 Candidate genes selection and sequencing 2.1.3.2
After screening the PDB6 locus (6721910 bp-18721437 bp), that spans approximately 
26.7 cM between markers D10S189 (19 cM) and D10S548 (45.7 cM) on chromosome 
10p13, and contains over 70 genes, we selected six candidate genes for the 
sequencing step based on their biological function, genetic mouse models and tissue 
expression data. The genes selected were genes expressed in bone cells or their 
precursors and/or those involved in the NF-κB pathway, in the proteasome pathway, 
in autophagy or apoptosis, in bone cell function and/or survival, in cellular adhesion 
(e.g. integrins), in intercellular communication (cytokines), or in the pathogenesis of 
other bone metabolic diseases. To search for variants within the PDB6 locus, the 
exons of the candidate genes, their exon–intron boundaries and the basal promoters 
were sequenced as previously described (Michou et al., 2012). Thirty samples from 
patients with PDB and five healthy controls from the French-Canadian population 
underwent Sanger sequencing, which we refer as the discovery group. For the 
association study, the SNPs rs3829923 and rs2234968 were selected to be genotyped 
in a group of 225 patients and 298 controls, based on their frequency in the discovery 
group and location in the gene. The allele frequencies were calculated as previously 
described (Michou et al., 2012).  
 Bioinformatics analysis 2.1.3.3
To identify the potential effect of the variants found in the coding regions we used the 
online translate tool Expasy (http://web.expasy.org/translate/). To search for the 
predicted deleterious effect of the variants found in the coding regions we used SIFT 
(http://siftdna.org/www/Extended_SIFT_chr_coords_submit.html), Condel 
(http://bg.upf.edu/condel/analysis), Polyphen (http://genetics.bwh.harvard.edu/pph2/) 
and Mutation taster (http://www.mutationtaster.org/) software. Potential splice sites 
were predicted for the intronic variants using the Human Splicing Finder tool 
(http://www.umd.be/HSF/). To identify transcriptional factor binding sites (TFBSs) 
for the variants located in promoter and intronic regions we used TFsearch 
(http://www.cbrc.jp/research/db/TFSEARCH.html) and Consite 
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(http://asp.ii.uib.no:8090/cgi-bin/CONSITE/consite/). To identify miRNA binding 
sites for the variants located in the 3’UTR we used miRBase (www.mirbase.org). To 
analyze the effect in the mRNA secondary structure we used RNA fold 
(http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi). To search for SNPs in linkage 
disequilibrium (LD) we used the SNAP tool 
(http://www.broadinstitute.org/mpg/snap/).  
2.1.4 Results 
 Discovery study – Variants identification in the 2.1.4.1
candidate genes 
The six best candidate genes at PDB6 locus were 1) OPTN (optineurin), 2) 
UCMA/GRP (upper zone of growth plate and cartilage matrix associated/gla-rich 
protein), 3) CAMK1D (calcium/calmodulin-dependent protein kinase ID), 4) PHYH 
(phytanoyl-CoA 2-hydroxylase), 5) CCDC3 (coiled-coil domain containing 3) and 6) 
SEPHS1 (selenophosphate synthetase 1) (Table 2.1).
Since OPTN and UCMA/GRP genes were already screened for variants in a previous 
work from our group (Michou et al., 2012), only the four later genes were analyzed. 
In this analysis, we have detected 65 genetic variants and their position is shown in 
Figure 2.1 and Table S2.1. 
 
Figure 2.1 - Representation of the candidate genes in the PDB6 locus. Candidate genes in PDB6 
locus of chromosome 10, including their names, size and orientation, are represented. The arrows 
indicate the transcription start site and orientation of each gene in the chromosome. Kb indicates the 
size in kilobases. The dotted region represents the localization of both overlapped OPTN and CCDC3 
first exons. The white * represents rs3829923, the grey * represents rs2234968 and the black * 
represents rs1561570. 
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Their respective frequency in the discovery group and in silico predicted functions are 
shown in Table S2.2 (Appendices section). Together with the previous reported 
variants in OPTN and UCMA/GRP, we found 9 variants with predicted effects on 
protein sequence, 71 variants predicted to cause the loss and/or gain of TFBSs, 35 
variants predicted to have an effect on splicing, and 50 variants predicted to cause the 
loss and/or gain of miRNA binding sites (Table S2.2). 
 Association study – Selection of the most relevant 2.1.4.2
variants found in the discovery study 
From the 65 variants found in the discovery study together with those previously 
described by our group (Michou et al., 2012), we selected rs3829923 (C/T) and 
rs2234968 (G/A) for genetic association with PDB in our French-Canadian cohort due 
to 1) the genomic localization; 2) the minor allele frequency (MAF) in the European 
population (25% and 18%, respectively) available in the dbSNP database and 3) the 
MAF obtained in our discovery sample. The variant rs3829923 was present in a large 
number of cases (MAF=43%) but it was not present in any control of our discovery 
group, which indicates that rs3829923 could be specific to PDB in our population. In 
addition, it is located in the CCDC3 first intron (which correspond to the OPTN 
promoter), and OPTN has been strongly associated with PDB. The variant rs2234968 
was present also in a large number of cases (MAF=53%) whereas the MAF reported 
in the European population is 18%. Also, this variant is located in the coding region 
of OPTN (exon 5) and could have an impact in OPTN protein. The genotypes of these 
variants were in Hardy-Weinberg equilibrium in controls (data not shown). The 
genetic association study of the two selected SNPs identified within the OPTN gene, 
demonstrated that only rs2234968 was associated with PDB (Table 2.2).  
 
Table 2.2- Genetic association analysis of the OPTN gene of the two selected 
variants in 225 unrelated PDB-affected patients and 298 healthy controls from 
the French-Canadian population. 
Variant' Minor'allele'
Minor'allele'frequency'
Uncorrected'
p3value'
Odds'
Ratio' 95%'CI'PDB$
patients$
Healthy$
controls$
rs2234968$G/A$ A$ 35%$ 25%$ 6$x$10−3$ 0.6674$ [0.50$;$0.89]$
rs3829923$C/T$ T$ 34%$ 34%$ 1$ 1.0006$ [0.76$;$1.32]$
CI#$#Confidence#Interval#
$ $  $ $ 
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2.1.5 Discussion 
In the present study, we investigated the functional role of numerous genetic variants 
within the PDB6 locus in PDB, in particular in the bone related genes that can have a 
role in PDB pathophysiology, such as OPTN. We detected 59 variants already 
reported in the NCBI database and 6 variants never reported to date. After the 
association study performed using 225 unrelated PDB affected patients and 298 
healthy controls only rs2234968 was shown to be associated with PDB. This SNP was 
selected for further studies regarding its functional effect on this bone disease. Since it 
is present in OPTN coding exon 5, we analyzed the possible effect of this variant in 
OPTN protein sequence, and the results showed that this is a synonymous variant that 
do not alter OPTN protein amino acid sequence (Table S2.2, Appendices section). 
However a more extensive work is necessary to analyze if it affects, for example, the 
interaction between OPTN and another partner protein. Also, our in silico analyses 
showed that this variant was predicted to cause an exon skipping due to a new branch 
point (Probability = 73%) (Table S2.2, Appendices section). That could be addressed 
through a PCR using cDNA from patients with both genotypes. This SNP can also 
change mRNA secondary structure and affect its stability, giving rise to lower levels 
of OPTN expression. Besides not being associated with PDB, rs3829923 functional 
effect should also be accessed, since it could give us some evidences of OPTN 
biological role and promoter activity. In this work this SNP was predicted to cause a 
change of E47, NRF2, E74A and SAP1 binding site. However transfection assays or 
functional studies such as electrophoretic mobility shift assay (EMSA) are needed to 
confirm its effect in OPTN promoter activity. In conclusion, the SNPs identified in 
this study indicate that rs2234968 is associated with PDB patients and that the 
association of PDB6 locus with PDB could be related with some of these genes that 
were shown to be involved with bone, namely with OPTN. 
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SUPPLEMENTARY TABLES 
Table S2.1 – Identification and localization of the variants found in PDB6 locus 
Gene' ID'variant' Localization'in'genome'
Localization'in'
gene'' Nucleotide'alteration''
CCDC3$T1$
rs3829923$ 13141144$ exon$2$(5'UTR)$ c.$N641$G>A$
New$variant$ 13141047$ intron$2$ c.$N581+46$N/A$
New$variant$ 13140511$ intron$2$ c.$N580N14$C>T$
rs7093805$ 13115942$ exon$4$(5'UTR)$ c.N344G>T$
rs4750306$ 13115887$ exon$4$(5'UTR)$ c.N289A>G$
rs72779542$ 13115802$ intron$4$ c.N270+66T>A$
rs61851395$ 13115776$ intron$4$ c.N270+92C>G$
rs663177$ 13091801$ intron$5$ c.$N1$+$127$A>C$
CCDC3$T2$
New$variant$ 13043228$ promoter$ g.$13043228$G>T$
New$variant$ 13042597$ intron$1$ c.$364$+$93$C>T$
rs116856516$ 12938874$ exon$3$ c.$797$C>A$
rs10752280$ 12938929$ 3'$UTR$ *$39$A>G$
CAMK1D$
rs11257730$ 12390561$ promoter$ g.12390561G>C$
rs11257731$ 12390563$ promoter$ g.12390563G>T$
rs7070092$ 12390653$ promoter$ g.12390653C>T$
rs11257733$ 12390767$ promoter$ g.12390767C>T$
rs145905575$ 12391618$ exon$1$(5'UTR)$ c$.N200$G>A$
New$variant$ 12391757$ exon$1$(5'UTR)$ c.$N61$G>A$
rs2895524$ 12595147$ intron$1$ c.$93$N$77$C>T$
rs34194224$ 12595329$ exon$2$ c.$198$A>G$
rs1077745$ 12595427$ intron$2$ c.$225$+$72$G>A$
rs1077744$ 12595443$ intron$2$ c.$225$+$88$C>T$
rs139311431$ 12833088$ intron$5$ c.$566$N$69$C>G$
rs45497595$ 12833270$ intron$6$ c.$641$+$38$G>A$
rs1644417$ 12858372$ intron$8$ c.$833$+$45$T>C$
rs1644418$ 12858409$ intron$8$ c.$833$+$82$A>G$
rs2482023$ 12866356$ intron$8$ c.$834$N$108$A>C$
rs12768271$ 12866366$ intron$8$ c.$834$N$98$C>G$
rs1757051$ 12867598$ exon$10$ c.$948$C>G$
rs2482075$ 12870714$ intron$10$ c.$1039$N$54$A>G$
PHYH$T1$
rs732704$ 13341889$ promoter$ g.$13341889$G>C$
rs511959$$ 13341836$ promoter$ g.$13341836$C>G$
rs608353$ 13341809$ promoter$ g.$13341809$A>C$
rs732701$ 13341731$ exon$1$(5'UTR)$ c.$N102$T>C$
rs1058596$ 13341579$ exon$1$(5'UTR)$ c.$50$C>G$
rs3802587$ 13341493$ exon$1$(5'UTR)$ c.$135$C>T$
rs3802586$ 13341378$ intron$1$ c.$208$+$42$G>A$
PHYH$T2$
rs36143400$ 13342902$ promoter$ g.$13342902$G>A$
rs4615920$ 13342654$ promoter$ g.$13342654$T>C$
rs72781364$ 13342538$ promoter$ g.$13342538$G>A$
rs72781363$ 13342401$ promoter$ g.13342401$C>T$
rs76403928$ 13340375$ intron$1$ c.$75$N$130$A>C$
rs10796054$ 13340339$ intron$1$ c.$75$N$94$C>T$
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rs7916926$ 13340293$ intron$1$ c.$75$N$48$T>C$
rs28938169$ 13340236$ exon$2$ c.$84$C>T$
rs72781358$ 13337699$ intron$2$ c.$134$N$93$C>T$
rs1747682$ 13337588$ exon$3$ c.$152$C>T$
rs473407$ 13330402$ exon$6$ c.$636$A>G$
rs7900830$ 13330291$ intron$6$ c.$678$+$69$C>A$
rs78560997$ 13330194$ intron$6$ c.$678$+$166$A>G$
rs648173$ 13325946$ intron$6$ c.679N107G>A$
rs62619919$ 13325784$ exon$7$ c.734G>A$
rs12411977$ 13320555$ intron$8$ c.$964$N$101$A>G$
rs11133$ 13320236$ exon$9$(3'UTR)$ *$65$G>A$
SEPHS1$
rs61851599$ 13390511$ promoter$ g.$13390511$G>A$
New$variant$ 13387154$ intron$1$ c.$N78$N125$A>G$
ESP_10_13386978$ 13386978$ exon$2$(5'UTR)$ c.$N$28$G>A$
rs2275128$ 13378445$ intron$3$ c.$298N95$T>C$
rs62641683$ 13378273$ exon$4$ c.$375$C>G$
rs2275129$ 13378181$ intron$4$ c.$405+62$G>C$
rs10752297$ 13375906$ exon$5$ c$.471$A>G$
rs61851591$ 13371855$ intron$5$ c.$561N67$G>T$
rs3740211$$ 13370315$ intron$7$ c.$751+36$G>A$
rs62641685$ 13364914$ exon$8$ c.$885$G>C$
rs10906347$ 13361421$ intron$8$ c.965N65G>A$
T1#$#Transcript#1#
$ $ $T2#$#Transcript#2#
$ $ $!
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3.1 Functional study of OPTN promoter variants 
found in Paget’s disease of bone patients 
Iris A.L. Silva 
Natércia Conceição 
Laëtitia Michou * 
M. Leonor Cancela * 
This chapter was submitted as a research paper for publication. 
 
3.1.1 Abstract 
Optineurin (OPTN) is a gene located in chromosome 10 that has been associated with 
several pathologies, including Paget’s disease of bone (PDB). OPTN is an important 
protein for several biological mechanisms such as membrane trafficking, maintenance 
of the Golgi complex, autophagy, and it seems to be part of the TNFα pathway. 
However little is known about the role of this gene in bone and how this gene is 
regulated. Using DNA samples from our cohort of PDB patients we found two SNPs 
in OPTN promoter that could alter OPTN expression and give new insights about 
OPTN regulation - rs3829923 (already described in the previous chapter) and RV -
9906 (a rare variant found in one PDB patient, described in a previous work from our 
group (Michou et al. 2012). By using a luciferase assay our results showed that 
rs3829923 T allele increases OPTN promoter activity due to a gain of E47 and E2F1 
excitatory effect, and the rare variant RV -9906 was responsible for an increase of 
OPTN promoter activity due to a loss of SP1 inhibitory effect. In conclusion, our 
 
Authors’ roles: Study design: MLC/0 and NC. Study conduct: IALS. Data collection: IALS.
 Data analysis: IALS and NC. Data interpretation: All authors. Drafting manuscript: IALS. Revising 
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work clarified the functional effect of these variants found in OPTN gene of PDB 
patients and how these variants could contribute to PDB pathophysiology. 
 
3.1.2 Introduction 
Optineurin (OPTN) is a very important protein for mechanisms such as membrane 
trafficking, maintenance of the Golgi complex and autophagy. In addition it seems to 
be part of the TNFα pathway. It is located in chromosome 10 in the positive strand 
and contains 4 non-coding exons and 13 coding exons, giving rise to 10 different 
transcripts due to splicing mechanisms (Michou et al., 2012). It encodes a 67-kDa 
cytoplasmic protein also called FIP-2 (14.7K-interacting protein 2) (Li et al., 1998) or 
NRP (NEMO-related protein) (Schwamborn et al., 2000) that contains several 
putative protein domains including a NEMO-like domain, multiple coiled-coil motifs, 
at least one leucine zipper, an ubiquitin-binding domain (UBD), a microtubule 
associated protein 1 light chain 3 (LC3)-interacting motif (LIR) (Wild et al., 2011b), 
and a carboxyl-terminal C2H2 type of zinc finger (Hattula and Peränen, 2000; Li et 
al., 1998; Schwamborn et al., 2000). OPTN mutations have been associated with 
normal tension glaucoma, a subtype of primary open-angle glaucoma, amyotrophic 
lateral sclerosis, Alzheimer’s disease, Parkinson’s disease, Creutzfeldt–Jakob disease, 
and Pick’s disease (Maruyama et al., 2010; Osawa et al., 2011). In addition, OPTN 
mutations were identified as one of the genetic risk factor for Paget’s disease of bone 
(PDB) (Albagha et al., 2010; Chung et al., 2010). PDB is the second most common 
bone disease after osteoporosis and it is characterized by the disruption of the balance 
between bone formation and bone resorption, leading to bone deformities (Ankrom 
and Shapiro, 1998).  
The role of OPTN in PDB (or in bone metabolism) is not fully known yet, however 
some groups suggest that the interaction of OPTN and TAX1 may explain this 
association. TAX1 has been known to bind NEMO, a cytoplasmic protein involved in 
NF-κB pathway, triggering the activation of IKKα and IKKβ (Chu et al., 1999; Harhaj 
and Sun, 1999; Jin et al., 1999) and in turn the activation of NF-κB in the nucleus. 
Since OPTN is highly similar to NEMO, it could be also capable of activating NF-κB 
pathway by interacting with TAX1.  
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Regarding the mechanisms of transcriptional regulation of human OPTN gene, the 
data available indicates that OPTN can be induced by tumor necrosis factor α (TNFα), 
NF-κB and IFNγ (Sudhakar et al., 2013, 2009), however the region analyzed was 
localized between exon 1 and exon 2. The first non-coding exon of OPTN was only 
described in 2012 (Michou et al., 2012) and therefore there might be unidentified 
regulators of OPTN promoter activity that are upstream of OPTN first transcription 
start site.  
In this work we analyze the functional effect of two variants - rs3829923 and RV -
9906 -, located in OPTN promoter and discovered in a screening using DNA from 
PDB patients (Silva et al., unpublished results; Michou et al., 2012). By using an in 
silico approach we analyzed the putative transcription factors binding sites (TFBSs) 
located in those variants and studied their effect in OPTN basal promoter activity, 
unraveling new potential OPTN regulators.  
3.1.3 Materials and Methods 
 Bioinformatics analysis 3.1.3.1
To search for putative TFBSs, we used TFsearch 
(http://www.cbrc.jp/research/db/TFSEARCH.html), Consite (Sandelin et al., 2004) 
and Genomatix MatInspector (Cartharius et al., 2005), the last with the default 
settings for the core and matrix similarity of 0.85. Two sequences of 1.2 kb spanning 
the regions between -309 bp and +846 bp, relative to the transcription initiation, that 
possesses both variants was used for this analysis. The TFBSs were confirmed using 
the data available in the ENCODE project (http://www.genome.gov/encode/). 
 Plasmid constructions 3.1.3.2
Four fragments of the OPTN promoter were amplified from human genomic DNA 
using four different sets of primers. A 1.2 kb fragment of the OPTN promoter ranging 
from -308 to +832 (related to the transcription start site) of the OPTN gene was 
amplified from human genomic DNA, using the primer set rs3829923 F1/R1 (Table 
S3.1). A point mutation, corresponding to the T allele of rs3829923 (position -305), 
was generated by PCR using the forward primer rs3829923 F2 (Table S3.1) and the 
same reverse primer. A 1.1 kb DNA fragment of the OPTN promoter ranging from -
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241 to +832 was also amplified from human genomic DNA using the primer set RV -
9906 F1/R1 (Table S3.1). A point mutation corresponding to the A allele of RV 
−9906 (position -232), was generated by PCR using a different primer forward (RV -
9906 F2; Table S3.1) and the same primer reverse. The amplified PCR products were 
cloned into pCRII TOPO (Invitrogen) and the fidelity of the sequence was confirmed 
by DNA sequencing. The PCR products were then cloned between the XhoI and KpnI 
sites of the pGL3-basic luciferase reporter gene vector (Promega) giving rise to 
construct F1 (corresponding to rs3829923 C allele), construct F2 (corresponding to 
rs3829923 T allele), construct F3 (corresponding to RV -9906 G allele), and construct 
F4 (corresponding to RV -9906 A allele). All constructs were confirmed by DNA 
sequencing. 
 Cell culture conditions 3.1.3.3
The human embryonic kidney HEK293 cell line was grown in Dulbecco's modified 
eagle medium (DMEM), supplemented with 10% fetal bovine serum (FBS), 2mM L-
glutamine and 1% penicillin/streptomycin (P/S). The cells were incubated at 37oC in a 
humidified atmosphere containing 5% CO2. The medium, FBS, antibiotics and 
glutamine were obtained from Invitrogen. 
 Cell transfections 3.1.3.4
HEK293 cells were plated on 24 well plates (5 x 104 cells/well) and then were 
transiently transfected using XtremeGENE HP (Roche), with 250 ng of OPTN 
reporter gene rs3829923 C allele (F1), rs3829923 T allele (F2), -9906 G allele (F3), -
9906 A allele (F4), or empty reporter vector (pGL3-basic). A renilla luciferase 
reporter (Promega), 25 ng/well, was used as control for transfection efficiency. Co-
transfection of an additional expression construct (50 ng) was performed using a 
similar approach. 48h after transfections, the cells were lysed and luciferase activity 
was assayed using a Dual-luciferase Reporter Assay kit in accordance with the 
manufacturer's instructions (Promega). All luciferase activities were normalized to the 
Renilla luciferase reporter pRL-TK Luc plasmid (Promega). All experiments were 
repeated at least three times. The SP1 expression plasmid and the RXR expression 
plasmids was the generous gift of Dr.!Roland Schüle (Freiburg, Germany), the E47 
expression plasmid was a generous gift from Dr. Xiao-Hong Sun (New York, USA), 
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the E2F family expression plasmids were a generous gift from Dr. Lieve Verlinden 
(Leuven, Belgium), and the SAP1 expression plasmid was a generous gift from Dr. 
Ralf Janknecht (Oklahoma, USA). 
 Preparation of human in vitro differentiated 3.1.3.5
mature osteoclasts  
Human mature osteoclasts were differentiated in vitro using mononuclear cells from 
blood of patients with PDB. Peripheral blood mononuclear cells (PBMCs) were 
obtained by density gradient centrifugation using Ficoll-Hypaque. The cells were 
resuspended (3x106 cells/mL) in OPTI-MEM (Life Tecnhologies) containing 10% 
FBS. The cell suspension was added to 6-well plates (9x106 cells/well) and to Lab-
Tek 8 well-slides (Sigma-Aldrich) (3-6x105 cells/well). After 24h, the cells were 
washed thoroughly and lymphocyte-free adherent cells were incubated for three 
weeks with M-CSF (25 ng/mL, Life technologies) and RANKL (30 ng/mL, 
Fitzgerald). 
 Western blot analyses 3.1.3.6
Osteoclasts derived from patients and controls PBMCs were washed once in PBS and 
lysed using Trizol (Sigma-Aldrich). The protein concentrations were determined 
using the Bradford reagent (Bio-Rad). Proteins were separated by 8 % SDS-
polyacrylamide gels and transferred onto PVDF membranes (Life technologies). After 
transfer, the membranes were blocked in 0.1 % TBS/Tween 20 containing 5 % nonfat 
dried milk at room temperature (RT) for 1'h. The membranes were then incubated 
overnight (ON) at 4 °C with anti-OPTN (1:500, #100000 Cayman), or anti-αTubulin 
(1:2000, #2144 Cell Signaling) in 0.1 % TBS/Tween 20, followed by extensive 
washing using 0,1% TBS/Tween 20 and an incubation with HRP-conjugated 
secondary antibody (1: 2000, Cell signaling) in 0.1 % TBS/Tween 20 during 1h, at 
room temperature. After extensive washing with 0.1 % TBS/Tween 20, specific 
proteins were detected using a chemiluminescence kit (GE Healthcare). The 
densitometric analysis was performed using ImageJ software. 
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 Statistical analyses 3.1.3.7
All data were expressed as means ± standard deviation of measurements from at least 
three independent experiments. Comparisons between two groups were made using a 
two-tailed Student’s t-test. For comparisons between multiple groups, one-way 
ANOVA followed by Tukey’s post-hoc test was used. Differences were considered 
statistically significant when p-value < 0.05. 
3.1.4 Results 
 In silico prediction of transcription factor binding 3.1.4.1
sites in OPTN promoter 
In order to explore the functional effect of the OPTN promoter SNPs, we searched for 
TFBSs that could be potentially interrupted by these variants, using the online tools 
Consite and TFSearch. Rs3829923 is a variant localized in OPTN promoter that 
causes a change from a C to a T allele (Figure 3.1A) that was described in a previous 
work (Silva et al., unpublished results). The bioinformatics software predicted the 
putative binding sites for SAP1, NRF2, E74A, and E2F family in the region of the 
rs3829923 carrying the C allele, and which are lost in the presence of the T allele. On 
the other hand, in the presence of the T allele the software predicted the putative 
binding site for E47 transcription factor (Figure 3.1B).  
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Figure 3.1 – In silico prediction of the effect of rs3829923. A) rs3829923 localization in OPTN gene 
showing that this variant is present in OPTN promoter and is responsible for a change from a C to a T. 
B) Bioinformatics prediction showing putative binding sites for NRF2, SAP1, E74A and E2F in the 
presence of the C allele, and a E47 putative binding site in the presence of rs3829923 T allele.   
 
Finally, we assessed the effect of OPTN RV -9906 G/A (Figure 3.2A) polymorphism 
previously reported in OPTN promoter activity (Michou et al., 2012). The in silico 
analysis revealed that SP1, PAX4 and RXR binding sites are potentially interrupted 
by -9906 A allele, possibly resulting in loss of their binding efficiency as compared 
with the -9906 G allele. In addition, putative binding sites for HNF4 and PPAR were 
identified only in the presence of the A allele (Figure 3.2B). 
F1     accacaccaactcgagggcccggaattgggtctggggcagt 
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Figure 3.2 – In silico prediction of the effect of RV -9906. A) RV -9906 localization in OPTN gene 
showing that this variant is present in OPTN promoter and it is responsible for a change from a G to a 
A. B) Bioinformatics prediction shows the presence of PAX4, SP1, and RXR putative binding sites in 
the presence of the RV -9906 G allele and the presence of HNF4 and PPAR putative binding sites in 
the presence of RV -9906 A allele. TSS1 represents the first transcription start site and TSS2 represents 
the second transcription start site. 
 Functional analysis of rs3829923 in OPTN 3.1.4.2
promoter 
To analyze the functionality of the cloned constructs we performed a luciferase assay 
in HEK293 cells. The results showed an increase in OPTN promoter activity in 
construct F2 (carrying the T allele) when compared to construct F1 (carrying the C 
allele) (Figure 3.3).  
F3     tggggttagcctcaggggcagggttgagagtcaggcttggc 
F4     tggggttagcctcaggggcagagttgagagtcaggcttggc 
A"
B"
RV"&9906"
G! G!
TSS1"TSS1"
RV"&9906"
A! A!
TSS1"TSS1"
PAX4"
RXR"
SP1"
PPAR"
HNF4"
*"RV"&9
906"
OPTN%
TSS1" TSS2"
CHAPTER(3(–(FUNCTIONAL(STUDY(OF(rs3829923(AND(RV(:9906(
!69!
 
Figure 3.3 - rs3829923 effect in OPTN basal promoter activity. Transient transfections of HEK293 
cells showing that the F1 construct (rs3829923 T allele) had a significantly higher activity than the 
construct F2 (rs3829923 C allele). Data are mean ± SD of at least three independent experiments. 
Significance was determined by one-way Anova. Asterisk *** represents a p-value < 0.001. **** 
indicates that the two constructs used are significantly different from the promoter less vector pGL3-
basic (p-value < 0.0001). 
 
The cells were then transfected with the F1 construct (carrying the C allele) or the F2 
construct (carrying the T allele) together with the transcription factors (TFs) predicted 
in the in silico analysis. The co-transfection of F1 construct with E47 showed no 
effect of this TF when a C allele is present. The co-transfection of F2 construct 
together with E47 showed a significant increase in OPTN promoter activity, 
suggesting that E47 has a potentiating effect only when the T allele is present. (Figure 
3.4A). These results confirm our in silico analysis. SAP1 seemed not to have a 
significant effect in both constructs used (Figure 3.4B). The presence of E2F3 resulted 
in a significant increase in reporter activity compared to the transfection conditions 
without the TF (p-value < 0.0001) in both constructs. However, in the presence of 
E2F1 there was an increase in OPTN promoter activity only when using F2 construct 
(Figure 3.4C). E2F2, E2F4 and E2F5 had no effect in both constructs used (Figure 
3.4C).  
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Figure 3.4 – Effect of E47, SAP1 and E2F family in OPTN promoter activity. A) Co-transfection 
assays showing that F2 construct (carrying the T allele) had a significant increase of luciferase 
expression, in the presence of E47 not observed with F1 construct (carrying the C allele. B) Co-
transfection with SAP1 revealed that this transcription factor does not have an effect in the presence of 
rs3829923 C or T alleles. C) Co-transfection assays showing that E2F3 have an activating effect in both 
F1 and F2 and that F2 (T allele) had a significant increase of luciferase expression in the presence of 
E2F1 that was not observed with F1, indicating that the effect of E2F1 is specific of the T allele. EF2, 
EF4 and EF5 did not have a significant effect on both constructs. Data are mean ± SD of at least three 
independent experiments. Significance was determined by one-way Anova. Asterisk * indicates a p-
value = 0.01; **** indicates a p-value < 0.0001. 
 
These results indicate that E47 and E2F1 only have an effect in the presence of the T 
allele while E2F3 has an effect in OPTN promoter but that effect is independent of 
rs3829923 C/T variant. Actually, E2F family have three additional putative binding 
sites in OPTN gene fragment used in transfection that could also contribute to explain 
that effect (Figure 3.5). 
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Figure 3.5 – E2F binding sites in F1 and F2 constructs. The in silico analysis performed using 
constructs F1 and F2 shows that E2F family have three more putative binding sites that can explain 
E2F3 effect in the constructs used. TSS1 represents the first transcription start site. TSS2 represents the 
second transcription start site. The length of each construct is represented above each construct in 
kilobases (kb).  
 
In order to access if this positive effect of rs3829923 T allele in OPTN promoter 
activity was translated into an increase in OPTN expression in patients cells, we 
performed a western blot analysis using osteoclasts derived from PDB patients 
peripheral blood mononuclear cells (PBMCs) that were differentiated in vitro as 
described in the material and methods section. However, the in vitro effect seen in the 
transfection assay was not reproduced in patients’ osteoclasts, since the presence of 
rs3829923 T allele did not affect the OPTN protein levels (Figure 3.6). 
 
Figure 3.6 - rs3829923 effect in OPTN protein expression. Analysis of OPTN protein expression in 
PBMCs-derived osteoclasts from non-mutated patients (CC) (n=2) and one patient homozygous for 
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rs3829923 (TT). Data are mean ± SD of at least three independent experiments. Significance was 
determined by a two-tailed Student’s t-test. 
 
 Functional analysis of the rare variant RV -9906 3.1.4.3
in OPTN promoter 
The transient transfections of HEK293 cells with constructs F3 and F4 showed that 
the construct with the G allele (construct F3) had a significantly lower activity than 
the construct with the A allele (construct F4) (Figure 3.7).  
 
Figure 3.7 - RV -9906 effect in OPTN basal promoter activity. Transient transfections of HEK293 
cells showing that the F3 construct (carrying RV -9906 A allele) had a significantly higher activity than 
the F4 construct (carrying the RV -9906 G allele). Data are mean ± SD of at least three independent 
experiments. Significance was determined by one-way Anova. Asterisk *** represents a p-value < 
0.001. **** indicates that both constructs are significantly different from the promoter less vector 
pGL3-basic (p-value < 0.0001). 
 
These results suggest that the presence of the A allele (F4 construct) increases the 
transcriptional activity of the OPTN gene. By transient co-transfections we showed 
that SP1 reduces luciferase expression only in the presence of the F3 construct (G 
allele) (Figure 3.8A), indicating that the effect obtained is specific for the construct 
containing the G allele.  
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Figure 3.8 – Effect of SP1 and RXR in OPTN promoter activity. A) Transient co-transfections of 
HEK293 cells showing that F3 construct (containing the G allele) had a significant inhibition of 
luciferase expression, in the presence of SP1 not observed with the F4 construct (containing the A 
allele). B) Co-transfections with RXR revealed that this transcription factor had an inhibitory effect in 
the presence of F3 and F4. Data are mean ± SD of at least three independent experiments. Significance 
was determined by one-way Anova. Asterisk * indicates that each construct (F3 and F4) transfected 
with RXR and its ligand (retinoic acid (RA)) is significantly different from their controls (p-value < 
0.05). Asterisk **** indicates that all the construct used are significantly different from the 
promoterless vector pGL3-basic (p-value < 0.0001) 
 
After co-transfections of HEK293 cells with F3 and F4 constructs and with RXR, we 
observed a decrease in OPTN promoter activity with both constructions when the cells 
were treated with the RXR ligand retinoic acid (RA) (Figure 3.8B), which indicates 
that, in fact, RXR has a binding site in OPTN promoter but that binding is not altered 
with RV -9906 G/A variant. Actually, RXR has two additional putative binding sites 
in OPTN gene fragment used in these transfection assays that could also contribute to 
that effect (Figure 3.9).  
The effect of RV -9906 in OPTN protein levels was not assessed in the PBMCs from 
PDB patients because this rare variant was present in one unique PDB patient that was 
lost to follow up. 
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Figure 3.9 – RXR binding sites in F3 and F4 constructs. The in silico analysis performed using 
constructs F3 and F4 sequences shows that RXR have two more putative binding sites that can explain 
the complex RXR/RA effect in the constructs used. TSS1 represents the first transcription start site. 
TSS2 represents the second transcription start site. The length of each construct is represented above 
each construct in kilobases (kb).  
 
3.1.5 Discussion  
In the present study we analyzed two variants in OPTN promoter that were found in a 
previous work using a group of 30 familial cases of PDB and 5 healthy controls. One 
- rs3829923 - was found in 15 cases and not found in any of the controls, the other - 
RV -9906 - was a rare variant found in one unique PDB patient. Since these variants 
were located in OPTN promoter it was hypothesized that they could alter OPTN 
expression and in that case its functional study would potentially unravel new OPTN 
regulators. Rs3829923 was shown to increase OPTN promoter basal activity and 
following co-transfections, we concluded that E47 and E2F1 have an excitatory effect 
only in the F1 construct (carrying the C allele). E47 is a member of bHLH family and 
it was described as important for osteoclast maturation and survival (Long et al. 
2012). Therefore the gain of a E47 binding site could explain the PDB phenotype 
since it might be related to an increase in osteoclast survival, giving rise to PDB 
features. E2F1 has been associated with osteoblast differentiation and mineralization 
(Yu et al., 2013), and cell proliferation (Berman et al., 2008), which may partially 
explain the deregulation in the number of osteoblasts (and also osteoclasts) in this 
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disease. We also analyzed a rare variant found in the OPTN promoter (RV -9906) in a 
unique PDB patient (Michou et al., 2012). Following co-transfections in HEK293 
cells with the OPTN promoter carrying either the G or the A allele with SP1 and RXR 
TFs, we were able to conclude that RV -9906 was in fact responsible for a loss of SP1 
inhibitory effect whereas it did not alter the RXR effect. Polymorphisms occurring in 
SP1 binding sites were previously associated with changes in bone mineral density 
and osteoporosis (Grant et al., 1996) and SP1 was already described as an important 
regulator for bone related genes, like NF-κB (Liu et al., 2005) and BMP2 (Xu and 
Rogers, 2007). SP1 seems to be an important regulator of OPTN promoter, since a 
single alteration in its sequence changed its activity probably due to a loss of SP1 
binding site. Taking into account our results on the inhibitory effect of SP1 in RV -
9906 G allele and the activating effects of E47 and E2F1 in rs3829923 T allele - 
giving rise to higher levels of OPTN expression - and the fact that OPTN was 
described as an important protein for the degradation of NF-κB inhibitor IκB (Journo 
et al., 2009), our hypothesis is that in normal conditions SP1 binds to OPTN promoter 
inhibiting its activity, giving rise to “normal” levels of OPTN expression. With RV -
9906 A allele this binding site is removed, increasing the OPTN promoter activity, 
which will increase the expression of OPTN in this PDB patient. E47 and E2F1 only 
bind to OPTN promoter increasing its activity when the rs3829923 T allele is present, 
giving rise to higher levels of OPTN expression. An increase in OPTN expression by 
these mechanisms will give rise to an increase in NF-κB in the nucleus and a 
consequent increase in osteoclastogenesis-related genes transcription, explaining the 
PDB phenotype (Figure 3.8).  
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Figure 3.8 - Hypothetical functional effect of rs3829923 and RV -9906 in PDB. A) In the presence 
of the non-mutated allele in each position there is a decrease in OPTN promoter activity due to the 
inhibitory effect of SP1 in RV -9906. This leads to a decrease in OPTN expression levels, and since 
OPTN is related with the translocation of NF-κB to the nucleus that will give rise to lower levels of 
osteoclastogenesis related genes transcription. B) In the presence of the A allele in RV -9906 the 
inhibitory effect of SP1 is lost and therefore there is an increase in OPTN expression. In the presence of 
the T allele in rs3829923 there is a new binding site for E2F1 and E47, which will also increase OPTN 
expression. An increase in OPTN expression will favor the translocation of NF-κB to the nucleus and 
the transcription of genes important for osteoclastogenesis, explaining the PDB phenotype that is 
characterized by an increase in the number of osteoclasts. 
 
To extend this analysis of the variants in OPTN promoter an electrophoretic mobility 
shift assay (EMSA) should be performed in order to confirm if in fact SP1, E47 and 
E2F1 are binding to the cloned promoters. A chromatin immunoprecipitation assay 
(CHIP) could also be performed aiming at providing additional data to confirm the 
presence of these bona fide TFBSs in vivo. In addition, to clarify the role in PDB of 
the promoter variants identified in this study and its effect in osteoclastogenesis, it 
would be of interest to do in vitro site directed mutagenesis and develop osteoclast 
precursor isogenic cell lines with and without the mutations, aiming at replicating the 
expression of the two identified transcript variants and analyzing its effect in the 
number and activity of resulting osteoclasts.  
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4.1.1 Abstract 
PDB6 locus was linked to Paget’s disease of bone (PDB) in previous works and it 
contains at least six candidate genes for metabolic bone diseases such as PDB. In our 
previous work we screened OPTN, PHYH, UCMA, SEPSH1, CAMK1D, and CCDC3 
and performed an association study to the most important variants found. From the 
ones selected only rs2234968 was found to be associated with PDB. Also, the 
common variant rs1561570, within the OPTN gene, was previously shown to be 
strongly associated with PDB in several populations but no functional studies were 
available to this date. Therefore we aim to unravel the functional effects of these two 
PDB associated variants in OPTN expression and PDB pathophysiology. Rs2238968 
functional effect may be explained by rs10906303 and rs79529484, found to be in 
linkage disequilibrium with this SNP. Both SNPs were predicted to create new 
CHAPTER(4(–(FUNCTIONAL(STUDY(OF(rs2234968(AND(rs1561570(
!80!
acceptor splice sites that may give rise to predicted truncated proteins, probably non-
functional. In this study we also showed that the C allele of rs1561570 was 
methylated, and it was also responsible for lower levels of OPTN gene expression 
when compared to the non-methylated T allele. In addition, we showed that patients 
with the T allele and cells treated with a demethylating agent have higher rate of 
translocation of NF-κB to the nucleus and higher expression levels of its target genes 
(such as NFATc1 and IL-6). The patient carriers of the T allele also presented a higher 
osteoclast differentiation rate, and osteoclasts with a higher number of nuclei and 
higher bone resorbing capacity. All together, these results show that higher levels of 
OPTN can give rise to higher levels of NF-κB in the nucleus, increasing the 
expression of its target genes expression, which may explain OPTN contribution to 
PDB. In conclusion, our work clarified the functional effect of rs1561570 and 
rs2234968 within OPTN gene in PDB, giving a new perspective about OPTN variants 
and also indicative of a new role of OPTN in bone biology. 
4.1.2 Introduction 
Paget’s disease of bone (PDB) is one of the most frequent metabolic bone disorders 
(Kanis, 1998), affecting between 1% and 3% of individuals over the age of 55 years 
in Caucasians (Altman et al., 2000; van Staa et al., 2002). Both genetic and non-
genetic factors have been implicated in this disease. Around 15–40% of affected 
patients have a first-degree relative with PDB, and numerous studies have described 
extended families with PDB exhibiting an autosomal dominant mode of inheritance 
(Hocking et al., 2000; Laurin et al., 2001; Morales Piga et al., 1995). Recently, a 
genome wide scan in British families with PDB has shown a linkage to the 10p13 
(PDB6) locus (Albagha et al., 2010; Hocking et al., 2001; Lucas et al., 2008), 
however no PDB causal mutation has been reported to date in this locus. A hot-spot in 
the GWAS that linked PDB6 locus to PDB was localized in the vicinity of a genetic 
variant located in the Optineurin (OPTN) gene (Albagha et al., 2010). OPTN gene 
was previously linked to glaucoma (Rezaie et al., 2002) and neurodegenerative 
diseases like Alzheimer’s disease, Parkinson’s disease or amyotrophic lateral sclerosis 
(Osawa et al., 2011). Besides further replicating the strong and statistically significant 
genetic association within the OPTN gene of rs1561570 (p-value = 5.65×10−7) with 
PDB in the French-Canadian population (Michou et al., 2012), our group also 
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identified a functional SNP in OPTN exon 5 with no predicted effect in the protein 
sequence but highly associated with PDB (p-value = 6 x 10−3), already described in 
chapter 2. OPTN biological role is not yet fully understood but OPTN seems to be 
involved in NF-κB pathway (Agou et al., 2004). This protein contains several putative 
domains including a NEMO-like domain, that is present in proteins that are part of 
IκB kinase (IKK) complex (Ying and Yue, 2012). IKK modifies the inhibitors of NF-
κB transcription factor promoting their degradation. The free NF-κB molecules can 
then enter the nucleus where they activate specific target genes (Agou et al., 2004; 
Bianchi and Meier, 2009). Also, recently, OPTN was characterized as an autophagy 
adaptor protein, which regulates selective autophagy of ubiquitin-coated cytosolic 
Salmonella enterica. This function depends on the phosphorylation of its LC3-
interacting motif by TANK-binding kinase 1 (TBK1) (Wild et al., 2011b). However, 
little is known about OPTN role in the autophagy-mediated degradation of misfolded 
protein inclusions. In this work, we thus proposed to assess the relative contributions 
of the most associated variants identified in the PDB6 (10p13) locus associated to the 
functionality of OPTN located in this locus and their involvement in the PDB 
physiopathology. 
4.1.3 Materials and Methods 
 Methylation analysis by bisulfite conversion and 4.1.3.1
Sanger sequencing of rs1561570 
To analyze if rs1561570 was changing the methylation status we used the MethPrimer 
(http://www.urogene.org/methprimer/index1.html), an in silico tool used to predict 
CpG island by examining the CG dinucleotides and to design specific primers to 
analyze those CpG islands. Sodium bisulfite treatment was performed on 1,5 µg of 
genomic DNA sample using the EpiMark® Bisulfite Conversion Kit (New England 
Biolabs Inc) following the manufacturers’ standard protocol. DNA samples from 130 
PDB patients and 225 healthy individuals (with CT and CC genotypes of rs1561570) 
were bisulfite converted, with fully-methylated (methylation level of 100%) and 
unmethylated DNA (0% methylation) samples as controls. The samples with 
incomplete bisulfite conversion were discarded from this analysis. Bisulfite-PCR 
amplification was conducted using Taq DNA polymerase and cycling conditions of 
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45 cycles with an annealing temperature of 56°C. The primers used (Rs1561570 
Bisulfite F and Rs1561570 Bisulfite R; Table S3.1) amplify a region of 267 bp around 
the rs1561570 genomic position. Methylated cytosine was detected by Sanger 
sequencing of the PCR products. 
 Cell culture conditions 4.1.3.2
The U937 and HEK293 cell lines were grown in Dulbecco's modified eagle medium 
(DMEM), supplemented with 10% fetal bovine serum (FBS), 2mM L-glutamine and 
1% penicillin/streptomycin (P/S). The T47D cell line was grown in RPMI-1640 
medium supplemented with 10% FBS, and 1% P/S. The medium, FBS, antibiotics 
and glutamine were obtained from Invitrogen. Both cell lines were incubated at 37oC 
in a humidified atmosphere containing 5% CO2.  
 Demethylating treatment and 4.1.3.3
immunofluorescence 
The localization of NF-κB in T47D and U937 cell lines treated for 72h with 5-
Azacitidine (5-Aza) (Sigma) and in osteoclasts derived from controls and patients 
PBMCs was assessed by immunofluorescence. The cells were washed with phosphate 
buffered saline (PBS), fixed with 4% paraformaldehyde, and permeabilized in PBS 
containing 0.1% Triton 100 for 4 min. Non-specific binding was blocked by 
incubating the cells with PBS supplemented with 0.5% FBS and 0.5% bovine serum 
albumin (BSA) for 30 min at RT. Cells were then incubated ON at 4oC with a rabbit 
polyclonal antibody directed against human NF-κB (#8242, Cell Signaling). A rabbit 
polyclonal antibody against LC3B (#2775, Cell Signaling) was also used in PDB 
patients’ osteoclasts to access effects in autophagy. After rinsing with PBS, the cells 
were incubated with the secondary antibody Alexa 488 (green) or Alexa 594 (red) 
goat anti-rabbit (Cell signaling), in 0.5% BSA-PBS for 45 min. The microscope slides 
were rinsed and mounted with the mounting medium for fluorescence.  
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 Preparation of human in vitro-differentiated 4.1.3.4
mature osteoclasts  
Human mature osteoclasts were differentiated in vitro using mononuclear cells from 
blood of healthy controls and patients with PDB. PBMCs were obtained by density 
gradient centrifugation using Ficoll-Hypaque. The cells were resuspended (3x106 
cells/mL) in OPTI-MEM (Invitrogen) containing 10% FBS. The cell suspension was 
added to 6-well plates (9x106 cells/well) and to Lab-Tek 8 well-slides (Sigma-
Aldrich) (3-6x105 cells/well). After 24h, the cells were washed thoroughly and 
lymphocyte-free adherent cells were incubated for three weeks with M-CSF (25 
ng/mL, Life Technologies) and RANKL (30 ng/mL, Fitzgerald). 
 Osteoclast morphology assessment and TRAP 4.1.3.5
assay 
Mature osteoclast formation was evaluated by quantification of TRAP-positive 
multinuclear cells using an Acid Phosphatase kit (Sigma-Aldrich), according to the 
manufacture’s recommendations. Briefly, after fixation, the cells were stained for acid 
phosphatase in the presence of 0.05 M sodium tartrate. The substrate used was 
napthol AS-BI phosphate. TRAP-positive and TRAP-negative cells were counted in 
at least 5 random fields using light microscopy. 
 In vitro assessment of bone resorption  4.1.3.6
The bone resorption activity of osteoclasts was tested in vitro, using a previously 
validated model (Itzstein et al., 2000). Briefly, monocytes were seeded onto cortical 
bone slices and differentiated as described previously. At the end of the culture, cells 
were removed and bone slices were stained with toluidine blue to score the percentage 
of bone resorbed area. Bone resorption was evaluated using ImageJ by doing the ratio 
of the total bone resorbed area versus the total bone slice area. 
 Quantitative real-time PCR 4.1.3.7
In order to test if the most strongly associated SNPs had an impact on OPTN gene 
expression, we performed qPCR as previously described (Michou et al., 2012). To 
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analyze rs2234968, we used RNA from PBMCs of six patients and three healthy 
donors and to analyze rs1561570, we used RNA from PBMCs of 22 patients and 12 
healthy donors. Normalization was performed using the reference gene peptidylprolyl 
isomerase B (PPIB), since it was defined as a suitable reference gene for mRNA 
quantification in peripheral whole blood (Pachot et al., 2004). To test the gene 
expression of OPTN and NF-κB target genes (NF-κB, IL-6, ELK1, and NFATc1) 
normalization was performed using the reference gene glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), since it was defined as a suitable internal control to 
evaluate gene expression after treatment with 5-Azacitidine (Kobune et al., 2012; 
Wang et al., 2013). A quantity of cDNA corresponding to 10 ng of total RNA was 
used in these analyses. The primers used are displayed in Table S3.1. 
 Western blot analyses 4.1.3.8
Osteoclasts derived from PBMCs from patients and controls were washed once in 
PBS and lysed using Trizol (Sigma-Aldrich). The protein concentrations were 
determined using the Bradford reagent (Bio-Rad). Proteins were separated by 8 % 
SDS-polyacrylamide gels and transferred onto PVDF membranes (Life technologies). 
After transfer, the membranes were blocked in 0.1 % TBS/Tween 20 containing 5 % 
nonfat dried milk at room temperature for 1'h. The membranes were then incubated 
ON at 4 °C with anti-OPTN (1:500, #100000 Cayman), anti-LC3B (1:1000, #2775 
Cell Signaling) or anti-αTubulin (1:2000, #2144 Cell Signaling) in 0.1 % TBS/Tween 
20, followed by extensive washing using 0,1% TBS/Tween 20 and an incubation with 
HRP-conjugated secondary antibody (1: 2000, Cell signaling) in 0.1 % TBS/Tween 20 
during 1h, at room temperature. After extensive washing with 0.1 % TBS/Tween 20, 
specific proteins were detected using a chemiluminescence kit (GE Healthcare). The 
densitometric analysis was performed using ImageJ software. 
 Statistical analyses 4.1.3.9
Statistical analyses were performed with GraphPad Prism 5 (GraphPad, La Jolla, CA). 
Comparisons between two groups were made using a two-tailed Student’s t-test. For 
comparisons between multiple groups, one-way ANOVA followed by Tukey’s post-
hoc test was used. Differences were considered statistically significant when p<0.05. 
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4.1.4 Results 
 Effect of rs2234968 in OPTN splicing and protein 4.1.4.1
sequence 
The possible functional effects of rs2234968 in 1) OPTN mRNA secondary structure 
according to RNA fold program revealed an absence of a predicted effect in mRNA 
structure (Figure 4.1A); 2) OPTN expression levels by qPCR using rs2234968qPCR 
F/R primers (Table S3.1) and patients and healthy donors samples with all genotypes, 
showed an absence of correlation between genotype and OPTN expression levels 
(Figure 4.1B); and 3) OPTN splicing pattern, according to Human Splicing Finder 
tool, indicated a prediction of a new branch point and consequently a possible exon 5 
skipping, which would change the protein sequence (Figure 4.1C). However, by doing 
a PCR using primers flanking exon 5 (rs2234968 qPCR F/qPCR R, Table S3.1) and 
cDNA from patients as template, we showed that rs2234968 was not responsible for 
exon 5 skipping (Figure 4.1D).  
 
Figure 4.1 - Effect of rs2234968 in mRNA secondary structure, OPTN expression and OPTN 
splicing. A) In silico analysis of the mRNA secondary structure in the region around rs2234968, 
showing that the A allele is not responsible for a change in OPTN mRNA structure. B) Analysis of 
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OPTN gene expression in PBMCs-derived osteoclasts from non-mutated controls (GG) (n=2), mutated 
controls (n=1), non-mutated patients (GG) (n=2), three patients heterozygous (GA) and one patients 
homozygous (n=4) for rs2234968, showing no statistical difference in OPTN gene expression. C) In 
silico prediction of the effect of rs3422968 in OPTN splicing, indicating that rs3422968 could be 
responsible for exon 5 skipping. D) Localization of the primers (red and blue arrows represent 
rs2234968 qPCRF1 and rs2234968 qPCR R1, respectively) used to amplify by PCR the region flanking 
exon 5 and electrophoresis results showing that the A allele is not responsible for a change of OPTN 
splicing. 1 and 2 represent patients with GG genotype, 3 and 4 patients with GA genotype and 5 and 6 
patients with AA genotype. M represents the 1kb marker. 
 
We then searched for SNPs in linkage disequilibrium (LD) with rs2234968, which 
may have a functional effect and explain the association of PDB with rs2234968. We 
found four SNPs [rs76647957 (r2 = 0.831; DPrime = 0.912), rs12415802 (r2 = 0.831; 
DPrime = 1), rs10906303 (r2 = 0.958; DPrime = 1) and rs79529484 (r2 = 0.801; 
DPrime = 0.954)] in LD with rs2234968 that are located in OPTN intron 2, 3, 5 and 6, 
respectively (Figure 4.2A). Using Human Splicing Finder tool, we determined that 
rs10906303 and rs79529484 were the most likely to have a functional effect on 
splicing (Figure 4.1B). This effect was tested by PCR using cDNA samples from 
patients with all genotypes and specific primers (Figure 4.2C). We found that both 
rs10906303 and rs79529484 may alter the splicing sites, causing the retention of the 
intron 5 and 6 respectively (Figure 4.2C), which may change the amino acid sequence 
and lead to a predicted premature stop codon (Figure 4.2D). By using an antibody 
against the complete OPTN protein in a western blot analysis, we were also able to 
see a decrease in OPTN protein levels in the presence of rs2234968 A allele (Figure 
4.2E), but no band of truncated protein size, suggesting that either the mRNA is 
degraded by nonsense-mediated mRNA decay or the truncated protein is degraded, 
since it loses all of its functional domains.  
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Figure 4.2 - SNPs in Linkage Disequilibrium with rs2234968. A) Localization of the SNPs in 
linkage disequilibrium with rs2234968; B) In silico prediction of the effects of the SNPs in linkage 
disequilibrium with rs2234968, in OPTN splicing; C) Localization of the primers (rs10906303 F1/R1, 
rs79529484 F2/R2, Table S3.1) used to amplify by PCR the different transcripts and electrophoresis 
results showing that with the presence of one mutated allele we have a change in OPTN splicing 
pattern. AA, AG, GG, TT, and TG represent different genotypes from patients samples and B represents 
the PCR negative control; D) OPTN protein sequence showing a premature stop codon - predicted by 
the position of the stop codon from the cDNA sequence from patients (represented by an *) - due to the 
effect of rs10906303 (grey box) and rs79529484 (black dashed box) in splicing. The bold and grey 
amino acids represent the new protein derived from the skipping of the intron. E) Analysis of OPTN 
protein expression in PBMCs-derived osteoclasts from non-mutated controls (GG) (n=3), non-mutated 
patients (GG) (n=2) and one patient heterozygous (GA) for rs2234968. 
 
 Rs1561570 increases osteoclast differentiation and 4.1.4.2
activity 
To better assess the effect of rs1561570 on osteoclasts formation, we performed a 
TRAP assay. The presence of at least one T allele increases significantly osteoclast 
formation, attested by the number of multinucleated cells yielded from PBCMs 
cultures, when compared to healthy controls (80% versus 10%, p-value = 0.001) 
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(Figure 4.3A, 4.3C). The osteoclasts generated contained more nuclei than the 
osteoclasts from healthy controls (p-value < 0.001) (Figure 4.3B, 4.3C).  
 
Figure 4.3 - Effect of rs1561570 in osteoclast differentiation. A) The osteoclast differentiation rate 
(displayed as a ratio between multinucleated osteoclasts and TRAP positive cells) was higher in 
patients with PDB carrying at least one T allele (p-value = 0.001). B) Osteoclasts from patients 
carrying at least one T allele contained significantly more nuclei than osteoclasts from healthy controls 
(p-value < 0.001). C) The distribution of the number of nuclei per osteoclast was observed in samples 
from healthy controls and PDB patients that were stained for TRAP and counterstained with 
haematoxylin.  
 
Bone resorption was also significantly increased in osteoclast cultures generated from 
patients with at least one T allele, resulting in 3-fold increase in the total resorption 
area when compared to cultures prepared from healthy controls (p-value < 0.001) 
(Figure 4.4A, 4.4B). 
Controls(CC( Pa+ents(CC( Pa+ents(CT/TT(
N
uc
le
i'p
er
'O
CL
'
A'
C'
Co
ntr
ols
'CC
'
Pa
4e
nts
'CC
'
Pa
4e
nts
'CT
/TT
'
Ra
4o
'M
ul
4'
O
CL
/T
RA
P'
+'
B'
Co
ntr
ols
'CC
'
Pa
4e
nts
'CC
'
Pa
4e
nts
'CT
/TT
'
n=3( n=2( n=3( n=3( n=2( n=3(
CHAPTER(4(–(FUNCTIONAL(STUDY(OF(rs2234968(AND(rs1561570(
!89!
 
Figure 4.4 - Effect of rs1561570 in osteoclast differentiation. A) Representative images of in vitro 
bone resorption assays (left) with B) quantification of the results (right) by using ImageJ.  
 
 Rs1561570 does not affect macroautophagy 4.1.4.3
OPTN has been suggested to be an autophagy adaptor and since impairment in 
autophagy was reported in PDB, we assessed the autophagy process in the presence of 
rs1561570 T allele. By immunofluorescence and western blot analysis we found that 
LC3B expression was impaired, however that effect did not seem to be dependent of 
the presence of a T allele (Figure 4.5A, 4.5B).   
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Figure 4.5 - rs1561570 effect in autophagy. A) LC3BII foci (red) in PBMC-derived osteoclasts from 
controls and PDB patients were analyzed by immunofluorescence. B) The levels of LC3BII protein 
expression were measured by western blot analysis and related to levels of α-Tubulin (ANOVA, * 
represents a p-value < 0.05). 
 
 Rs1561570 causes a change in methylation and 4.1.4.4
increases OPTN expression  
Since our previous study has shown a strong association between rs1561570 (located 
in OPTN intron 7) and PDB (Michou et al., 2012), we determined the functional 
effect of rs1561570 on PDB by employing the splice site prediction algorithm, and 
showed that the allele harboring a C was likely to create a potential new acceptor site 
for splicing and disrupt a potential branch point (Consensus value for mutant 
sequence = 69.7%). To validate this finding, we performed RT-PCR and qPCR using 
cDNA samples from patients and controls with the three genotypes. Retention of 
intronic sequences was not observed in any genotype (Figure 4.6).  
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Figure 4.6 - Schematic representation of possible rs1561570 effect in OPTN splicing. A) 
Bioinformatics prediction from Human Splicing Finder showing that rs1561570 was predicted to cause 
a new acceptor site. Boxes represent OPTN exons. Arrows represent the primers used (red arrow – 
rs1561570 qPCR F; blue arrow – rs1561570 qPCR R, Table S3.1). The red asterisk represents the SNP 
rs1561570. B) Electrophoresis results showing that the presence of the mutated allele do not change 
OPTN splicing pattern. 1-3 - PDB patients with CC genotype, 4-9 - PDB patients with CT, 10 -13 - 
PDB patients with TT genotype, B represents the PCR negative control, and M represents the 1 kb 
marker. 
 
We then studied the predicted impact of rs1561570 in the OPTN methylation status 
using the Methprimer tool. We found that allele C was predicted to cause a CpG 
dinucleotide, creating a methylation site, which was not present in the presence of the 
T allele (Figure 4.7A). After bisulfite treatment, we confirmed that all samples with at 
least one C allele in their rs1561570 genotype were in fact methylated (results not 
shown). To correlate the methylation site created by the C allele with the OPTN 
transcriptional levels, we performed qPCR and western blot analysis using 
lymphocytes from patients with the three genotypes. Samples carrying a T allele (CT 
or TT) showed levels of OPTN gene and protein expression higher than samples with 
CC genotype (Figure 4.7B, 4.7C). This result suggested that the methylated C allele is 
associated with a decrease in OPTN gene expression levels. The protein expression 
levels were measured by western blot analysis in PBMC-derived osteoclasts and were 
in accordance with the results obtained by qPCR and western blot analysis in 
lymphocytes (Figure 4.7D). 
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Figure 4.7 - Rs1561570 effect in methylation and OPTN expression. A) In silico prediction using 
Methprimer tool showing a methylation site only in the presence of the allele C (not the allele T). B) 
Analysis of OPTN gene expression in lymphocytes from several controls (n=12) and patients (n=22) 
with the three genotypes. The levels of OPTN gene expression were measured by qPCR normalized to 
PPIB gene expression levels. Values are the mean of at least three independent replicates. C) Analysis 
of OPTN protein expression in lymphocytes from non-mutated controls (n=5), and patients carrying at 
least one T allele (n=19). D) Analysis of OPTN protein expression in osteoclasts from non-mutated 
controls (n=3), non-mutated patients (n=2) and patients carrying at least one T allele (n=3). The levels 
of OPTN protein expression were measured by western blot analysis and related to levels of α-Tubulin 
(t-test and ANOVA, * represents a p-value < 0.05, ** represents a p-value < 0.005, *** represents a p-
value < 0.001).  
 
 Rs1561570 increases NF-κB translocation into the 4.1.4.5
nucleus  
To determine the role of rs1561570 on PDB phenotype, we analyzed the NF-κB 
cellular localization by immunofluorescence following treatment with the 
demethylating agent, 5-Azacitidine. By using two different cell lines which carry the 
rs1561570 C allele – T47D (CT genotype) and U937 (CC genotype) - we were able to 
confirm that before the demethylating treatment NF-κB was localized in the 
cytoplasm and in the nucleus. However, after OPTN demethylation, NF-κB 
localization is almost exclusive in the nucleus, confirming that a decrease in OPTN 
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methylation (as seen in PDB patients with rs1561570 T allele) increases the 
translocation of NF-κB into the nucleus (Figure 4.8A and 4.8B).  
 
Figure 4.8 - Effect of OPTN demethylation in NF-κB localization. NF-κB localization in (A) U937 
cells (CC genotype), and in (B) T47D cells (CT genotype), following 5-Azacitidine (Aza) treatment. 
After OPTN demethylation, NF-κB was translocated exclusively to the nucleus.  
 
To confirm the effect of the demethylating agent we measure OPTN expression and to 
confirm that the presence of NF-κB in the nucleus was affecting the expression of its 
target genes, we measured the expression of NF-κB, IL-6, ELK1, and NFATc1. Our 
results showed that there was an increase in OPTN expression, which was expected 
after the demethylation treatment, and in the expression of the NF-κB target genes 
analyzed. NF-κB levels were maintained as expected (Figure 4.9).  
 
Figure 4.9 - Effect of OPTN demethylation in expression of NF-κB target genes. Analysis of NF-
κB target genes expression. The levels of OPTN, NF-κB and NF-κB target genes (IL-6, ELK1, 
NFATc1) expression were measured by qPCR related to levels of GAPDH gene. Values are the mean 
of at least three independent replicates. (t-test, * represents a p-value < 0.05, ** represents a p-value < 
0.005, *** represents a p-value < 0.001, **** represents a p-value < 0.0001). 
 
Since rs1561570 was found to have an in vitro effect on the NF-κB translocation into 
the nucleus, we further analyzed the NF-κB localization in PBMC-derived osteoclasts 
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from PDB patients carrying different genotypes of rs1561570 and from healthy 
controls, as well as NFATc1 expression (since it is the most relevant NF-κB target 
gene for osteoclast differentiation). Our results showed that, in accordance with our in 
vitro assays, the patients with at least one T allele had an increase in NF-κB 
translocation to the nucleus (showed also as a ratio between co-localization of NF-κB 
and DAPI) (Figure 4.10A) and an increase in NFATc1 expression (Figure 4.10B) – 
another strong evidence that an increase of OPTN expression due to the effect of the T 
allele in the OPTN methylation status leads to an increase of NF-κB translocation into 
the nucleus and an increase of its target genes expression.  
 
Figure 4.10 - Effect of rs1561570 in NF-κB localization in osteoclasts and in the expression of 
NFATc1. A) NF-κB localization in osteoclasts derived from healthy controls and patients PBCMs 
showing an increase of the translocation of NF-κB into the nucleus, in the presence of at least one T 
allele. This was also confirmed by co-localization ratio between NF-κB and DAPI – the nuclear 
Merge%
Co
nt
ro
ls(
CC
(
Pa
+e
nt
s(C
C(
α'NFκB% DAPI%
Merge%α'NFκB% DAPI%
Merge%α'NFκB% DAPI%
Pa
+e
nt
s(C
T/
TT
(
A%
**%
NFκB/DAPI%
Co
/lo
ca
liz
a+
on
(c
oe
ﬃ
ci
en
t(
Pa
+e
nts
(CT
/TT
(
Co
ntr
ols
(CC
(
B%
n=12( n=24(
Pa
+e
nts
(CT
/TT
(
Co
ntr
ols
(CC
(
NF
AT
c1
(re
la
+v
e(
ge
ne
(e
xp
re
ss
io
n(
(H
K(
ge
om
ea
n)
(
CHAPTER(4(–(FUNCTIONAL(STUDY(OF(rs2234968(AND(rs1561570(
!95!
staining. B) Analysis of NFATc1 gene expression in several controls (n=12) and patients (n=24) with 
all genotypes. The levels of NFATc1 expression were measured by qPCR related to levels of the mean 
of the housekeeping genes (ATPO5, HPRT1, PPIB, PPIA, and 18S). Values are the mean of at least 
three independent replicates. (t-test, ** represents a p-value < 0.005). 
 
 Rs1561570 may have an effect on PDB severity 4.1.4.6
By comparing the PDB clinical phenotype of patients carrier of the CC 
genotype of OPTN rs1561570 with patients carrying one or two T alleles, we can 
observe a tendency although not significant for an: i) increase of total sALP levels, ii) 
increase of mean number of affected bones, and iii) increase of disease extension 
measured by Renier’s index – related with the number of T alleles in the genotype 
(Table 4.1). These results suggest that rs1561570 can be a susceptibility variant that 
could have a dose effect depending on the number of T alleles present in the genotype.  
4.1.5 Discussion 
In the present study, we investigated the functional role of the two most associated 
variants with PDB within the PDB6 locus. We focused our analysis in the rs2234968, 
discovered in our previous work and in rs1561570 (C>T), previously described has 
having a strong association with PDB in the literature (Michou et al., 2012). 
Regarding rs2234968 we found it was associated with PDB in our population but it 
has no functional effect on PDB pathogenesis. Instead we found two SNPs 
(rs10906303 and rs79529484) in LD with rs2234968 that could have a functional 
effect. Then, we analyzed the effect of rs10906303 and rs79529484 in the splicing 
pattern of OPTN gene, and showed that these SNPs cause the retention of intron 5 and 
intron 6 respectively, producing new OPTN transcripts, both leading to premature 
stop codons. We hypothesize that these new transcripts encode smaller proteins, 
which may contribute to the PDB phenotype since those truncated proteins will lose 
the main functional domains (NEMO and LIR) and therefore are likely to be non-
functional. Similarly to the deleterious effect of SQSMT1 mutations that impair its 
main functional domain - UBA (Laurin et al., 2002), the predicted loss of OPTN 
protein domains, namely the NEMO, UBD and LIR domains, should impair its 
function.
!96!
Table 4.1. Comparisons of main clinical characteristics between French-Canadian patients with Paget's disease of bone carrier of the 
rs1561570 TT or TC genotype to CC genotype carrier, considered as the reference.  
 
Categories of patients 
Comparison of TC 
to CC genotype 
Comparison of TT 
to CC genotype 
 CC 
genotype 
(n=35) 
TC 
genotype 
 (n=93) 
TT 
genotype 
(n=99) 
p-value p-value 
Male sex, n (%) 22 (63) 58 (59) 59 (58) 0.66 0.60 
Age at diagnosis (years), mean ± SD 61.9±8.7 63.1±12.0 63.2±11.5 0.60 0.55 
Total sALP levels a 2.6±1.6 3.1±3.3 3.4±3.5 0.38 0.18 
Number of affected bones, mean ± SD  2.3±1.8 2.4±2.4 2.6±2.6 0.82 0.53 
Renier’s index (%), mean ± SD 9.2±7.4 9.5±8.1 10.5±8.7 0.86 0.44 
a sALP = serum phosphatase alkaline; for total sALP levels, values are the number of time the Mid point of Normal range ± SD 
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Accordingly, an OPTN transcript with a retained intron 5 was already described in 
patients with other disease - juvenile open-angle glaucoma (Willoughby et al., 2004), 
thus indicating that the presence of this abnormal transcript can alter OPTN function 
or the normal regulation of its protein expression (Lewis et al., 2003). However, 
further studies will be required to clarify the effect of these transcripts in PDB 
patients. By quantifying their expression and comparing it with the expression of the 
normal transcripts, and analyzing if OPTN function is impaired when only the mutant 
and “short” transcript is expressed should be highly relevant to further understand its 
effect in associated pathologies such as PDB. In addition, by analyzing the resulting 
autophagy process or the expression of osteoclast related genes may also contribute to 
clarify the effect of these variants in PDB pathophysiology.   
Regarding rs1561570 (C>T), the studies previously reported showed that the C allele 
was more frequent in controls while the T allele was more frequent in PDB patients. 
Using in silico tools, we found that the rs1561570 T allele was predicted to cause a 
loss of a methylation site. With bisulfite treatment, we confirmed that the C allele in 
that position was always methylated. Furthermore, both qPCR and western blot 
analysis correlated the presence of the C allele with a decrease of OPTN expression 
levels. Our immunofluorescence analysis allowed us to confirm that an increase of 
OPTN levels (due to the demethylation treatment in cells and due to the presence of 
the T allele in PDB patients) is related to an increase in NF-κB translocation into the 
nucleus and to an increased expression of NF-κB target genes related with 
osteoclastogenesis, such as NFATc1 – a master transcription factor of osteoclast 
differentiation (Lorenzo et al., 2007). Journo and its co-workers had already described 
the mechanism behind the translocation of NF-κB into the nucleus due to OPTN. 
(Journo et al., 2009) Altogether, our results suggest that, in the presence of two C 
alleles (more frequent in healthy controls), the presence of a methylated site at 
rs1561570 maintains OPTN expression at basal levels, which in turn leads to basal 
levels of NF-κB translocation to the nucleus, giving rise to normal levels of 
osteoclastogenesis-related gene expression. However, when patients have at least one 
T allele at rs1561570, that site is no longer methylated, and that correlates with an 
increase of OPTN expression and increase of translocation of NF-κB into the nucleus. 
This gives rise to an increase in expression of osteoclast related genes, such as the 
osteoclast major transcription factor, NFATc1, probably contributing to the increase in 
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osteoclast differentiation rate, number of nuclei per cell, and resorbing activity 
observed in patients with at least one T allele (Figure 4.11).  
 
Figure 4.11 - Functional effect of rs1561570 in PDB – a hypothesis. A) In healthy control samples, 
the most frequent allele is the C and the functional data in this work showed that this nucleotide was 
methylated. Since methylation was associated with transcription repression, this methylated site should 
maintain OPTN expression in basal levels, leading to lower levels of NF-κB in the nucleus thus 
maintaining basal expression levels of genes related to osteoclastogenesis. B) In PDB patients, the most 
frequent allele was the T that was no longer methylated. The loss of that methylation site will lead to 
higher levels of OPTN transcription, higher levels of NF-κB translocation into the nucleus, and higher 
levels of expression of genes related to osteoclastogenesis, thus increasing osteoclast number and 
resulting resorbing activity, therefore contributing to PDB pathogenesis. 
 
A correlation between the hypermethylation status in different genes resulting in a 
decrease in gene transcription levels affecting related diseases has been previously 
reported for other genes in the literature (Brenet et al., 2011; Hrašovec et al., 2013; 
Iwamoto et al., 2011). The change in the OPTN expression levels may also be due to 
the already reported binding of an enhancer - JUND, a member of the AP1 family that 
is present in osteoclasts (Beranger et al., 2007; David et al., 2001; Inoue et al., 1997) – 
in the genomic region containing the T allele, which is lost in the presence of the C 
allele, as confirmed by the ENCODE project (http://www.genome.gov/encode/). The 
ENCODE project shows regions of transcription factor binding derived from a large 
collection of ChIP-seq experiments together with DNA binding motifs identified 
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within these regions by the ENCODE Factor book repository. The presence of an 
enhancer might explain why a single change in the DNA sequence of these patients 
causes an alteration in OPTN expression levels. However, our results are not in direct 
accordance with some previous studies about OPTN in PDB. Some groups show that 
the depletion of OPTN increased the differentiation of osteoclasts (p-value = 0.002), 
showing that OPTN might be a negative regulator of osteoclast differentiation. 
However the same study also refers that OPTN expression significantly increases 
during days 2 to 5 of in vitro osteoclast differentiation (Obaid et al., 2012). Also, 
another group showed OPTN as having a negative effect on osteoclast differentiation 
but, unlike in our study, that analysis was performed in one patient carrier of a P392L 
mutation within the SQSTM1 gene and the effect was mediated by the presence of 
measles virus nucleocapsid protein (MVNP) (Sun et al., 2014). Our study is unique 
since it analyses the single effect of rs1561570 in OPTN gene and protein expression 
using several SQSTM1 negative pagetic patient samples, different cell types 
(lymphocytes and osteoclasts derived from PBMCs), in vitro and ex vivo techniques, 
and provides clear evidences that truly support our hypothesis at several levels.  
In conclusion, there are several genes within the PDB6 locus that could have a 
functional role contributing to PDB, the OPTN being the best candidate. Furthermore, 
we showed that rs1561570 is responsible for a change in the methylation status of 
OPTN and in its gene expression levels, which may contribute to PDB pathogenesis. 
Therefore, to this date, OPTN is still the most likely gene within this locus to have a 
functional effect that could contribute to PDB pathophysiology. We have also 
identified two SNPs in linkage disequilibrium with rs2234968 that are responsible for 
a change in splicing and possibly for creating a new truncated protein, probably non-
functional. 
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5.1 Comparative analysis of human and zebrafish 
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5.1.1 Abstract 
Paget’s disease of bone (PDB) is the second most frequent metabolic bone disease 
after osteoporosis and genetic factors play an important role in PDB, but to date the 
only PDB causal gene identified is the Sequestosome 1 (SQSTM1) gene. Because 
zebrafish has been validated as model for human genetic diseases our objective was to 
investigate if the gene structure and chromosomal environment of the SQSTM1 was 
similar between zebrafish and human, thus providing a basis for developing a mutant 
fish capable of modeling PDB. Through a comparative in silico analysis, we 
confirmed that zebrafish sqstm1 shares not only the same gene structure as its fish and 
mammalian orthologs, but they also present, within their promoter regions, similar 
putative binding sites for common transcriptional factors known to affect bone 
metabolism. The synteny of SQSTM1 was also determined and results indicate that 
the cluster of surrounding genes was conserved throughout evolution. The protein 
comparison revealed a high degree of conservation, with particularly in the functional 
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domains of the protein. The most common mutation in PDB patients is p.Pro392Leu 
and the residue Pro392 was found to be 100% conserved in all species analyzed, 
including zebrafish, confirming its known functional relevance. In conclusion, this 
study demonstrated that SQSTM1 is well conserved throughout evolution and 
therefore fish models, like zebrafish, could be an interesting tool to further investigate 
the biological role of SQSTM1 in PDB and in bone development. 
 
5.1.2 Introduction  
Paget's disease of bone (PDB) is the second most common metabolic bone disorder, 
after osteoporosis, affecting between 1% and 3% of individuals over the age of 55 
years in Caucasian populations (Kanis, 1998). The cause of PDB is currently an area 
of intensive investigation, and both genetic and non-genetic factors have been 
implicated in the pathogenesis of this disease. Montagu group first raised the 
possibility that heredity might play a role in the pathogenesis of PDB (Montagu, 
1948), and over recent years there has been an increasing interest towards 
understanding the role of genetic factors in the pathogenesis of this disease. Genetic 
factors are clearly an important component of the etiology of PDB, since ethnic 
differences in the incidence of PDB have been noted, and these persist with 
emigration to other regions. For example, PDB is common in persons of Anglo-Saxon 
origin, but the prevalence is low in the Far East and does not change when 
populations from this region move to areas of higher prevalence, such as the United 
Kingdom (Cooper et al., 2006). Another argument that favors the genetic inheritance 
of PDB is that 15–40% of affected patients have a first-degree relative with PDB and 
numerous studies have described extended families with PDB exhibiting an autosomal 
dominant mode of inheritance (Leach et al., 2001; Morales Piga et al., 1995).  
In 2002, Laurin et al. reported a point mutation (p.Pro392Leu) in SQSTM1, in 
chromosome 5q35, in two French-Canadian families with PDB and several unrelated 
patients (Laurin et al., 2002). SQSTM1 encodes Sequestosome 1, also known as p62, 
which is an ubiquitin-binding protein involved in the IL-1, TNFα, and RANKL 
signaling pathways. SQSTM1 is the gene most frequently linked to PDB and 
mutations on this gene have been detected in up to 40% of the families with PDB 
studied (Laurin et al., 2002). The crucial role of SQSTM1 during RANKL-induced 
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osteoclastogenesis was demonstrated in the SQSTM1-/- knockout mice, which 
displayed altered RANKL-induced osteoclast formation, NF-κB activation, and 
NFATc1 expression (Durán et al., 2004). Hiruma et al. (2008) and Daroszewska et al. 
(2011) also published the presence of some PDB-like phenotypes in Pro394Leu 
mutant mice, however this model has some clinical and cellular differences from what 
is observed in humans and therefore does not reproduce the full phenotype of pagetic 
osteoclasts (Daroszewska et al., 2011; Hiruma et al., 2008). Thus there are still some 
answers that remain unexplained. In another study, the full PDB phenotype is 
observed in mice transfected with measles virus nucleocapsid protein (MNVP) alone, 
but again this does not exactly reproduce what happens in humans, in which PDB 
phenotype is found in patients without any measles virus infection (Brown and 
Michou, 2011; Kurihara et al., 2011). Anecdotal reports published symptoms of 
osteitis deformans (referred in humans as PDB) in other animals, like macaque 
(Hughes and Lang, 1971), rat snake (Hajkova and Knotek, 1998) and python (Preziosi 
et al., 2007), but once again these models did not develop the full PDB phenotype. 
More recently, in 2009, Chamoux et al. showed that the p.Pro392Leu mutation 
actually activates pagetic osteoclasts derived from cultures of peripheral monocytes or 
bone marrow cells from PDB patients; however they hypothesized that additional 
events, like environmental or other genetic factors, were eventually needed to lead to 
the complete phenotype of PDB (Chamoux et al., 2009). Since there are still other 
questions that remain to be answered, mostly regarding all the factors that are 
important for the onset of PDB or why do some patients have several bones affected 
and others have just monostotic lesions, it is imperative to try to develop another 
model to better understand the more basic aspects of this gene’ expression and its 
contribution to the physiology of PDB disease. Ray-finned fish, particularly zebrafish 
(Danio rerio), are used as experimental models in various research areas such as 
environmental and developmental biology, genetics, pharmacology and cancer 
research. Fish relevant features, that demonstrate their suitability for developmental 
studies, include i) presence of orthologs for many mammalian genes, ii) strong 
resemblance of biochemical and physiological processes between fish and mammals, 
and iii) several technical advantages such as external fertilization, transparent 
embryos and larvae, rapid and external growth and a large progeny (Bolis et al., 
2001). In addition, other similarities to mammals, like organ morphology and systems 
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composition, as well as a complex ossified skeleton, the existence of osteocytic bone 
and multinucleated osteoclast (Hall and Witten, 2007; Witten and Huysseune, 2009), 
have turned zebrafish into an unique animal model to study different pathologies, 
including those affecting bone (Lieschke and Currie, 2007). Although there are many 
similarities between fish and mammalian bone there are but also differences 
(Apschner et al., 2011), being the existence of acellular bone (devoided of osteocytes) 
and mononucleated osteoclasts in most teleost fish species, while mammals have 
exclusively cellular bone and multinucleated osteoclasts, the major difference. Fish 
mononucleated osteoclasts are active bone resorbing cells and were shown to 
contribute to allometric bone growth (Witten et al., 2001). The availability of fish 
mutants exhibiting features resembling human pathologies, the fact that amino acid 
sequences of functionally relevant protein domains have been evolutionarily 
conserved with many similarities to mammalian sequences both at the protein and 
nucleotide levels (Lieschke and Currie, 2007), among others, has contributed to 
accept zebrafish as an important and suitable model to study human biological 
processes, in particular the mechanisms underlying skeleton development and the 
onset of skeletal disorders. For example, in 2004 Kan group described a transgenic 
mice overexpressing BMP4 that developed fibrodysplasia ossificans progressiva 
(FOP)-like phenotype (Kan et al., 2004). FOP is a rare genetic disorder of progressive 
extraskeletal ossification and results in profoundly decreased mobility of affected 
individuals. However it was only when Shen’s group developed a zebrafish model of 
FOP that the full molecular mechanism of BMP independent cascade was elucidated 
(Shen et al., 2009). They showed that the recurrent single nucleotide missense 
mutation (c.617G→A) in the gene encoding ACVR1, a BMP type I receptor that 
causes FOP in all classically affected individuals, induced enhanced chondro-osseous 
differentiation and activate the BMP signaling pathway in a BMP-independent 
manner, showing that zebrafish is an excellent tool to unravel the molecular 
mechanisms related to human bone diseases. Only then the mouse model harboring 
the same mutation and the full FOP phenotype was developed (Chakkalakal et al., 
2012), highlighting the important role of zebrafish to assess the functional mutation 
that caused FOP. Recently, Wiweger et al (2012) have shown that zebrafish harboring 
mutations in exostosin (ext2) gene are a model for Multiple Osteochondromas (MO) 
since ext2−/− fish have skeletal defects that resemble those seen in osteochondromas 
and have also dental defects associated with the formation and the morphology of 
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teeth (Wiweger et al., 2012). Their findings from zebrafish model were validated in a 
dental survey in MO patients showing the presence of the malformed and/or displaced 
teeth with abnormal enamel. Several studies show how bone remodeling in zebrafish 
can be compared to the same process in mammals. Zebrafish osteoclasts exhibit a 
high level of tartrate-resistant acid phosphatase (TRAP) activity (Witten et al., 2001), 
first inside bone-resorbing cells and then at bone surfaces undergoing resorption. 
These eroded bone surfaces are then covered with an overlay of new bone, showing a 
parallelism between fish and human bone remodeling processes (Witten et al., 1997). 
Besides bone, fish scales can also be a good system to study the cells and mechanisms 
responsible for regeneration, development and skeletal remodeling (de Vrieze et al., 
2011). The availability of zebrafish mutants, like panther, that lacks a functional c-
fms (receptor for macrophage colony-stimulating factor) gene, crucial for osteoclast 
proliferation and differentiation, also shows that zebrafish can be a highly relevant 
model to study phenotypes related to osteoclast dysfunction and altered bone 
remodeling (Chatani et al., 2011). In addition to bone phenotype, there is more and 
more evidence that SQSTM1 mutations may be causal in frontotemporal dementia and 
amyotrophic lateral sclerosis (ALS). Protein aggregation was found in patients with 
theses pathologies and some findings provide evidence of a direct genetic role of 
SQSTM1 in ALS pathogenesis as it is supposed to be involved in protein-recycling 
systems by regulating protein degradation pathways (Fecto et al., 2011). However 
there are still some molecular mechanisms that are not fully understood. Since 
zebrafish was shown to be a good animal model to analyze protein aggregation in the 
neural system (Bellipanni et al., 2000; Xi et al., 2011), it may also be a good model to 
study SQSTM1 role in protein aggregation. 
Although no work is available in zebrafish for sqstm1, our analysis of the available 
sequences encoding functional regions of the sqstm1 gene indicate that they are fully 
conserved between zebrafish and human, suggesting that its function may also be 
conserved. This emphasizes the likeliness that phenotypes with some similarities to 
those observed in mice and human SQSTM1 mutants may also be developed in fish. 
For that the main goal of our work was to provide an initial contribution aiming to 
validate the zebrafish as an animal model to study SQSTM1. To achieve this goal we 
first compared (1) the SQSTM1 gene structure, (2) the neighbor genes surrounding 
SQSTM1 and (3) the corresponding protein sequences, collected from several fish 
species, with the available human data. Then we focused our analysis only in the 
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human and zebrafish species and compared (4) the regulatory motifs in the promoters 
of SQSTM1 genes, (5) the splicing isoforms and their tissue specificity and (6) the 
conservation of SQSTM1 3D structure between these two species, to provide insights 
towards the suitability of zebrafish to be used as a model for SQSTM1-related PDB.  
5.1.3 Materials and Methods 
 Sequence collection 5.1.3.1
Databases at GenBank (www.ncbi.nlm.nih.gov) and Ensembl (release v72; 
www.ensembl.org) were searched for annotated SQSTM1 sequences. A total of 32 
species were selected, including fifteen mammals (Bos taurus, Callithrix jacchus, 
Cricetulus griseus, Gorilla gorilla, Homo sapiens, Loxodonta africana, Macaca 
mulatta, Macaca fascicularis, Mus musculus, Oryctolagus cuniculus, Ovies aries, Pan 
troglodytes, Pongo abelii, Rattus norvegicus and Sus scrofa), eight teleosts (Danio 
rerio, Gasterosteus aculeatus, Oreochromis niloticus, Oryzias latipes, Salmo salar, 
Takifugu rubripes, Tetraodon nigroviridis and Xiphophorus maculatus), three birds 
(Gallus gallus, Meleagris gallopavo and Taeniopygia guttata), one reptile (Anolis 
carolinensis), two amphibian (Xenopus laevis and Xenopus tropicalis), and three 
insects (Apis florea, Megachile rotundata and Nasonia vitripennis).  
 Sequence alignment and analysis 5.1.3.2
The amino acid sequence alignments were created using T-Coffee multiple sequence 
alignment software (Notredame et al., 2000) with parameters set to default. Pairwise 
sequence identity values were computed as percent of identical residues over the total 
number of aligned residues using T-Coffee generated alignments and the Sequence 
Manipulation Suite (Stothard, 2000).  
 Assessments of conserved synteny 5.1.3.3
To examine patterns of conserved synteny, chromosomal loci of SQSTM1 genes in 
human, mouse, zebrafish, tilapia, platyfish, tetraodon, turkey, lizard and frog were 
compared by identifying all neighbor genes of SQSTM1. The position of each of these 
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genes was searched in all species using the Ensembl database search function (release 
v72; http://www.ensembl.org). 
 Identification of alternative spliced isoform and 5.1.3.4
alternative promoter of SQSTM1 genes 
The alternative splicing events in both human and zebrafish were revealed by aligning 
the cDNAs against the genomic sequences, using the mRNA alignment tool Spidey 
(ncbi.nlm.nih.gov/spidey/spideyweb.cgi). The presence and features of alternative 
promoters, tissue expression and protein interactions of the human SQSTM1 gene 
were examined with the AceView database 
(http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/index.html). The presence and 
features of spliced isoforms of the zebrafish sqstm1 gene were examined using the 
Ensembl database.  
 Prediction of human and zebrafish SQSTM1 5.1.3.5
three dimensional structures 
Human and zebrafish SQSTM1 three-dimensional (3D) structures were predicted with 
I-TASSER software (http://zhanglab.ccmb.med.umich.edu/I-TASSER) (Roy et al., 
2010). Different models were obtained and the best one was chosen according to the 
DOPE (discrete optimized protein energy) score method (Shen and Sali, 2006). 3D 
overlapping illustrations were produced using Chimera v1.5 
(http://www.cgl.ucsf.edu/chimera) (Pettersen et al., 2004). 
 Analysis of putative transcription factor (TF) 5.1.3.6
binding sites in SQSTM1 regulatory regions 
The promoter sequences (1,500 bp upstream of the translation start site) of the 
SQSTM1 genes from human and zebrafish were retrieved from Ensembl database, and 
analyzed for binding sites of 12 TFs (ETS1, MEF2, AP1, TWIST, KRUEPPEL, RXR, 
LIM, CART1, NF-κB, ERE, GATA, and NFAT) using the web server ConTra 
(http://bioit.dmbr.ugent.be/contrav2/index.php) (Broos et al., 2011).  
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5.1.4 Results 
 SQSTM1 gene structures were conserved 5.1.4.1
throughout evolution 
By searching the Ensembl database, we found that the zebrafish sqstm1 gene is 
located in chromosome 14 and appears to be a single copy gene, as already suggested 
by Mostowy et al. (2013) (Mostowy et al., 2013). The sqstm1 cDNA was aligned with 
the sqstm1 genomic sequence, and sites of exon-intron borders were deduced by 
comparison. The sqstm1 gene, spanning approximately 5.5 kb in length, is organized 
into 8 exons and 7 introns and comparison with its orthologs from other metazoan 
organisms revealed a generally well-conserved exon-intron organization. Indeed, only 
one gene was identified in all the species analyzed (Figure 5.1).  
 
Figure 5.1 - Structural organization of SQSTM1 gene among species. Schematic diagram of 
SQSTM1 genes in humans (Homo sapiens), mice (Mus musculus), turkey (Meleagris gallopavo), 
zebrafish (Danio rerio), platyfish (Xiphophorus maculatus), tetraodon (Tetraodon nigroviridis), tilapia 
(Oreochromis nilotcus), green anole (Anolis carolinensis), and Western clawed frog (Xenopus 
tropicalis). Panels show a SQSTM1 gene structure comparison among several taxonomic groups 
(mammalia, osteichthyes, sauropsida, reptilla and amphibia). Six human SQSTM1 transcripts and two 
zebrafish sqstm1 transcripts are also shown. Dark grey boxes represent coding exons, light grey boxes 
represent non-coding exons. Numbers below the boxes represent their length, in nucleotides. Only exon 
sizes are to scale. Homo sapiens 1 - ENST00000376929; NM_001142298; uc011dgr.2; Homo sapiens 
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2 -NM_001142299, uc011dgs.2; Homo sapiens 3 - ENST00000389805; NM_003900; uc003mkw.4; 
Homo sapiens 4 - ENST00000510187; Homo sapiens 5 -ENST00000360718; uc003mkx.3; Homo 
sapiens 6 - ENST00000402874. ENST00000514093, ENST00000422245, ENST00000508284, 
ENST00000504627, ENST00000453046 are protein-coding isoforms (and appear in Table S5.1) but 
the sequences are not complete. 
 
Zebrafish sqstm1 exon 1 contains the 5´UTR and the start codon and exon 8 contains 
the termination codon and the 3´UTR, including two consensus polyadenylation 
signals (Figure 5.1 and results not shown). We have identified two zebrafish sqstm1 
transcripts coding for protein isoforms Danio rerio_1 (ENSDART00000140061) and 
Danio rerio_2 (ENSDART00000113012) with 1939 and 1827 bp, with ORFs 
encoding sequences of 452 and 353 amino acids, respectively (Figure 5.1 and Table 
S5.1). The transcript Danio rerio_1 seems to have retained the intron 3 when 
comparing with the genomic structure among the other species, and thus, to allow an 
easier comparison, we have maintained the same numbering for the zebrafish sqstm1 
exons (Figure 5.1).  
The human SQSTM1 gene is located in chromosome 5 and spans 32 kb in length and 
at least six transcripts coding for protein isoforms were identified (Figure 5.1) with 
2913, 2848, 2986, 1714, 2253 and 2000 bp, with ORFs encoding sequences of 356, 
356, 440, 378, 356 and 356 amino acid, respectively (Figure 5.1 and Table S5.1). 
Exons 1, 2, 3 and 4 are usually skipped by alternative splicing at the mRNA level to 
produce the following isoforms: Homo sapiens_1 (lacks both exons 2 and 4), Homo 
sapiens_2 (lacks both exons 1 and 4), Homo sapiens_3 (lacks exons 1-3), Homo 
sapiens_4 (lacks exons 1-3 and 10), Homo sapiens_5 (lacks exons 1-4 and retains part 
of intron 4), and Homo sapiens_6 (lacks exons 1-3 and partial 4). We also examined 
the occurrence of splicing isoforms of human SQSTM1 gene by using the AceView-
NCBI database, a database generated from the experimental data of cDNA sequencing 
from various human tissues mRNA (Thierry-Mieg and Thierry-Mieg, 2006). As 
shown in Table S5.1, we found that the human SQSTM1 encodes multiple open 
reading frames and has 17 alternatively spliced isoforms (named in alphabetical order, 
a to q, based on their protein size) expressed in different tissues. As an example, 
SQSTM1 isoform a is encoded by 8 exons and results in a 2986 bp mRNA transcript 
encoding a protein with 440 amino acids, which is expressed in melanoma, skin, lung, 
and 16 other tissues.  
The gene structures for all the species analyzed were constructed according to 
available data on transcript exons size and number obtained from Ensembl database 
CHAPTER(5(–(CAN(ZEBRAFISH(BE(A(VALID(MODEL(TO(STUDY(PDB?(
!112!
after alignment with the genomic sequence using Spidey facilities. We observed that 
almost every species had a conserved overall gene structure when compared with the 
human ortholog. It is worthy to mention that although in human there are evidences 
for the existence of SQSTM1 transcripts with 5’ non coding exons (Figure 5.1) we did 
not found the same evidences in other species. More important, the coding exons for 
each species are extremely well conserved which could indicate that this gene encodes 
a protein with important functions and thus was subjected to an evolutionary pressure 
responsible for maintaining its molecular structure and sequence.  
In order to better understand the relationships between zebrafish and human SQSTM1, 
we next examined the genomic context of SQSTM1 gene in human chromosome 5, 
and how this is conserved in other vertebrate species (Figure 5.2). The overall clusters 
of genes that surround SQSTM1 were maintained in all the species analyzed showing 
conservation also at the level of its genomic environment. 
 
Figure 5.2 - Overall synteny relationships between SQSTM1 genes. Location of SQSTM1 genes of 
two mammals, four teleosts, one bird, one reptile and one amphibian are shown in boxes. Depending 
on gene clusters, syntenic blocks represented by blue, pink, light grey, and orange boxes. Numbers 
below bars represent the chromosome or scaffold number in each species. UR in Tetraodon nigroviridis 
represents UnRandom. 
 
The genes flanking the SQSTM1 orthologs can be found in two major clusters: one 
more conserved in mammalian species, which can also be found in zebrafish, 
including LTC4S, MGAT4b, RNF130 and FLT4 (represented in blue and pink in 
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Figure 5.2), and another one more conserved in fish species, which includes abca1b, 
arap3, selt2, cox18, polr2b and igfbp7 (represented in grey and orange in Figure 5.2). 
The arrangement of the genes close to SQSTM1 was conserved to a large degree in 
human, mouse, turkey and anole lizard. Genome sequence data in frog was rather 
limited, and thus synteny analysis was less informative in this vertebrate. 
In order to study the evolutionary relationship of zebrafish Sqstm1 with mammalian 
SQSTM1, we constructed a phylogenetic tree by aligning all 32 collected amino acid 
sequences of this protein (Figure 5.3). The phylogenetic tree reflects both the 
taxonomy and the specificity. In agreement with the generally accepted taxonomy of 
vertebrates, Sqstm1 sequences were clustered into major taxonomic groups (such as 
insects, reptiles, bony fish, amphibians, birds and mammals).  
 
Figure 5.3 - Phylogenetic analysis of SQSTM1 proteins. Phylogenetic relationship of SQSTM1 
proteins and evolutionary distances among different species. Neighbor-joining tree was constructed 
with MEGA facilities using taxonomic data available at NCBI. SQSTM1 proteins are clustered in 
major taxonomic groups (such as insects, reptiles, amphibians, bony fishes, birds and mammals). 
 
M
am
m
alia&
Aves& Am
phibia&
Rep/lia&
Ac/nopterygii&
Insecta&
CHAPTER(5(–(CAN(ZEBRAFISH(BE(A(VALID(MODEL(TO(STUDY(PDB?(
!114!
 SQSMT1 primary and tertiary structures are 5.1.4.2
conserved between human and zebrafish 
In order to study the protein conservation at the amino acid level, between zebrafish 
and human, we performed pairwise alignments using species ranging from fish to 
mammals and the identity percentage acquired with Manipulation Suite facilities 
revealed an overall sequence identity of 91% between mammalian SQSTM1 proteins 
and 50% between fish SQSTM1 proteins (Figure 5.4). Particularly, the amino acid 
sequence of zebrafish Sqstm1 is 43% identical the human SQSTM1 (Figure 5.4).  
 
Figure 5.4 - Pairwise percent identities among SQSTM1 protein sequences. Diagonal values are 
sequence lengths in amino acids and shaded areas indicate identities within different groups of 
organisms (purple - amphibian; orange - mammalian; green - teleosts). The identity values were 
calculated from alignments described in the text. Atlantic salmon (Salmo salar, Ssa), African clawed 
frog (Xenopus laevis, Xla), African savanna elephant (Loxodonta Africana, Laf), cattle (Bos taurus, 
Bta), chimpanzee (Pan troglodytes, Ptr), common marmoset (Callithrix jacchus, Cja), house mouse 
(Mus musculus, Mmu), human (Homo sapiens, Hsa), Nile tilapia (Oreochromis niloticus, Oni), Norway 
rat (Rattus norvegicus, Rno), pig (Sus scrofa, Ssc), rabbit (Oryctolagus cuniculus, Ocu), rhesus monkey 
(Macaca mulatta, Mm), sheep (Ovies aries, Oar), Southern platyfish (Xiphophorus maculatus, Xma), 
spotted green pufferfish (Tetraodon nigroviridis, Tni), stickleback (Gasterosteus aculeatus, Gac), 
Sumatran Orangutan (Pongo abelii, Pab), torafugu (Takifugu rubripes, Tru), Western clawed frog 
(Xenopus tropicalis, Xtr), Western gorilla (Gorilla gorilla, Ggo), zebrafish (Danio rerio, Dre). 
 
Protein size was also found to be conserved along evolution, with zebrafish presenting 
a Sqstm1 encoding 452 amino acids, and the human SQSTM1 encoding 440 amino 
acids (Figure 5.4). Interestingly, based on T-coffee alignment, the amino acid 
sequences identity in the main domain of the SQSTM1 are high, with 81% identity in 
ubiquitin-associated (UBA) domain (Figure 5.5), a domain known to be involved in 
SQSTM1 autophagy (Daroszewska et al., 2011; Ravikumar et al., 2010). On the other 
Dre 452
Gac 48 421
Tru 48 60 420
Tni 49 61 69 421
Oni 47 58 58 63 436
Ssa 58 48 48 48 48 463
Xma 51 61 63 64 66 51 397
Mmus 43 44 46 43 42 43 46 442
Hsa 43 44 45 43 41 42 46 91 440
Ggo 43 44 45 43 41 42 46 91 99 440
Cja 43 44 45 43 41 42 45 91 96 96 439
Rno 43 44 46 43 42 43 45 97 91 91 91 439
Ssc 44 44 45 44 41 43 45 91 93 93 92 91 440
Bta 43 44 45 44 41 42 45 88 92 92 90 89 94 440
Ocu 43 45 46 45 42 42 46 90 93 93 91 90 94 91 521
Laf 41 40 41 43 40 40 46 78 80 81 80 78 81 79 79 445
Ptr 43 44 43 43 41 42 46 91 100 100 96 91 93 93 93 81 440
Pab 43 44 44 43 41 42 45 90 99 99 95 90 92 92 92 80 99 436
Mmu 43 44 45 43 41 42 46 90 98 98 96 91 93 92 93 81 98 97 440
Oai 43 44 45 44 41 42 46 89 94 94 92 89 94 98 92 80 94 93 93 440
Xtr 41 41 43 43 39 39 44 54 53 53 53 53 53 52 54 47 53 53 53 53 452
Xla 41 41 44 43 39 40 44 52 52 52 52 52 52 52 53 47 52 52 52 53 90 454
Dre Gac Tru Tni Oni Ssa Xma Mmus Hsa Ggo Cja Rno Ssc Bta Ocu Laf Ptr Pab Mmu Oar Xtr Xla
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hand the LIM/p38MAPK domain is less conserved, sharing only 17% of the amino 
acid sequence (Figure 5.5).  
 
Figure 5.5 - SQSTM1 protein domains conservation between zebrafish and human. A) Schematic 
representation of SQSTM1 protein domains in human (Homo sapiens) and zebrafish (Danio rerio) 
proteins. B) Alignment of SQSTM1 proteins from human and zebrafish. The boxes highlight the 
protein domains represented in panel A. C) Comparison of protein domains size in both species and 
pairwise percent identities among these domains. aa – amino acids. . SH2 - Src-homology 2 domain, 
AID - acidic interaction domain, RIP/ZZ - AMPA receptor interacting protein/zinc finger region, PEST 
- proline, glutamic acid, serine, and threonine rich domains, PB1 - Phox and Bem1p domain, 
(p38/MAPK) - p38 mitogen-activated protein kinase, TRAF6 - tumor necrosis factor receptor-
associated factor 6 binding domain, LIR - LC3-interacting region, UBA - ubiquitin-associated domain. 
 
Of relevance to the conservation of these domains and possibly their function is the 
fact that residue Pro392, shown in Figure 5.6¸ known to be the most frequently 
mutated in PDB patients (Hocking et al., 2001; Laurin et al., 2002, 2001), is 100% 
conserved in protein sequences from all species analyzed (Figure 5.6).  
Protein(
Domain(
Homo$sapiens(
lenght(((((((((((
(aa)(
Danio$rerio$
length(((
(aa)(
Share(iden3ty((((
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SH2$ 50$ 40$ 38$
AID$ 16$ 16$ 75$
RIP/ZZ$ 35$ 35$ 71$
LIM/p38MAPK$ 50$ 52$ 17$
TRAF6$ 26$ 26$ 54$
PEST$ 29$ 30$ 30$
LIR$ 21$ 19$ 48$
PEST$ 33$ 40$ 45$
UBA$ 50$ 50$ 81$
Homo sapiens    MASLTVKAYLLGKEDAAREIRRFSFCCSPEPEAEAEAAAGPGPCERLLSRVAALFPALRPGGFQAHYRDEDGDLVAFSSDE 81 
Danio rerio     M-SMTVKAYLIGKEDCNKEIRRFAVDQDV-----------STSFEYLQRKVLDVFVGLRTAPFQMYYKDEDGDMIAFSSDD 69 
 
Homo sapiens    ELTMAMSYVKDDIFRIYIKEKKECRRDHRP-----------------PCA-----------------QEAPRNMVHPNVIC 128 
Danio rerio     ELMMGLALVKDDTFRLFIKQRKEHKRDSSPHGIPGFPFTTPHFSPPGPCHMGPSPMGPPGPPHMGGPPHHPHPMVHPGVTC 150 
 
Homo sapiens    DGCNGPVVGTRYKCSVCPDYDLCSVCEGKGLHRGHTKLAFPSPFGHLSEGFSHSRWLRKVKHGHFGWPGWEMGPPGNWSPR 209 
Danio rerio     DGCDGPVAGTRYKCTVCPDYDLCPTCQSKGLHKEHALLPIFHPMANVFEWLPRGKFWRKMRHC--MWANAQAQAQNQPQPG 229 
 
Homo sapiens    PPRAGEARPGPTA--ESASGPSEDPSVNFLKNVGESVAAALSPLGIEVDIDVEHGGKRSRLTPVSPESSST-EEKSSSQPS 287 
Danio rerio     PSGAQQNQDAPENPNENGATASSQANVEYLKNIGEEVAAMLSPLGIDVDIDVEHEGKRTKVTPTPPASSGPSSARSDSGSV 310 
 
Homo sapiens    CCSDPSKPGGNVEGATQSLAEQMRKIALESEGRPEEQMESDNCSGGDDDWTHLSSKEVDPSTGELQSLQMPES-------E 361 
Danio rerio     LLSRGSGPGSQ-----------------ATEESVSEGTKKDQCS--DEEWTHLSAKEVDPSTGELQSLRLEQDGADLPAPL 372 
 
Homo sapiens    GPSSLDPSQEGPTGLKEAALYPHLPPEADPRLIESLSQMLSMGFSDEGGWLTRLLQTKNYDIGAALDTIQYSKHPP-PL 440 
Danio rerio     NTASGTSTRDGPTGLREAALYPHLPQDADPRLVESLSQMLSMGFTDEGGWLTRLLHTKNYDIGGALDTIQYSKTPGQQK 452 
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Figure 5.6 – Conservation of Pro392 amino acid. Alignment of SQSTM1 proteins with ClustalW 
showing the conservation of the Pro392, an important amino acid for SQSTM1 and highly associated 
with Paget’s disease of bone, in all species analyzed, represented by the grey box.   
 
Zebrafish Sqstm1 not only presents protein domains similar to those found in the 
human protein but they also show remarkable three-dimensional (3D) structure 
conservation (Figure 5.7), an additional evidence for the existence of an evolutionary 
pressure to maintain the structure and function of SQSMT1.  
 
Figure 5.7 – Human and zebrafish SQSTM1 3D structure. Prediction of human and zebrafish 
SQSTM1 three dimensional (3D) structure. A) 3D structure of Sqstm1 from zebrafish. B) 3D structure 
of SQSTM1 from human. C) 3D alignment of zebrafish (dark grey) and human (orange) SQSTM1.  
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Bos_taurus     EGPTGLKEAALYPHLPPEADPRLIESLSQMLSMGFSDEGGWLTRLLQTKNYDIGAALDTIQY!
Callithrix_jacchus   EGPTGLKEAALYPHLPPEADPRLIESLSQMLSMGFSDEGGWLTRLLQTKNYDIGAALDTIQY!
Gorilla_gorilla    EGPTGLKEAALYPHLPPEADPRLIESLSQMLSMGFSDEGGWLTRLLQTKNYDIGAALDTIQY!
Homo_sapiens    EGPTGLKEAALYPHLPPEADPRLIESLSQMLSMGFSDEGGWLTRLLQTKNYDIGAALDTIQY!
Loxodonta_africana   EGPTGLKEAALYPHLPPEADPRLIESLSQMLSMGFSDEGGWLTRLLQTKNYDIGAALDTIQY!
Macaca_mulatta    EGPTGLKEAALYPHLPPEADPRLIESLSQMLSMGFSDEGGWLTRLLQTKNYDIGAALDTIQY!
Mus_musculus    EGPTGLKEAALYPHLPPEADPRLIESLSQMLSMGFSDEGGWLTRLLQTKNYDIGAALDTIQY!
Oryctolagus_cuniculus   EGPTGLKEAALYPHLPPEADPRLIESLSQMLSMGFSDEGGWLTRLLQTKNYDIGAALDTIQY!
Ovis_aries     EGPTGLKEAALYPHLPPEADPRLIESLSQMLSMGFSDEGGWLTRLLQTKNYDIGAALDTIQY!
Pan_troglodytes    EGPTGLKEAALYPHLPPEADPRLIESLSQMLSMGFSDEGGWLTRLLQTKNYDIGAALDTIQY!
Pongo_abelii    EGPTGLKEAALYPHLPPEADPRLIESLSQMLSMGFSDEGGRLTRLLQTKNYDIGAALDTIQY!
Rattus_norvegicus   EGPTGLKEAALYPHLPPEADPRLIESLSQMLSMGFSDEGGWLTRLLQTKNYDIGAALDTIQY!
Sus_scrofa     EGPTGLKEAALYPHLPPEADPRLIESLSQMLSMGFSDEGGWLTRLLQTKNYDIGAALDTIQY!
Danio_rerio    DGPTGLREAALYPHLPQDADPRLVESLSQMLSMGFTDEGGWLTRLLHTKNYDIGGALDTIQY!
Gasterosteus_aculeatus   LGQTGLKEAALYPHLPQEADPRLVESLSLMLSMGFTDEGGWLTRLLQAKNFDIGAALDAIQY!
Oreochromis_niloticus   AGPSGLREAALYPHLPQEADPRLVESLASMLSMGFTDEGGWLTRLLQAKNFDIGAALDAIQY!
Salmo_salar                  QKSLTLAEAAAYPHLPQDADPRLVESLSQMLAMGFTDEGGWLTRLLHTKDCDVGAALDTIHY!
Takifugu_rubripes   QHPTGLKEAALYPHLPDEADPRLVESLAQMLSMGFTDEGGWLTRLLQAKNYDIGAALDAIQY!
Tetraodon_nigroviridis   --PAGLKEAALYPHLPEEADPRLVESLAQMLSMGFTDEGGWLTRLLQAKNFDIGAALDAIQF!
Xiphophorus_maculatus   QGPTGLREAALYPHLPQEADPRLVESLAAMLSMGFGDEGGWLTHLLQAKNGDIGAALDAIQY!
Xenopus_laevis    HAPTGLREAALYPHLPPEADPRLIETLSQMLSMGFSDEGGWLTRLLEAKQYDIGSALDAMQS!
Xenopus_tropicalis   HAPTGLREAALYPHLPPEADPRLIESLSQMLSMGFTDEGGWLTRLLEAKQFDIGSALDAMQS!
A" B"
C"
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Accordingly, and as shown in Figure 5.7, despite differences existing at the amino 
acid level, the predicted 3D structure of zebrafish Sqstm1 is very similar to that of its 
human counterpart, with the important structural amino acids being conserved in the 
same spatial position, further indicating that zebrafish Sqstm1 is likely to have an in 
vivo function similar to that of human SQSMT1, and emphasizing the relevance of 
zebrafish as a suitable animal model for SQSMT1 related research. 
 SQSTM1 is regulated by bone related 5.1.4.3
transcription factors both in human and in 
zebrafish  
Transcription factors (TFs) are nuclear proteins that regulate the expression of target 
genes. We examined the presence of transcription factors binding sites (TFBSs) 
known from the literature to bind human SQSTM1, in the promoters of human and 
zebrafish SQSTM1 using Contra facilities. Data in Figure 5.8 also suggests that both 
human and zebrafish SQSTM1 appear to be putative targets of TFs known to be 
important for regulation of bone metabolism like ETS1, NF-κB, AP1, Twist, GATA, 
ERE, RXR, Krueppel, LIM, Cart-1, Mef2 and NFAT, which could explain its role in 
bone biology. Interestingly, the transcription factor binding elements Cart-1 and AP1 
identified in the human promoter are found to be conserved in the same position in the 
zebrafish promoter. In addition to TFBSs, both a TATA and a CAAT boxes were also 
conserved in the zebrafish promoter, which may indicate the existence of similar 
mechanisms for regulation of expression. 
 
Figure 5.8 – Comparative SQSTM1 promoter analysis between human and zebrafish. Sequence 
analysis of SQSTM1 promoter. Several putative transcription factors binding motifs were identified 
with Contra analysis. The numbering is related to the translation start site. 
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5.1.5 Discussion 
Fish and humans present large similarities when comparing gene structure and 
function and their involvement in physiological processes. In the case of zebrafish 
sqstm1, given its conservation in terms of gene structure and protein organization 
when compared to mammalian genes and its predicted regulation by bone related TFs, 
it is likely that it also plays an important role in fish bone. In this work we analyzed 
SQSTM1 gene and protein conservation between human and zebrafish and the results 
showed that SQSTM1 is well conserved throughout evolution. The overall clusters of 
genes that surround SQSTM1 were maintained in all the species analyzed showing 
conservation also at the level of its genomic environment. Postlethwait et al. (1998) 
compared the chromosomal locations of zebrafish genes with their mammalian 
orthologs and found highly conserved syntenic relationships between them 
(Postlethwait et al., 1998). These comparative analyses could help to predict the 
positions of some genes from mammalian gene maps and also provide new insights 
into the corresponding gene function by comparison with the known functions of its 
human orthologs (Gates et al., 1999). Interestingly, both in human and in zebrafish, 
the gene closer to SQSTM1 is MGAT4b, a gene encoded in the opposite direction, 
which in zebrafish is 11,7 kb apart, while in human both genes share the first exons 
(exons 1-3). 
Regarding the protein sequence, the results showed a high amino acid sequences 
identity in the main domain of the SQSTM1, with 81% identity in ubiquitin-
associated (UBA) domain, a domain known to be involved in SQSTM1 autophagy 
(Daroszewska et al., 2011; Ravikumar et al., 2010). More interesting is the 
conservation of the residue Pro392, known to be the most frequently mutated in PDB 
patients (Hocking et al., 2001; Laurin et al., 2002, 2001), is 100% conserved in 
protein sequences from all species analyzed (Figure 5.6). This finding confirms that 
this key amino acid in the UBA domain is crucial to SQSMT1 function, providing 
additional evidence for the maintenance of the autophagy function in this protein. 
Studies in mouse showed that this mutation is sufficient to cause several aspects of the 
PDB phenotype but by itself was not sufficient to induce the complete PDB 
phenotype (Daroszewska et al., 2011; Hiruma et al., 2008). It was hypothesized that 
further events, like environmental or other genetic factors were eventually needed to 
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lead to the full development of PDB phenotype (Chamoux et al., 2009; Hiruma et al., 
2008; Roodman, 2010). Interestedly, the residue Pro392 is located in the human 
SQSMT1 exon 10, an exon that is lost in one of the identified transcript isoforms 
(Homo sapiens_4; Figure 5.1). This exon codes for the second PEST domain (formed 
by amino acids 345-377, Figure 5.5) a region rich in proline (P), glutaminic acid (E), 
serine (S), and threonine (T) (Rechsteiner and Rogers, 1996; Rogers et al., 1986) and 
containing many S/TP sequences, which are minimum consensus phosphorylation 
sites for protein kinases. It was hypothesized that disruption of a PEST sequence 
could result in a mutant SQSTM1 protein that is more stable than the wild type, 
inducing a more sustained signaling (Beyens et al., 2006).   
Using bioinformatics tools we found in zebrafish sqstm1 promoter some putative 
TFBSs already known to regulate human SQSTM1 (Du et al., 2009; Thompson et al., 
2003; Vadlamudi and Shin, 1998), like ETS1 and NF-κB (Figure 5.8), and found that 
one ETS1 position in the zebrafish sqstm1 promoter is conserved, showing that also 
SQSTM1 regulation mechanisms seems to be preserved.(
Our work shows that, by using bioinformatics tools, we can predict that zebrafish, 
which presents unique advantages over other vertebrate models (Bolis et al., 2001), is 
likely to be a suitable model to study some aspects of the function of SQSTM1 in 
PDB, providing a convenient and powerful in vivo platform in which genetic and 
physiologic characteristics of PDB can be identified and studied (Lieschke and Currie, 
2007; Santoriello and Zon, 2012), with particular emphasis on skeletal defects 
associated to PDB, as already observed for other genetic diseases affecting the 
skeleton.  
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5.2.1 Abstract 
Optineurin (OPTN) is a protein encoded by the OPTN gene. This protein is involved 
in several cellular mechanisms such as autophagy, NF-κB signaling, cellular 
morphogenesis, membrane and vesicle trafficking, and transcription activation. 
Mutations in OPTN have been described in glaucoma, amyotrophic lateral sclerosis 
and other neurological diseases. More recently a polymorphism in this gene was also 
identified by a genome wide association study (GWAS) to be associated with Paget’s 
disease of bone (PDB), making OPTN a strong candidate gene to be involved in PDB; 
however defining the molecular mechanisms by which variants in this gene may 
contribute to this bone disease requires further studies. Because zebrafish has been 
validated as a good model to study bone related diseases, the objective of the present 
work was to evaluate if zebrafish could be a good system to study the molecular 
mechanisms through which OPTN may contribute to PDB pathogenesis. Through a 
comparative analysis we observed that OPTN is encoded by a single copy gene both 
in human and zebrafish and its genomic structure is also conserved. The neighbor 
genes and chromosomal localization were also maintained, which strongly suggest 
that zebrafish optn is the ortholog of human OPTN. Bioinformatics analysis indicate 
that zebrafish and human OPTN seem to be regulated by common transcriptional 
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factors related to bone such as TWIST, KRUEPPEL, LIM domain, NFAT, NF-κB 
and RXR. Furthermore, OPTN protein comparison between several species revealed a 
high degree of conservation in the functional domains of the protein and in its 3D 
structure. In conclusion, this study demonstrated that OPTN is well conserved 
throughout evolution, and therefore fish models, like zebrafish, which has been 
previously validated as a good model to study bone related pathologies, could be 
considered to further study the biologic role of OPTN in bone diseases and bone 
development. 
5.2.2 Introduction 
Optineurin (OPTN) is a gene linked to several conditions that go from neurological 
diseases, such as open-angle glaucoma and amyotrophic lateral sclerosis (ALS) 
(Kachaner et al., 2012; Osawa et al., 2011; Ying and Yue, 2012), to bone diseases, 
such as Paget's disease of the bone (PDB) (Albagha et al., 2010). OPTN was 
originally identified as a gene responsible for primary open-angle glaucoma, a 
progressive blinding disease, with the loss of the retinal ganglion cells and damage to 
their axons that make up the optic nerve (Rezaie et al., 2002). Subsequent groups have 
implicated many different mutations in OPTN with this disease (Chalasani et al., 
2009; Funayama et al., 2004; Leung et al., 2003; Swarup et al., 2013). ALS is a 
progressive debilitating condition where the loss of spinal motor neurons leads to 
paralysis and death, and researchers have also found mutations in OPTN to be 
associated with various forms of this disease (Belzil et al., 2011; Czell et al., 2013; 
Iida et al., 2012; Lattante et al., 2012; Millecamps et al., 2011). This gene encodes a 
cytosolic protein that interacts with a number of proteins and therefore is important in 
basic cellular functions such as vesicle trafficking, maintenance of the Golgi 
apparatus, NF-κB pathway, antibacterial and antiviral signaling, cell division control, 
and autophagy. Mutation or level alteration of OPTN expression results in adverse 
consequences in the cells leading to diseases (Gao et al., 2014; Park et al., 2010; 
Turturro et al., 2014). The molecular mechanisms, however, are not yet understood. 
The human OPTN gene encodes a protein that contains multiple coiled-coil domains, 
at least one leucine zipper and a C-terminal zinc finger (Li et al., 1998). The OPTN 
protein from different species has high amino acid homology and the amino acid in 
the position 50, which is often mutated in several diseases, is conserved (Rezaie and 
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Sarfarazi, 2005). Animal models where the effect of mutations in OPTN expression is 
analyzed are mainly focused in mimicking neurological diseases, such as glaucoma or 
ALS. Chi et al. (2010) described the phenotypic characteristics of transgenic mice 
overexpressing wildtype or mutated OPTN (E50K, H486R, and a deletion of the 
leucine zipper) (Chi et al., 2010). After 16 months, histologic abnormalities were 
exclusively observed in the retina of E50K mutant mice, with loss of retinal ganglion 
cells and connecting synapses in the peripheral retina, thinning of the nerve fiber layer 
at the optic nerve head at normal intraocular pressure, and massive apoptosis and 
degeneration of the entire retina. Introduction of the E50K mutation disrupted the 
interaction between Optn and Rab8 GTPase, a protein involved in the regulation of 
vesicle transport from Golgi to plasma membrane. Chi et al. (2010) concluded that 
alteration of the Optn sequence could initiate significant retinal degeneration in mice 
(Chi et al., 2010). Two other different knock-in mouse lines have been developed that 
interfere with OPTN function: the OPTND477N line interferes with ubiquitin binding 
(Gleason et al., 2011) and the OPTN470T line causes a C-terminal truncation, which 
also eliminates the ubiquitin-binding domain (Munitic et al., 2013). Neither of these 
published works described any obvious phenotype for these mouse lines, with the 
exception of an increase in embryonic lethality related to the genetic background of 
the OPTN470T line (Munitic et al., 2013). In addition, another paper showed that 
transient knockdown of optn in zebrafish embryos resulted in abnormal morphology 
and defects in spinal motor axon guidance, a defect that can be related to problems in 
directed cell migration (Korac et al., 2013). Another work developed in the attempt to 
try to explain the in vivo effects of optn mutation was performed by Paulus and Link 
(2014). This group assessed the cellular consequences of optn knock-down in 
zebrafish embryos and they showed that the loss of optn expression resulted in 
increased cell death, as well as subtle cell morphology, cell migration and vesicle 
trafficking defects (Paulus and Link, 2014). However no bone phenotypes were 
accessed in any of those models.  
Zebrafish is used as an experimental model in various research areas and has relevant 
features, including several technical advantages such as external fertilization, 
transparent embryos and larvae, rapid and external growth and a large progeny, strong 
resemblance of biochemical and physiological processes with mammals and presence 
of orthologs for many mammalian genes. Other similarities to mammals, like a 
complex ossified skeleton, the existence of osteocytic bone and multinucleated 
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osteoclast makes zebrafish an unique animal model to study different pathologies, 
including those affecting bone (Bolis et al., 2001; Lieschke and Currie, 2007). 
Zebrafish can be a good model to compare the bone remodeling mechanisms since 
zebrafish osteoclasts exhibit high activity of tartrate-resistant acid phosphatase and the 
eroded bone surfaces are covered with new bone, just like in human (Hall and Witten, 
2007; Witten and Huysseune, 2009), and there are models that lack crucial genes for 
osteoclast proliferation and differentiation, such as panther (Chatani et al., 2011). 
5.2.3 Materials and methods 
 Sequence collection 5.2.3.1
Sequence databases at NCBI GenBank (www.ncbi.nlm.nih.gov) and Ensembl (release 
v72; www.ensembl.org) were searched for annotated OPTN sequences. A total of 11 
species were selected, including two mammals [human (Homo sapiens) and mouse 
(Mus musculus)], seven teleosts [zebrafish (Danio rerio), stickleback (Gasterosteus 
aculeatus), Nile tilapia (Oreochromis niloticus), medaka (Oryzias latipes), salmon 
(Salmo salar), fugu (Takifugu rubripes), and platyfish (Xiphophorus maculatus)], one 
bird [chicken (Gallus gallus)], and one amphibian [frog (Xenopus tropicalis)]. 
 Sequence alignment and analysis 5.2.3.2
The amino acid sequence alignments were created using T-Coffee software 
(Notredame et al., 2000) with parameters set to default. Sequence composition logos 
were constructed from the resulting alignments using the WebLogo facility (Crooks et 
al., 2004) - sequence logos are pictorial representations of the protein sequence in 
which the height of each amino acid letter is proportional to its frequency at a 
particular site. For each protein alignment, pairwise sequence identity and similarity 
values (p-distances) were computed as percent of identical and similar residues over 
the total number of aligned residues using the Sequence Manipulation Suite, 
respectively (Stothard, 2000).  
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 Assessments of gene synteny 5.2.3.3
To determine the patterns of conserved gene synteny, we annotated the genes 
upstream and downstream of the OPTN gene in the four teleost fish species, plus 
human, chicken and frog using the Ensembl database search function (release v72; 
http://www.ensembl.org). The synteny pattern was then confirmed using Synteny 
Database (Catchen et al., 2009). 
 Prediction of human and zebrafish OPTN three 5.2.3.4
dimensional structures 
Human and zebrafish OPTN three-dimensional (3D) structures were predicted with I-
TASSER software (http://zhanglab.ccmb.med.umich.edu/I-TASSER) (Roy et al., 
2010). Different models were obtained and the best one was chosen according to the 
DOPE (discrete optimized protein energy) score method (Shen and Sali, 2006). 3D 
overlapping illustrations were produced using Chimera v1.5 
(http://www.cgl.ucsf.edu/chimera) (Pettersen et al., 2004). 
 Analysis of putative transcription factor binding 5.2.3.5
sites (TFBSs) in OPTN regulatory regions 
The promoter sequences (1,500 bp upstream of the transcription start site) of the 
OPTN gene from human and zebrafish were retrieved from Ensembl database, and 
masked for repetitive elements by the program RepeatMasker 
(www.repeatmasker.org) using the default mode. The sequences were then analyzed 
using the web server ConTra (http://bioit.dmbr.ugent.be/contrav2/index.php) (Broos 
et al., 2011) to determine binding sites for 14 TFs (E2F, E47, SP1, ETS1, MEF2, 
TWIST, KRUEPPEL, RXR, LIM, CART1, NF-κB, ERE, GATA, and NFAT).  
 In silico EST-based gene expression profiles 5.2.3.6
To determine if OPTN genes were differentially expressed in human and in zebrafish 
tissues, gene expression profiles were analyzed with NCBI Unigene EST profiles. 
These analyses determined approximate gene expression patterns inferred from 
transcript counts and cDNA library sources as reported by sequence submitters to the 
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Unigene database. The EST and Unigene data of NCBI are available in a standardized 
format, which makes it possible to extract information from the two databases and 
obtain sufficient data to estimate gene expression profiles. Gene mRNA levels are 
described as gene transcript units per million transcripts (TPM). 
5.2.4 Results 
 OPTN gene structure structures were conserved 5.2.4.1
throughout evolution 
Human and zebrafish OPTN gene sequences and structures were obtained by 
searching the Ensembl database, and we found that the zebrafish optn gene is located 
in chromosome 4 and appears to be a single copy gene. The optn gene has 
approximately 11 kb and it is organized into 14 exons and 13 introns and comparison 
with its human ortholog revealed a generally well-conserved exon-intron organization 
for the coding exons (Figure 5.9).   
 
Figure 5.9 - Comparative analysis of human and zebrafish OPTN gene structure. The comparison 
between human and zebrafish overall gene structure revealed a high conservation at genomic level. The 
gene structure, namely the number of coding exons is conserved, which is the first indication of a 
strong gene function conservation. Dark grey boxes represent exonic coding regions, light grey boxes 
represent exonic non-coding regions. Numbers below the boxes indicate exons length in base pairs. 
 
Zebrafish optn exon1 and 2 span the 5´UTR and the start codon is present in exon 2. 
Exon 14 contains the termination codon and the 3´UTR that includes one consensus 
polyadenylation signal (Figure 5.9). We have identified two zebrafish optn transcripts 
coding for protein isoforms: Danio_rerio_1 (ENSDART00000014036) and Danio 
rerio_2 (ENSDART00000133616) with 2,455 and 1,614 bp, and open reading frames 
encoding sequences of 517 and 314 amino acids, respectively. The transcript 
Danio_rerio_2 seems to have a different cDNA sequence due to alternative splicing in 
exon 11 as well as an incomplete 5’ coding sequence region (Figure 5.9).  
Danio&rerio_1&
Danio&rerio_2&
1" 6" 7" 8" 9" 11"
             188      156     194    147   62    111 79  116    150  85  156   143  92         776 
2" 3" 4" 12" 14"
6" 7" 8" 9" 11" 12" 14"
""""""""""14"
""""""""""14"
5" 10"
10"
13"
13"
                         111 79  116   150   85  141   143  92         776 
Homo_sapiens_1& 3 8" 9" 11" 13"
         221    152  54       192    203    183   74    153  103 116   150  94  159   131  80        1532 
4" 5" 6" 14" 14"""""""""""16"7" 12" 15"2"1" 10"
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The human OPTN gene is located in chromosome 10 and spans 39 kb in length and at 
least eight transcripts coding for protein isoforms were identified. The gene is 
organized in three non-coding exons that span the 5’UTR and 13 protein coding exons 
(Figure 5.9). The most interesting feature is the similar coding exon sizes of these two 
species, suggesting that these genes have sufficiently important functions to result in 
their sequence being highly conserved throughout vertebrate evolution.  
 Synteny within chromosomal locations of OPTN 5.2.4.2
gene 
To determine whether OPTN occurs within syntenic regions in mammals and fish, we 
evaluated the positions of an additional six to ten genes with chromosomal proximity 
to OPTN (Figure 5.10). Analysis of synteny within the chromosomal regions that 
harbor the OPTN gene demonstrated that genes flanking the OPTN orthologues are 
conserved in their positions in the mammalian and fish species analyzed. Not only the 
fish species revealed a highly conserved block but also species such as chicken and 
frog showed a block of OPTN neighbor genes conserved when compared with the 
human ortholog (Figure 5.10).  
 
Figure 5.10 - Syntenic relationships between OPTN genes. OPTN has the same neighbor genes in 
several species, despite their taxa. The direction of the arrows indicates the direction of the respective 
gene in the genome. Chr represents chromosome. In Takifugu rubripes the S means Scaffold and in 
Oreochromis*nilo-cus*GL831319.1((((
Oryzias*la-pes*UC269(
Homo*sapiens*Chr(10(
Danio*rerio*Chr(4(
Takifugu*rubripes*S168(
Gallus*gallus*Chr(1(
Xenopus*tropicallis*GL172774.1(
NUDT5*
CCDC123*
CAMK1D*
CCDC3*
MCM10*
UCMA*
PHYH*
SEPSH1*
OPTN*
ARID2*
ELK3*
CDK16*
CAMK1D'
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Oryzias latipes the UC means UltraContig, meaning that in these species the genes were not assigned 
to a specific chromosome. 
The conserved synteny drawn using Synteny Database (Catchen et al., 2009), which is 
specifically designed to identify conserved synteny using Ensembl data, showed that a 
large region of human chromosome 10 surrounding OPTN shares a well-recognizable 
synteny with the optn region on chromosome 4 of zebrafish, providing another solid 
evidence for a conserved synteny (Table S5.2). A gene-by-gene comparison showed 
16 pairs of orthologous genes surrounding the OPTN orthologues, confirming our 
results. In summary, the syntenic relationships of the zebrafish optn gene are 
conserved in the other fish species analyzed, and the same syntenic conservation is 
maintained with respect to human OPTN, showing that not only OPTN but that the 
entire chromosomal context was conserved throughout evolution. 
 OPTN is regulated by bone related transcription 5.2.4.3
factors both in human and in zebrafish  
Because transcription factor (TFs) can be “switch” genes regulating the expression of 
other genes, we selected 14 bone related TFs known to regulate several genes and 
examined the frequency of their binding sites in the human OPTN promoter and 
compared it to its frequency in the corresponding promoter of zebrafish optn gene. 
The results indicate that both human and zebrafish OPTN appear to be putative targets 
of TFs like ETS1, NF-κB, TWIST, GATA, ERE, RXR, KRUEPPEL, LIM, CART1, 
MEF2 and NFAT, all of them previously associated to skeletal metabolism, and thus 
could explain the OPTN role in bone biology (Figure 5.11). Interestingly, the 
transcription factor binding elements CART1, GATA, E47, NFAT and MEF2 
identified in the human promoter are found to be conserved in the same position in the 
zebrafish promoter. In addition, the NF-κB binding site is located just upstream of the 
transcription start site, which may indicate the existence of similar mechanisms for 
regulation of expression by this known OPTN regulator. 
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Figure 5.11 - Comparison of 1.5 kb promoter region between human and zebrafish. The analysis 
of 1.5 kb of OPTN regulatory region in these two species shows the conservation of several TFBSs. 
The arrow represents the transcription start site. The numbers correspond to the length in base pairs of 
the fragment analyzed. 
 
Also, we analyzed the putative TFBSs studied in a previous work (Silva et al., 
unpublished results) and that have an effect in human OPTN promoter activity. In this 
analysis the results show that zebrafish optn seems to have an E47 binding site in the 
same region as in the human gene and two SP1 binding sites around the same region 
as in human OPTN promoter. On the contrary, we did not find any E2F family 
binding sites in the zebrafish optn promoter, which suggests that this TF might not be 
involved in optn regulation in zebrafish (Figure 5.11). 
 OPTN is expressed in similar tissues in human 5.2.4.4
and in zebrafish  
The expression profiles of the OPTN genes in human and zebrafish tissues are shown 
in Figure 5.12. OPTN gene expression seems to have a similar pattern in these two 
species, being expressed in the neural tissues, such as brain, both in human and 
zebrafish. Also, OPTN is known to be highly expressed in the human eye and our 
results showed that optn expression was also found in the zebrafish eye. However, 
human OPTN seems to be highly expressed in the reproductive system while in 
zebrafish its expression was barely detected. Optn expression in the zebrafish skin 
seems to be relevant and higher than the expression in the eye for example, while in 
human that is not observed. However the most relevant result is the fact that one of 
the tissues with the highest expression is bone, in both species (Figure 5.12), 
indicating that this gene can have an important role in bone development or bone 
biology, which was conserved in evolution. 
TWIST% KRUEPPEL% RXR% ETS1%
LIM% CART1% NF3κB% ERE%
GATA% MEF2% NFAT%
31500%
31500%
Homo$sapiens$
Danio$rerio$
E2F% E47% SP1%
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Figure 5.12 - OPTN expression profile in human and zebrafish. Analysis of ESTs in some tissues 
available in the Unigene database (http://www.ncbi.nlm.nih.gov/unigene) reveal that OPTN is 
expressed in the same tissues in zebrafish and in human, particularly it is highly expressed in bone, 
both in human and in zebrafish, suggesting a major role in this tissue. 
 OPTN primary and tertiary structures are 5.2.4.5
conserved between human and zebrafish 
Orthologues to the human OPTN gene were identified in the teleost fish genomes of 
zebrafish, stickleback, medaka, torafugu, platyfish, salmon and tilapia. Pairwise 
protein alignments and their percentage identity values revealed that the percentage of 
conservation between mammalians and fish is around 35-40% (Figure 5.13). Protein 
size was found to be very similar, with medaka’s being the smallest protein and 
mouse’s the largest protein. Overall the protein size for OPTN is conserved between 
human and the teleost fish analyzed (Figure 5.13). 
 
Figure 5.13 - Conservation of OPTN proteins. Pairwise alignments and identity percentage reveal 
that OPTN is well conserved throughout evolution. Dre – Danio rerio, Gac – Gasterosteus aculeatus, 
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Ola – Oryzias latipes, Oni – Oreochromis niloticus, Ssa – Salmo Salar, Tru – Takifugu rubripes, Xma 
– Xiphophorus maculatus, Hsa – Homo sapiens, Mmu – Mus musculus, Gga – Gallus gallus, Xtr – 
Xenopus tropicallis.  
However, more important than an overall protein structure is the conservation of the 
residues that constitute the main OPTN functional domains. NEMO domain, which 
confers the same cellular function as the NEMO/IKKγ subunit, is 67% similar 
between zebrafish and human; the LIR domain, which serves as an interacting 
domains with LC3 autophagy protein, is 100% similar; UBD, the domain that allows 
the binding of ubiquitin to OPTN and therefore is important for its function in binding 
to proteins that were signalized to degradation, is 62% similar; and finally the ZnF 
domain is 62% similar between these two species (Figure 5.14). 
 
Figure 5.14 - Conservation of OPTN protein domains. Alignment of human and zebrafish OPTN 
protein sequences shows that the functional domains of OPTN are highly conserved, which presumes a 
maintenance both in protein function as in expression patterns. UBD represents the ubiquitin binding 
domain, the LIR represents the LC3 interacting region, and ZnF represents the zinc finger domain. 
Also, not only the primary structure of the most important domains is well conserved 
but also the predicted three-dimensional (3D) structure. To analyze the predicted 
tertiary structure of OPTN human and zebrafish proteins, we modeled the 3D 
structure of the human OPTN protein (Figure 5.15A) and zebrafish Optn (Figure 
5.15B), since there was no published data about any OPTN 3D structure in the Protein 
Database. Predicted 3D structures of human and zebrafish OPTN were overlaid to 
NEMO% LIR% UBD% ZnF%1% 577%
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highlight its conservation (Figure 5.15C), showing just some differences in the N- 
terminal and C- terminal residues. The high conservation of OPTN domains from 
primary to tertiary structure and both in zebrafish and mammals strongly suggests that 
OPTN function has been maintained throughout evolution, thus validating zebrafish 
as a suitable model for OPTN research. 
 
Figure 5.15 - Conservation of the predicted 3D structure of OPTN proteins. OPTN 3D structure is 
also conserved between human and zebrafish. A) The 3D structures of human (grey) and B) zebrafish 
(pink) were obtained using I-TASSER software. C) Overlap of the two OPTN proteins highlight the 
conservation of their structure, and it shows that there are only some differences in the N- and C- 
terminal regions. 
5.2.5 Discussion 
The objective of this work was to provide preliminary data towards the use of 
zebrafish as an alternative model to study optn gene expression and Optn role in bone 
and also complement data available for human and mouse systems. Our strategy 
included in silico analysis to determine (i) the molecular characterization of optn, by 
analyzing its gene structure, (ii) the study of optn promoter, by predicting the binding 
of several transcription factors, (iii) the analysis of optn tissue expression by data 
A" B"
C"
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available in the Unigene database in NCBI, and (iv) the characterization of protein 
structural conservation between zebrafish and human. 
By sharing with mammals a number of important characteristics (e.g. organ systems, 
gene functions, developmental organization and physiological/biochemical 
mechanisms, including mechanisms of cartilage and bone formation), fish have been 
considered a suitable model organism to study mechanisms underlying vertebrate 
development, including skeletogenesis (Berghmans et al., 2005; Kabashi et al., 2011). 
Also, the zebrafish is widely accepted as a valuable model for studies of vertebrate 
development (Driever et al., 1994; Kimmel, 1989) and is being used as a model 
organism for several human diseases (Zon, 1999), presenting unique advantages over 
other vertebrate models. In this work, OPTN was shown to be conserved between 
human and zebrafish, both at gene and protein levels. Zebrafish optn was shown to 
have a gene structure similar to human, to be putatively regulated by the same bone 
related TFs and to be expressed in many of the same tissues, namely in bone, which 
suggest that optn might have an important role in zebrafish bone.  
To identify the location of the optn gene in the zebrafish genome we searched the 
Ensembl database (http://www.ensembl.org/) and found only a single copy of this 
gene, located in chromosome 4, providing evidence that optn evolved to single copy 
in the zebrafish lineage after the teleost genome duplication (Amores et al., 1998; 
Postlethwait et al., 2000; Taylor, 2003). This result is in agreement with information 
collected from databases for other teleosts. Indeed, only one gene was also identified 
in medaka (Oryzias latipes), Southern platyfish (Xiphophorus maculates), torafugu 
(Takifugu rubripes), three-spined stickleback (Gasterosteus aculeatus) and Atlantic 
salmon (Salmo salar). The zebrafish optn gene spans approximately 11 kb of 
chromosomal DNA and it is organized in 13 coding exons, a structure comparable to 
those described for its mammalian orthologues. The zebrafish optn gene was mapped 
to chromosome 4 in a region showing extensive conserved synteny with the small arm 
of human chromosome 10, where OPTN is located together with coiled-coil domain 
containing 3 (CCDC3), upper zone of growth plate and cartilage matrix 
associated/gla-rich protein (UCMA/GRP), minichromosome maintenance complex 
component 10 (MCM10) and phytanoyl-CoA 2-hydroxylase (PHYH). Taken together,!
our results confirmed that the zebrafish sequence reported here is a true ortholog of 
human OPTN. By comparing the chromosomal locations of zebrafish genes and their 
mammalian orthologues (including human), Postlethwait et al. (1998) discovered 
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highly conserved syntenic relationships (Postlethwait et al., 1998). Indeed, a growing 
number of studies have shown extensive conserved synteny between zebrafish and 
human chromosomes (Amores et al., 1998; Barbazuk et al., 2000; Cancela et al., 
2012; Catchen et al., 2009; Fazenda et al., 2012; Gates et al., 1999). The analysis of 
these syntenic regions demonstrated that the genes flanking OPTN are conserved in 
their positions in all teleost fish genomes analyzed, as well as in human. 
Unsurprisingly, we also observed a more conserved synteny among the teleost fish 
analyzed than between teleost and human. Therefore, it is of interest to determine the 
chromosomal locations of optn in other fish species to be able to reconstruct the 
ancestral gene organization and fully understand their evolution in the fish lineage. In 
addition, comparative mapping of optn in various teleost genomes will contribute to 
improve our understanding of their evolutionary and functional implications among 
vertebrates. 
Comparative analysis of genomic sequences has become an important tool to identify 
regulatory regions in genomic DNA and their conservation in non-coding regions has 
been related to their importance for regulating gene expression (Koop and Hood, 
1994). Our in silico analysis showed that the transcription factor NF-κB has a putative 
binding site in OPTN promoter, both in zebrafish and in human. It is known that NF-
κB regulates human OPTN (Sudhakar et al., 2009) and these results show that 
probably NF-κB is also an important regulator of optn in zebrafish. In addition, our 
latest results showed that E47 and SP1 have an effect in human OPTN promoter 
activity (Silva et al., unpublished results) and our in silico analysis show that these 
TFs might regulate also zebrafish optn. These results indicate that human and 
zebrafish OPTN might share the same regulatory mechanisms. The analysis of tissue 
specific expression available in Unigene database shows that OPTN is expressed in 
many of the same tissues in both species, reinforcing the theory of a common 
regulatory network. 
The more important results are regarding the protein sequence, where we showed an 
important amino acid sequences similarity in the main domains of the OPTN protein, 
with 67% similarity in NEMO-like domain, 62% similarity in ubiquitin-associated 
domain (UBD), a domain known to be involved in OPTN autophagy (Ying and Yue, 
2012) and 100% similarity in the LIR domain, which is vital for OPTN interaction 
with LC3 and OPTN participation in the autophagy process (Wild et al., 2011b). The 
identification of genetic signatures and domains in coding regions can provide 
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relevant data for studying the functional and evolutionary characteristics of aligned 
regions (Nielsen, 2005). The highly conserved nature of the OPTN domains – from 
fish to human – strongly suggests that OPTN functions have been maintained 
throughout vertebrate evolution. 
Our study provides novel insights about the similarities between zebrafish and human 
OPTN and contributes to the establishment of zebrafish as a suitable model to study 
the role of OPTN in bone metabolism, osteoclastogenesis, gene transcription and to 
investigate functionally OPTN-related human pathologies. Moreover, zebrafish have 
life-cycle related traits that make them ideal study subjects such as, ease of 
reproduction, high fecundity and growth rate with juveniles exhibit external 
development, plus they can be easily manipulated genetically through the use of 
transgenic overexpression constructs and specific transcription inhibition. Because of 
these advantages, zebrafish appears to be an ideal model for studying the 
consequences of functional inactivation or overexpression of OPTN and thus 
contributing to better understand the genetic events occurring in humans that lead to 
pathologies such as Paget’s disease of bone. 
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SUPPLEMENTARY TABLES 
Table S5.1 – Known mRNA and protein features and corresponding tissue expression of alternatively spliced isoforms encoding human 
and zebrafish SQSTM1. 
Gene$ Isoform$ Exons$ mRNA$(bp)$$ Protein$(aa)$$ Tissue$
Hsa$
SQSTM1&
a$ 8$ 2986$ 440$ skin$(39),$lung$(34),$melanotic$melanoma$(32)$and$55$other$tissues$
b$ 7$ 1714$ 378$ placenta$cot$25Bnormalized$(1),$thyroid$gland$(1)$
c$ 9$ 2913$ 356$ pancreas$(3),$placenta$(3),$pancreatic$islet$(3)$and$20$other$tissues$
d$ 7$ 2253$ 356$ skin$(23),$lung$(20),$eye$(15),$melanoma$(15)$and$84$other$tissues$
e$ 8$ 2000$ 356$ amygdala(3),$hippocampus$(2),$hypothalamus(2)$and$14$other$tissues$
f$ 3$ 602$ 190$ liver$(1)$
g$ 6$ 842$ 167$ NA$
h$ 4$ 628$ 140$ lung$(2),$leiomyosarcoma$(1),$leukocyte$(1)$and$4$other$tissues$
i$ 4$ 572$ 73$ brain$
j$ 4$ 578$ 69$ endometrium,$adenocarcinoma$cell$line$from$uterus$
k$ 3$ 2405$ NPP$ NA$
l$ 2$ 1722$ NPP$ NA$
m$ 3$ 921$ NPP$ NA$
n$ 4$ 808$ NPP$ NA$
o$ 2$ 656$ NPP$ NA$
p$ 4$ 562$ NPP$ NA$
q$ 4$ 532$ NPP$ NA$
$ $ $ $ $ $
Dre$
sqstm1$
a$ 8$ 1939$ 452$ NA$
b$ 9$ 1827$ 353$ NA$
c$ 5$ 557$ NPP$ NA$
d$ 3$ 1010$ NPP$ NA$
e$ 3$ 531$ NPP$ NA$
$ $ $ $ $ $
Hsa&–&Homo&sapiens;&Dre&–&Danio&rerio;&bp&–&base&pairs;&aa&–&amino&acid.&NA&<&Information&not&available;&NPP&<&No&protein&product.  
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Table S5.2 – Conserved syntenic block around OPTN genes in zebrafish (Danio 
rerio) and human (Homo sapiens) performed by Synteny Database  
Danio&rerio& && Homo&sapiens&
ENSDARG00000017549. .. ENSG00000107537.
(phyh)& .. (PHYH)&
Dre:.4.position:.7,008k. .. Hsa:.10.position:.13,320k.
.. .. ..
ENSDARG00000027799. .. ENSG00000165623.
(ucma&a)& .. (UCMA)&
Dre:.4.position:.7,022k. .. Hsa:.10.position:.13,264k.
.. .. ..
ENSDARG00000045815. .. ENSG00000065328.
(mcm10)& .. (MCM10)&
Dre:.4.position:.7,031k. .. Hsa:.10.position:.13,204k.
.. .. ..
ENSDARG00000078073. .. ENSG00000165609.
(nudt5)& .. (NUDT5)&
Dre:.4.position:.7,051k. .. Hsa:.10.position:.12,207k.
.. .. ..
ENSDARG00000075025. .. ENSG00000151465.
(cdc123)& .. (CDC123)&
Dre:.4.position:.7,056k. .. Hsa:.10.position:.12,238k.
.. .. ..
ENSDARG00000074905. .. ENSG00000183049.
(camk1d&a)& .. (CAMK1D)&
Dre:.4.position:.7,068k. .. Hsa:.10.position:.12,391k.
.. .. ..
ENSDARG00000026052. .. ENSG00000151468.
(ccdc3)& .. (CCDC3)&
Dre:.4.position:.7,182k. .. Hsa:.10.position:.12,939k.
.. .. ..
ENSDARG00000002663. .. ENSG00000123240.
(optn)& .. (OPTN)&
Dre:.4.position:.7,197k. .. Hsa:.10.position:.13,141k.
.. .. ..
ENSDARG00000075501. .. ENSG00000185267.
(cdnf)& .. (CDNF)&
Dre:.4.position:.8,650k. .. Hsa:.10.position:.14,861k.
.. .. ..
ENSDARG00000058030. .. ENSG00000187522.
(hspa14)& .. (HSPA14)&
Dre:.4.position:.8,655k. .. Hsa:.10.position:.14,880k.
.. .. ..
ENSDARG00000045704. .. ENSG00000152457.
(dclre1c)& .. (DCLRE1C)&
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Dre:%4%position:%8,666k% %% Hsa:%10%position:%14,939k%
%% %% %%
ENSDARG00000045705% %% ENSG00000197889%
(meig1)( %% (MEIG1)(
Dre:%4%position:%8,672k% %% Hsa:%10%position:%15,001k%
%% %% %%
ENSDARG00000062983% %% ENSG00000134452%
(fbxo18)( %% (FBXO18)(
Dre:%4%position:%8,916k% %% Hsa:%10%position:%5,932k%
%% %% %%
ENSDARG00000003822% %% ENSG00000134461%
(ankrd16)( %% (ANKRD16)(
Dre:%4%position:%10,523k% %% Hsa:%10%position:%5,904k%
%% %% %%
ENSDARG00000005451% %% ENSG00000057608%
(gdi2)( %% (GDI2)(
Dre:%4%position:%10,529k% %% Hsa:%10%position:%5,807k%
%% %% %%
ENSDARG00000079698% %% ENSG00000196372%
(asb13(a)( %% (ASB13)(
Dre:%4%position:%10,544k% %% Hsa:%10%position:%5,681k%
%% %% %%
ENSDARG00000032765% %% ENSG00000173848%
(net1)( %% (NET1)(
Dre:%4%position:%10,638k% %% Hsa:%10%position:%5,455k%
 
 
Dre – Danio rerio 
Hsa – Homo sapiens 
ENSDRAG – assession number of zebrafish genes 
ENSG – assession number of human genes 
Position – Gene’s position in genome 
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6. FINAL& CONCLUSIONS& AND& FUTURE&
PERSPECTIVES(
Paget’s disease of bone (PDB) is the most common metabolic bone disorder after 
osteoporosis, affecting more than 3% of the Caucasian population. Besides SQSTM1 
gene, no other genes were associated to PDB. However after the GWAS published in 
2010 several other candidate genes were suggested to be associated to this disease. 
One of the most relevant results was the strong association between rs1561570 in 
PDB6 locus, a SNP located in the intron 7 of OPTN gene, and PDB with a p-value of 
6 × 10−13. This strong association was replicated in the French-Canadian population 
but no functional studies had been performed to explain this association.  
This work presents new and exciting insights into the role of PDB6 locus and OPTN 
gene in the pathogenesis of PDB and in bone metabolism. In this study, we sought to 
identify novel genetic variants in the PDB6 locus that could be risk factors for PDB, 
in patients without SQSTM1 mutations, using a candidate gene approach to explain 
the contribution of the PDB6 locus to PDB. After screening the entire PDB6 locus, we 
selected the best candidate genes to play a role in bone metabolism: OPTN, 
UCMA/GRP, CCDC3, SEPSH1, PHYH and CAMK1D. By using a discovery group 
consisting in 30 familial cases and 5 healthy controls, we identified 82 genetic 
variants in these genes. Due to their frequency, we selected rs2234968 and rs3829923 
to be tested for genetic association in a sample of 225 PDB patients without mutations 
in SQSTM1 and 298 healthy controls. This sample has more than 90% power to detect 
significant association (p<0.05) when risk allele frequency differs from at least 0.09 
between cases and controls. Rs2234968 was shown to be associated with PDB (p-
value = 6 x 10−3) but rs3829923 was not associated.  
Functional studies were performed in order to explain rs2234968 association to PDB. 
Rs2234968 was shown to be in linkage disequilibrium with rs10906303 and 
rs79529484 and we demonstrated that these variants induced a new acceptor site, 
changing OPTN splicing pattern. We predict that this change in OPTN splicing alters 
the open reading frame and creates a premature stop codon, giving rise to a truncated 
(probably not functional) protein. However there are still some questions that remain 
to be answered. It would be interesting to prove that OPTN splicing mechanisms are 
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effectively altered due to the presence of rs2234968 A allele, by using cDNA from 
PDB patients with rs2234968 A allele and cloning the full OPTN open reading frame, 
to analyze the new cDNA sequence and confirm the existence of a premature stop 
codon. Also, in the western blot performed in this work, we used an antibody 
detecting the entire OPTN protein and the results showed the presence of the expected 
67kDa band correspondent to the full-length OPTN protein, however with lower 
levels. Whether the antibody used did not react with the possible short-size band 
corresponding to the protein produced by the effect of rs2234968 A allele or this 
mRNA isoform was unstable and rapidly degraded is unknown. In a future work, an 
antibody that recognizes the N- terminal of OPTN protein should be used to assess if 
there is indeed production of a shorter isoform by revealing the existence of a short-
size band in the western blot. Also, the mRNA half-life could be assessed by doing a 
mRNA decay assay to confirm the existence of a shorter non functional OPTN 
transcript rapidly degraded by the cell, thus explaining the lower OPTN protein levels 
that we detected in patients harboring rs2234968 A allele. In addition, further studies 
will be required to clarify the effect of these transcripts in PDB patients. By 
quantifying their expression and comparing it with the expression of the normal 
transcripts, and analyzing if OPTN function is impaired when only the mutant and 
“short” transcript is expressed, should be highly relevant to further understand its 
effect in associated pathologies, such as PDB. Analyzing the autophagy process, by 
quantifying the LC3B expression in the presence of autophagy drugs such as 
Bafilomycin A1 or Rapamycin, or the expression of osteoclast related genes in PDB 
patients with rs2234968 A allele, might also contribute to clarify the effect of these 
variants in PDB pathophysiology.   
We also analyzed rs3829923 and RV -9906 effect in OPTN promoter activity and the 
results showed that these SNPs are responsible for an increase in OPTN promoter 
basal activity, probably due to both the activating effect of E47 and E2F1 only in the 
presence of the rs3829923 A allele, and the inhibitory effect of SP1 in RV -9906 G 
allele. The presence of two DNA fragments that only differ in the alleles 
corresponding to each variant provides the first evidence that rs3829923 C allele is 
needed for E47 and E2F1 binding to OPTN promoter and that RV -9906 A allele is 
sufficient to disrupt the SP1 effect. However an electrophoretic mobility shift assay 
(EMSA) should be performed in order to confirm that, in fact, E47 and E2F1 are 
binding in the rs3829923 region and that SP1 is binding in the RV -9906 region. A 
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chromatin immunoprecipitation assay (CHIP) could also be performed to provide 
additional in vivo data, to confirm if these transcription factors are able to bind to 
OPTN promoter in the osteoclasts derived from the PBMCs from PDB patients. In 
addition, to clarify the role of this variant in osteoclastogenesis, it would be of interest 
to do an in vitro site directed mutagenesis and develop osteoclast precursor isogenic 
cell lines with and without the variants, aiming at replicating the expression of the two 
identified variants and analyzing its effect in the number and activity of resulting 
osteoclasts. To assess the effect of these variants in a more physiological context we 
could perform co-cultures of osteoclasts derived from PBMCs from PDB patients 
harboring this variant together with stromal cells or pre-osteoblasts. This would 
permit to investigate if the stromal cells or pre-osteoblasts from PDB patients 
harboring these variants produce in fact more RANKL, giving rise to an increase in 
osteoclastogenesis, or if the osteoclasts of these PDB patients are more sensitive to the 
same concentration of RANKL. 
The most relevant result is, without a doubt, the explanation on how does rs1561570, 
the most associated SNP to PDB, contributes to this disease, to osteoclastogenesis and 
to bone metabolism. Using different techniques, such as in silico analysis, bisulfite 
treatment, osteoclast differentiation, demethylating treatment, gene expression 
analysis by qPCR, and protein analysis by western blot and immunofluorescence, we 
were able to show that rs1561570 T allele is responsible for a loss of a methylation 
site, an increase in OPTN expression, an increase of NF-κB translocation to the 
nucleus resulting in an increase in expression of its target genes, and thus contributing 
to promote the increase in number, size and activity of osteoclasts, all possibly 
contributing to PDB phenotype. Despite some limitations, such as a low number of 
patients and controls, which may have resulted in lack of statistical power in some of 
the gene and protein expression analyses performed, the results obtained appear to be 
quite consistent and have provided evidence towards confirming our hypothesis. 
Indeed, our study gave several indications, from gene to protein analysis, from in vitro 
to patient samples, from genetic to morphological cellular features, that show that 
OPTN is important for NF-κB translocation into the nucleus, activation of its target 
genes and consequent increase in the osteoclastogenesis, providing the first input on 
how rs1561570 can contribute to the PDB phenotype and/or its severity by acting as a 
modifier. In fact, together with our results on autophagy impairment in PDB patients, 
we can hypothesize that in healthy individuals, the autophagy process works normally 
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both in the presence of the C allele, when the OPTN expression is controlled at basal 
levels (Figure 6.1), and in the presence of the T allele, when the OPTN expression is 
potentiated due to the loss of a methylation site but the efficient autophagy process 
signals the excessive OPTN for degradation by ubiquitination, and OPTN expression 
is controlled to a basal level. In both situations this will give rise to normal levels of 
NF-κB in the nucleus and regular osteoclastogenesis rate (Figure 6.1). In PDB 
patients, where the autophagy process is defective, with no alteration in the rs1561570 
position the PDB phenotype might be explained by the presence of other genetic 
variants that lead to an increase of osteoclastogenesis (Figure 6.1). The effect of 
rs1561570 T allele in PDB patients is explained by the increase in OPTN expression 
and decreased degradation due to the autophagy defect present in these patients. 
Therefore, there is an accumulation of OPTN that leads to NF-κB translocation to the 
nucleus at a much higher rate than normal, giving rise to more osteoclasts, and thus 
explaining the PDB phenotype in these patients (Figure 6.1). 
 
Figure 6.1 - Hypothetical mechanism of rs1561570 effect in PDB. In controls the autophagy process 
can control the OPTN levels potentiated by the presence of the T allele in the rs1561570 position. Basal 
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levels of OPTN give rise to basal levels of NF-κB in the nucleus, basal levels of osteoclastogenesis and 
the maintenance of the normal bone metabolism. In PDB patients with the C allele other genetic 
variations might explain the PDB phenotype, however in the presence of the T allele, there is an 
accumulation of OPTN due to a defective autophagy process that is unable to control OPTN levels. The 
increase in OPTN will increase NF-κB translocation to the nucleus, NF-κB target gene expression and 
an increase in osteoclastogenesis, explaining the PDB phenotype. Ub represents the ubiquitin chains. 
 
These results also suggest that the overexpression of OPTN could be a good 
pretherapeutic target in order to prevent the major PDB symptoms. By inhibiting the 
increase of OPTN expression using, for example, a microRNA targeting OPTN, the 
defective autophagy in patients would not represent a problem, and the phenotype 
would not be as critical. In fact, in our in silico analysis of the OPTN variants we 
detected putative binding sites for several microRNAs related to bone, such as miR-
320a, miR-302d-3p, miR-3128, miR-145 and miR-365a (Baglìo et al., 2013; 
Franceschetti et al., 2014; He et al., 2015; Jia et al., 2013; Peng et al., 2011), which 
indicates that OPTN might be a target for these microRNAs, which could be used to 
inhibit OPTN overexpression caused by genetic variants, such as rs1565170. Also, to 
complete our model, the cause of the autophagy defect in PDB patients should be 
analyzed in detail, since this is probably the best therapeutic target to prevent PDB 
phenotype.  
In addition, these results also elucidate the role of OPTN overexpression as a risk 
factor for other diseases, such as glaucoma. Glaucoma is characterized by an increase 
in the intraocular pressure that give rise to degeneration of the optic nerve, retinal 
ganglion cell death, and progressive axonal and visual field loss (Kerrigan et al., 
1997; Kuehn et al., 2005; Quigley, 2011). The role of OPTN as an osteoclastogenesis 
enhancer can explain the increase of calcium in the blood stream and in the eye. In 
excess, calcium acts as an oxidant and therefore OPTN overexpression will cause an 
increase in the oxidative stress in the eye and damage the trabecular meshwork. This 
will lead to an increase of the intraocular pressure due to aqueous humor retention, 
causing the main symptoms in glaucoma. Also, calcium deposits may obstruct the 
draining of the aqueous humor by the Schlemm's canal in the eye. Taking this into 
account, future pre-therapeutical inhibition of OPTN expression may be valuable not 
only for PDB patients but also for glaucoma patients, for example. 
In need of an alternative animal model, we questioned if zebrafish could be a good 
model to study PDB biological mechanisms or potential therapeutics, since zebrafish 
has been described as an excellent model to study bone related pathologies and can 
CHAPTER(6(–(FINAL(CONCLUSIONS(AND(FUTURE(PERSPECTIVES(
!146!
thus be considered a promising tool for the initial development and validation of new 
therapeutic approaches (Barrett et al., 2006; Berghmans et al., 2005; Huttner et al., 
2013; Jagadeeswaran and Liu, 1997; Kabashi et al., 2011; Sadler et al., 2005; 
Swanhart et al., 2011). Keeping that in mind, we analyzed the evolutionary 
conservation between zebrafish and human of the only gene associated with PDB - 
SQSTM1 - and of OPTN, the other candidate gene. Our results provide evidence 
supporting the use of zebrafish as a valid model to study both SQSTM1 P392L 
mutation and OPTN function in bone, since this gene is highly expressed in zebrafish 
bone. To understand the mechanistic effects of OPTN and SQSTM1 mutations, it 
would be interesting to generate zebrafish transgenic lines using the CRISPR-Cas9 
system, by microinjection of zebrafish zygotes with constructs containing a mutation 
in OPTN exon 5 that led to a premature stop codon, to mimic rs2234968, or 
containing the mutation P308L in the zebrafish sqstm1 gene that is equivalent to the 
P392L observed in the human SQSTM1. A combination of the two mutations in these 
genes to assess the combined effect of OPTN and SQSTM1 mutations could also be 
performed. In addition, it would be interesting to use the Tol2 system with a TRAP 
promoter to overexpress OPTN in pre-osteoclasts, to reproduce the effect of the most 
associated SNP in OPTN, rs1561570. A combination of the effect of rs1561570 and 
Sqstm1 P308L should be also studied. 
Although much remains to be done, novel and valuable data have been collected 
within the scope of this work, which contributed towards a better understanding of 
OPTN function and regulation but also towards the evolutionary relationship between 
SQSTM1 and OPTN and the feasibility of zebrafish as a valid animal model for 
studying PDB. Ultimately this work contributed to further clarify the contribution of 
PDB6 locus and OPTN in PDB. 
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Table S2.2 – Detection of genetic variants in the candidate genes in PDB6 locus in the discovery sample and in silico analysis 
Variant'
Minor'allele'
frequency'' Functional'predicted'effect'
PDB'
patients'
Healthy'
controls'
Protein'
sequence'
TF'binding'
Splicing'
miRNA'binding'
GAIN' LOSS' GAIN' LOSS'
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-'
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Hsa-miR-
4729' -'
rs7093805'G/T' 0.16' 0.30' -' -' ADR1,'CAP' -' -' -'
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ADR1,'STRE,'
MZF1,'
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HSF' -' Hsa-miR-5010-3p'
Hsa-miR-
4778-3p'
rs72779542'T/A' 0.20' 0.20' -'
OCT1,'BR-C'Z,'
BROAD'
COMPLEX'1/4,'
HUNCHBACK,'
HFH2'
TBP' -' -' Hsa-miR-4777-5p'
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rs61851395'C/G' 0.20' 0.20' -' -' -' -' Hsa-miR-5095' -'
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Hsa-miR-
5680''
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Hsa-miR-
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Hsa-miR-
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4498,v'Hsa-
miR-4433-
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4665-3pv'
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Hsa-miR-
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Hsa-miR-
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Hsa-miR-22-
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rs72781364'G/A' 0.03' 0.00' -' -' -' -' -' -'
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Hsa-miR-
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rs76403928'A/C' 0.36' 0.40' -' HNF-3BETA' -' -' -' Hsa-miR-5096'
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rs7916926'T/C' 0.39' 0.20' -' STUAP,'SNAIL' -' -' -'
Hsa-miR-
3622a-5p,'''''''''''''''''
Hsa-miR-
3622b-3p'
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rs72781358'C/T' 0.03' 0.00' -' -' -' -' Hsa-miR-25-3p'
Hsa-miR-
1228-3p,'
Hsa-miR-
3124-5p'
rs1747682'C/T' 1.00' 1.00' p.Asn51' CDXA,'SOX'5,'ATHB-1' HFH-2,'BZIP910' -' -' -'
rs473407'A/G' 0.27' 0.30' p.Thr112' HSF2,'HSF1,'BSAP' HSH-2'
New'acceptor'
site' -' -'
rs7900830'C/A' 0.18' 0.30' -'
HSF,'SRY,'CF2-
II,'AGL3,'TBP,'
HFH-1'
-' New'acceptor'site' -' -'
rs78560997'A/G' 0.02' 0.10' -' SN,'DELTAE,'MYOD'
NHF-3BETA,'FREAC-4,'
SOX'5'
New'acceptor'
site' -'
Hsa-miR-
5010-5p'
!!170!
rs648173'G/A' 0.50' 0.70' -' HSF,'SRY,'HUNCHBACK' -'
New'acceptor'
site'
Hsa-miR-
3611'
Hsa-miR-
3202,'Hsa-
miR-519c-
5p,'Hsa-
miR-520a-
5p,'Hsa-
miR-523-5p,'
Hsa-miR-
518e-5p,'
Hsa-miR-
522-5p,'
Hsa-miR-
519a-5p,'
Hsa-miR-
519b-5p'
rs62619919'G/A' 0.02' 0.10' p.Arg245Gln'
SN,'DELTAE,'
MYOD,'USF,'
ARNT,'N-MYC'
-'
New'
donor/acceptor'
site'
Hsa-miR-
324-3p'
Hsa-miR-
4640-5p'
rs12411977'A/G' 0.52' 0.30' -' HSF,'CDXA' HUNCHBACK,'SOX'5,'ATHB-1'
New'acceptor'
site' -' -'
rs11133'G/A' 0.30' 0.40' -'
HFH-2,'HNF-
3BETA,'SOX'17,'
ATHB-1,'
BROAD'
COMPLEX-4'
HSF-2,'BROAD'
COMPLEX-1/4,'SOX'5,'
FREAC-4'
-' Hsa-miR-3915'
Hsa-miR-
664-5p,'
Hsa-miR-
515-5p'
!!
171!
rs61851599'G/A' 0.12' 0.30' -'
USF,'CREB,'
AP1,'DELTAE,'
HLF,'BZIP910'
PACC,'MYC-MAX' New'donor'site' -' -'
c.'-78'-125'A>G' 0.02' 0.00' -' -' TST1,'CDXA,'TBP,'AGL3,'CF2-II' -' -' -'
ESP_10_13386978'
G/A' 0.02' 0.00' -' HSF,'CAP' AP4' -' -'
Hsa-miR-
3147'
rs2275128'T/C' 0.50' 0.70' -'
MZF1,'DORSAL-
1,'DORSAL-2,'
NF-KAPPAB,'C-
REL,'P50'
-' -' -' Hsa-miR-1247-3p'
rs62641683'C/G' 0.02' 0.00' p.Leu125' CAP,'MYF' SPZ1' New'acceptor'site'
'Hsa-miR-
378g'
'Hsa-miR-
151a-3p'
rs2275129'G/C' 0.33' 0.40' -' -' -' New'donor'site' -' Hsa-miR-3922-3p'
rs10752297'A/G' 0.49' 0.70' p.Thr157' BZIP910' MYF,'TAL1BETA-E47A,'SNAIL'
New'
donor/acceptor'
site'
-' -'
!!172!
rs61851591'G/T' 0.12' 0.30' -'
SRY,'BR-C'Z,'
SBF-1,'DFD,'
BROAD'
COMPLEX'4,'
SOX'5,'HFH-1'
EVI-1' New'donor'site' -' -'
rs3740211'G/A' 0.36' 0.40' -' -' ADR1,'STRE,'SNAIL'
New'
donor/acceptor'
site'
-' -'
rs62641685'G/C' 0.03' 0.00' p.Val293' TTK69' MYF,'SNAIL'
New'
donor/acceptor'
site'
-'
Hsa-miR-
338-5p,'
Hsa-miR-
3065-3p'
rs10906347'G/A' 0.35' 0.40' -' SRY,'SPZ1,'AML1' MYF,'HEN1'
New'acceptor'
site' -'
Hsa-miR-
3675-5p'
RV'(-9906)'G>A' 0.02' 0' -' -' CAP,'GCBOX' -' -' -'
rs3829924'G>A' 0.016' 0' -' HUNCHBACK,'HMG-IY' -' -' -'
Hsa-miR-
578'
rs2234968'G>A' 0.30' 0.42' -' CF2-II' MAX,'USF,'ARNT,'N-MYC,'FREAC-4'
New'branch'
point'
Hsa-miR-
302a-3p,'
Hsa-miR-
302d-3p,'
Hsa-miR-
619'
!!
173!
Hsa-miR-
5188'
rs11258194'T>A' 0.03' 0.08' p.Met98Lys' -' UBX' -' -' -'
rs72043574'delta' 0.42' 0.33' -' -'
HMG-YV,'HFH2,'
BROAD'COMPLEX'
1/4,'HUNCHBACK'
-' -' -'
rs1561570'T>C' ' ' -' -' AGL3,'CF2-II,'TAL1BETA-E47'
New'
donor/acceptor'
site'
-' -'
rs2244380'C>T' 0.84' 0.92' -' STATX,'TATA,'HMG'IY,'SQUA' SU_H'
New'acceptor'
site' -'
Hsa-miR-
145-5p,'
Hsa-miR-
452-5p'
rs11258211'G>A' 0.02' 0' -' GATA1,'GATA2,'NIT2,'SPZ1' THING1-E47'
New'
donor/acceptor'
site'
-' -'
rs765884'T>C' 0.38' 0.58' -' -' SQUA' New'acceptor'site' -'
Hsa-miR-
3164'
!!174!
rs489040'A>G' 0.58' 0.75' -' -' MATALP,'CDXA,'SKN1' -' -' -'
rs523747'A>G' 1' 1' p.Lys322Glu' HSF' AP4,'HEN1' New'acceptor'site'
Hsa-miR-
891a'
Hsa-miR-
19a-3p'
rs676302'G>T' 0.72' 0.75' -' NKX2,'HMG'IY' ADR1,'HUNCHBACK' New'acceptor'site'
Hsa-miR-
3128' -'
rs825411'A>G' ' ' -' V-MYB,'GATA2,'SPZ1' HFH2,'SOX'5'
New'
donor/acceptor'
site'
-' -'
rs10906310'C>A' 0.22' 0.08' -'
BROAD'
COMPLEX'1/4,'
HFH1,'
HUNCHBACK,'
SOX'5'
SNAIL' -' -'
Hsa-miR-
653,'Hsa-
miR-365a-
5p'
rs2095388'A>G' ' ' -' FTZ,'AGL3' S8,'BROAD'COMPLEX'4' -' -' -'
' ' ' ' ! ' ' ' '"!indicates!that!the!variant!does!not!have!a!predicted!functional!effect.!!!
!!175!
Table S3.1 – Primers list 
Name Sequence (5' - 3') 
Sense primers   
Rs1561570 qPCR F CAGAAAGGTCATCTGAGGACC 
Rs2234968 qPCR F GAGAACCACCAGCTGAAAGAAG 
Rs10906303 F1 TGAAAGCACAGGAAATGGAC 
Rs79529484 F2 AAGAGCGTCTAATGGCCTTG 
Rs3829923 F1 CTCGAGGGCCCGGAATTGGGTCT 
Rs3829923 F2 CTCGAGGGCCTGGAATTGGGTCT 
RV -9906 F3 CAGGGGCAGGGTTGAGAGTCAGGCT 
RV -9906 F4 CAGGGGCAGAGTTGAGAGTCAGGCT 
Rs1561570 Bisulfite F TTGTTATAATTGTGTTTGGGTATAGGG 
OPTN qPCR F CAATGTCCCATCAACCTCTCAGC 
NF-κB qPCR F CAGGAGAGGATGAAGGAGTTGTG 
ELK1 qPCR F TCTCCTCCACAGAAAACACACAGC 
IL6 qPCR F GAAAGCAGCAAAGAGGCACTGG 
NFATc1 qPCR F ATGTCGGAGTTTCTGAGTTTCA 
Antisense primers   
Rs1561570 qPCR R CCTTCTGCTTCTCCTTCAGCC 
Rs2234968 qPCR R GTCATCAGTGGGGTCCTCAGA 
Rs10906303 R1 CTTGGTGGTGAGCTCCCTTCT 
Rs79529484 R2 TTATAGATGGTGCAGATGGGC 
Rs3829923 R1 TGCCGAGGAAACAGTGACCCTGA 
RV -9906 R1 TGCCGAGGAAACAGTGACCCTGA 
Rs1561570 Bisulfite R ACTCAAAAAATCCTACCTCCTCAA 
OPTN qPCR R ACGCTCTTTTGCTTCTTTGCTCTG 
NF-κB qPCR R CATAAGTGTTTTGGAAGGAGCAGGA 
ELK1 qPCR R ACTCACATCCAAAAACGCAGACAG 
IL6 qPCR R GGTTGGGTCAGGGGTGGTTATT 
NFATc1 qPCR R TCTCCACGAAAATGACCTTG 
